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Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor. 
Median survival is less than two years due to several factors, including challenges in surgical 
removal and chemotherapy resistance, underlining the need for more effective therapeutic 
options. To identify genes that contribute to chemotherapy resistance, we conducted a synthetic 
lethal screen in a chemotherapy-resistant GBM derived cell line (T98G) with the clinical 
alkylator temozolomide (TMZ) and an siRNA library tailored towards “druggable” targets.  This 
screen for TMZ-sensitizing genes indicated that a subset of genes that were over-expressed in 
GBM cells increased the cell’s sensitivity to TMZ when knocked down.   
 An ubiquitin ligase, UBE3B, and a DNA glycosylase, UNG, were among the TMZ-
sensitizing genes identified using the siRNA library.  We demonstrate that UBE3B and UNG are 
sensitizing genes in the screen validation studies using unique siRNA and shRNA sequences.  
Although UNG is one of four human DNA glycosylases that remove uracil lesions, UNG was the 
only uracil removing glycosylase to sensitize GBM cells in the validation studies.  Notably, 
analysis of archived transcription datasets revealed that over-expression of UNG was correlated 
with poor outcomes in glioma patients.   
In order to uncover functional groupings of TMZ-sensitizing proteins, we conducted in 
situ pathway analysis of gene candidates for synthetic lethal functions from our screen.  This 
analysis discovered statistically significant enrichment of ontogeny clusters related to base 
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excision repair (BER), response to DNA damage, cellular proliferation and protein modification.  
Interestingly, this pathway topography overlapped with TMZ-sensitizing genes identified from 
similar experiments in yeast and bacteria.   
In order to facilitate rapid in vitro identification of lesion-specific repair activity in cancer 
cells, we developed a novel fluorescent assay that extends the state of the art.  The molecular 
beacon assay measures real-time DNA repair rates of specific DNA lesions by defined DNA 
repair proteins.  These studies reveal that GBM up-regulates several TMZ-sensitizing genes that 
correlate with poor patient survival and inhibiting these genes may increase TMZ cytotoxicity in 
a tumor specific manner.  These TMZ-sensitizing genes are not only potential targets for 
adjuvant therapy, but also represent potential biomarkers to predict TMZ response.   
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1.0  INTRODUCTION 
1.1 GLIOBLASTOMA MULTIFORME 
1.1.1 Incidence, pathogenesis and prognosis 
Cancer is the second leading cause of death in the United States, is the leading cause of 
death among men and women under the age of 85 years, the second most common cause of death 
in children (ages 1-14), and is one of the top five leading causes of death in any age group (1).  
The lifetime risk of developing an invasive cancer is approximately 44% for men and 38% for 
women (1).  Glioblastoma multiforme (GBM) comprises over 22% of all brain tumors and is the 
most common and aggressive primary brain tumor (2, 3).  The incidence of GBM tumors is 
approximately 2-4 cases per 100,000 people per year (2, 3).  There are approximately 10,000 
newly diagnosed GBM tumors annually in the United States.  GBM is a grade four tumor as 
determined by the World Health Organization and confers a very poor prognosis, with the best 
therapy yielding a median survival of 14.6 months and a seven percent three year survival rate 
(2, 3).  The peak age of diagnosis is between the ages of 45-75 with a slight male predominance 
(3 males: 2 females).  GBM is diagnosed by a neuropathologist who rates several different 
criteria, including mitotic index, cellular appearance, and cellular differentiation that help to 
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determine tumor type and grade.  Vascular (endothelial) proliferation and a necrotic tumor center 
are hallmark features of GBM and are required to differentiate between grade III and IV tumors.   
Glioblastomas arise from either a primary glioblastoma or as secondary tumors from 
lower grade anaplastic astrocytoma.  A lower grade anaplastic astrocytoma can evolve over 
several years to develop into a glioblastoma.  The two mechanisms for glioblastoma 
development creates two different types of glioblastomas with primary glioblastomas having an 
older age of onset (median age of onset 64 years old), while glioblastomas derived from 
secondary to lower grade gliomas tend to affect a younger population (median age of onset 45 
years old) (2).  There are genetic differences between the two glioblastoma subtypes.  Primary 
glioblastomas are characterized by a loss of heterozygosity of chromosome 10q, deletion of 
cyclin-dependent kinase inhibitor 2A (p16) and phosphatase and tensin homologue (PTEN) and 
amplification and mutations of epidermal growth factor receptor (EGFR) (2).  This differs from 
secondary glioblastomas that typically affect younger patients and contain mutations to tumor 
protein p53 (p53), dysfunction of the retinoblastoma 1 (RB) and cyclin-dependent kinase 
inhibitor 2A (p16) pathways and over-expression of the platelet derived growth factor receptor 
(PDGFR) (2).  The two subtypes share a similarity, in that both primary and secondary 
glioblastomas frequently lose heterozygosity of chromosome 10q (2).   
1.1.2 Treatment overview 
Temozolomide (TMZ), radiation and surgery are currently used for treatment of GBM, 
yet median survival is still less than 2 years, with a three year survival rate of 7% (3-5).  
Chemotherapy resistance and difficulties in surgical removal contribute to poor prognosis (6).  If 
possible, maximal surgical debulking is recommended and improves patient symptoms by 
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relieving tumor mass effects.  Further, the surgery allows placement of carmustine laced wafers 
which also improve survival and the surgical material removed can be used for staging, typing 
and research studies to improve future outcomes (2).  Unfortunately, the highly infiltrative nature 
of glioblastomas preclude complete surgical removal, but the improvements from decreased 
mass effects still benefit the patient (2).   
Radiotherapy is central to treating glioblastoma and has shown to increase survival from 
3-4 months to 7-12 months (2).  The radiation is fractionated up to 2 gray (Gy) doses for 5 days a 
week, up to a cumulative total dose of 60 Gy.  Although radiation improves survival, 
approximately 90% of tumors recur at the original tumor site, suggesting that primary tumor 
cells survive and grow to form the recurrent tumor (2).  Simultaneous treatment of TMZ with 
radiation improves median survival from 12.1 to 14.6 months compared to radiation alone (5).  
Further, adjuvant TMZ improved the two-year survival rate from 10.4% to 26.5% compared to 
radiation alone (5).  Finally, the addition of adjuvant biodegradable carmustine wafers to the 
tumor location during surgical resection can improve median survival from 11.6 months to 13.9 
months compared to placebo wafers (2).  The basis of the wafers is to deliver a highly localized 
dose of carmustine directly to tumor cells that remain after surgical resection.  This localized 
dose is released over several weeks as the wafers biodegrade.   
However, treating the tumor is only a subsection of treating the patient as a whole, 
because the brain tumor affects the normal brain tissue.  Therefore, there are many medical 
interventions necessary for patient management, which are not designed to decrease tumor 
burden.  Some common complications include seizures, peritumeral edema, thromboembolism, 
and cognitive dysfunction (2).  Patients may be treated with antiepileptic drugs, corticosteroids, 
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and low-molecular-weight heparin to combat these complications which directly impact their 
care and outcomes (2).   
1.1.3 Temozolomide 
Temozolomide (TMZ) is an alkylating agent and like all alkylating agents, TMZ can 
modify protein, lipids, RNA and DNA in cells (7).  It was developed at Aston University by 
Malcolm Stevens and colleagues (8).   TMZ is an imidazotetrazine pro-drug which undergoes 
spontaneous degradation at physiological pH to yield the intermediate, monomethyl triazeno 
imidazole carboxamide (MTIC).  MTIC is also an intermediate formed by the chemotherapy 
dacarbazine.  However, unlike TMZ, dacarbazine is converted to MTIC by Cyp450 enzymes in 
the liver (9).  MTIC itself is not the clinically active compound for TMZ or dacarbazine.  MTIC 
spontaneously breaks down to 4-amino-5-imadizole-carboxamide and a methyldiazonium ion, 
with the methyldiazonium ion being the active alkylating agent from both TMZ and dacarbazine 
(9).  Thus TMZ undergoes two spontaneous chemical reactions to yield the active alkylating 
agent, the methyldiazonium ion.  One benefit of the in vivo conversion process is the inherent 
hydrophobicity and relative stability of TMZ compared to the reactive diazonium ion allowing 
TMZ to distribute throughout the body yielding good bioavailability (8-10).  TMZ easily 
penetrates the blood-brain barrier, with a concentration of 30-40% of peak plasma levels (10).  
TMZ is used as an oral medication and is stable in the stomach’s low pH before being 
intestinally absorbed with peak plasma levels occurring ninety minutes after an oral dose (9, 10).  
TMZ is primarily excreted in urine with a smaller fraction fecally eliminated (11).  The most 
common side effects involve the gastrointestinal tract and include nausea, vomiting, constipation 
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and diarrhea.  Other common general side effects include fatigue and headache.  The most 
prevalent serious adverse effect that may stop TMZ treatment is myelosupression (12).  
Temozolomide’s cytotoxicity is mediated through the DNA lesions created by TMZ.  The 
main DNA lesions induced by TMZ are N7-methylguanine, N3-methyladenine and O
6
-
methylguanine (13).  TMZ has a similar alkylation spectrum to the other alkylating agents used 
in these studies, including methyl methanesulfonate (MMS) and methylnitronitrosoguanidine 
(MNNG).  Their lesion spectrum is impacted by both the electronegativity of the methyl acceptor 
and the mechanism of action of the methyl donor (14).  The N7 atom of guanine is the most 
electronegative atom of a DNA base and is therefore the most modified base of electrophilic 
alkylating agents.  All three alkylating agents used are electrophiles that react by donating a 
methyl group to an electron rich methyl acceptor.  However, MMS’s mechanism of action differs 
from TMZ and MNNG and because of this difference, yields a slightly different lesion spectrum.  
Both TMZ and MNNG modify DNA via a SN1 mechanism (7, 14).  The SN1 reaction allows 
more modifications by the O
6
 position of guanine compared to alkylators that use a SN2 
mechanism (7, 14).  In contrast to TMZ and MNNG, MMS uses a SN2 mechanism to alkylate 
DNA and similar to other alkylators with a SN2 mechanism, MMS yields significantly lower O
6
-
methylguanine lesions compared to SN1 type alkylators (7, 14).  All three alkylators are used in 
this study and their most common DNA lesions are found below (Table 1) (13, 14).   
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Table 1. Lesion spectrum induced by the DNA alkylators used in this study 
 DNA Lesion (%) 
Alkylator N3-methyladenine N7-methylguanine O
6
-methylguanine 
TMZ (13) 9.2 >70 5 
MMS (14) 10.4 - 11.3 81 – 83 0.3 
MNNG (14) 12.0 67.0 7.0 
 
1.1.4 Tumor resistance to therapies 
Radiation, temozolomide and carmustine can damage protein, fats, RNA and DNA in 
cells, with the damaged DNA playing a major role in their cytotoxicity (7, 15).  The tumor cells 
are preferentially killed compared to normal tissue due to their high replication rate.  However, 
like normal cells, many tumors contain the ability to repair DNA damage and develop resistance 
to the therapies.  Temozolomide and carmustine are alkylating agents that damage DNA by the 
addition of alkyl groups to DNA.   
  The main DNA lesions produced by TMZ are the N7-methylguanine (N7-MeG), N3-
methyladenine (N3-MeA) and the O
6
-methylguanine (O
6
-MeG) (13).  The N7-MeG and N3-
MeA DNA lesions account for approximately 80% of the DNA lesions induced by TMZ, yet 
result in negligible clinical toxicity due to repair by the BER pathway (13).  Virtually all of 
TMZ’s clinical cytotoxicity is attributable to the O6-methylguanine (O6-MeG) lesion, which 
accounts for approximately 5% of TMZ induced lesions (13). The O
6
-MeG lesion is repaired via 
a direct reversal mechanism by the protein O
6
-methylguanine-DNA methyltransferase (MGMT), 
which transfers the O
6
-methyl group from the guanine base onto a Cys residue in the MGMT 
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protein (16). If the O
6
-MeG lesion is not removed by MGMT, during cellular replication the mis-
pairing of O
6
-MeG with thymine is detected by the mismatch repair (MMR) enzymes, triggering 
apoptosis signaling and cytotoxicity (13, 17, 18). However, 5-year survival rates still remain low 
in TMZ treated patients (4, 5), and TMZ resistance by recurrence of chemotherapy resistant 
tumors is common.  Resistant cells can harbor mutations in mismatch repair proteins such as the 
mutS homolog 6 (MSH6) (19) or have elevated expression of MGMT (as in the T98G cell line) 
(20).  Earlier endeavors to enhance TMZ efficacy by using MGMT inhibitors to prevent the 
repair of O
6
-MeG lesions have not shown an increase in sensitivity or efficacy in clinical trials 
(21-23), especially in TMZ-resistant GBM (24, 25).   
1.1.5 Base Excision Repair Overview 
The N7-MeG and N3-MeA lesions are predominantly repaired by the BER pathway, a 
DNA repair mechanism that involves as many as 20 different proteins (26).  BER proteins are 
responsible for the recognition and repair of small base lesions, abasic sites and single strand 
breaks (27).  There are a myriad of different alkylation and especially oxidative DNA lesions 
recognized and removed by BER, and they may arise from endogenous or exogenous sources 
(15).  Although other DNA repair mechanisms may have substrate overlap with some BER 
lesions, BER is thought to be the primary mechanism to remove small base lesions.  While the 
small base lesions do not look as impressive as the large adducts or double strand breaks that are 
repaired by other DNA repair pathways, BER and its associated proteins are used to repair 
approximately 10,000 of the estimated 20,000 endogenous DNA lesions in a diploid mammalian 
cell every day (7, 27).  This is an astounding number and reinforces the importance of BER in 
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maintenance of the mammalian genome, especially considering the several trillion cells in a 
human that encounter endogenous DNA damage.   
Although BER is initiated by one of eleven lesion specific DNA glycosylases, there are 
several steps that are constant throughout any BER process (28).  All BER processes involve 
lesion recognition, lesion removal, strand scission, gap tailoring, DNA synthesis, and DNA 
ligation (15).  The proteins that fulfill these functions are dependent on the lesion type that 
partially dictates the specific protein that recognizes and removes the lesion.  This is because 
downstream steps are determined by the specific DNA chemistries in the lesion and repair 
intermediates.  The lesion alone does not always dictate what repair intermediates occur, since 
some lesions can be removed by multiple proteins yielding different products and thus different 
repair intermediates. The typical BER pathway for TMZ DNA lesions is initiated by 
methylpurine DNA glycosylase (MPG) which recognizes and removes the N7-MeG and N3-
MeA lesions that are induced by TMZ (15). The resulting abasic site is a substrate for APEX 
nuclease (multifunctional DNA repair enzyme) 1 (APE1), which cleaves the sugar phosphate 
backbone, leaving a 3’OH and a 5’-deoxyribose-phosphate moiety (26). Poly (ADP-ribose) 
polymerase 1 (PARP1) recognizes and binds the nick or single strand break (SSB), which 
activates PARP1 to recruit downstream proteins such as X-ray repair cross complementing group 
1 (XRCC1) and DNA polymerase ß (Polß) (26). Polß is recruited by XRCC1 and PARP1 to 
hydrolyze the 5’-deoxyribose-phosphate and fill the nucleotide gap, followed by ligation 
mediated by the XRCC1/DNA ligase III heterodimer or DNA ligase 1 (26, 29, 30).   
1.1.5.1 DNA glycosylases 
The eleven lesion specific DNA glycosylases initiate BER by recognizing and removing 
the DNA lesion.  Many of the glycosylases are evolutionarily conserved and uracil DNA 
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glycosylase can even be found in some DNA viruses (31).  The glycosylases can be classified 
into three different categories based on their lesion removal mechanism: mono-functional, bi-
functional with associated β-elimination, and bi-functional with associated β,δ-elimination (15).  
The mono-functional glycosylases have only one function, to remove the base lesion but leave 
the DNA backbone intact.  The bi-functional glycosylases differ in their ability to both remove 
the offending base lesion, but also to initiate strand cleavage by either a β-elimination or β,δ-
elimination mechanism, thereby leaving different repair intermediates at the DNA gap (15). 
Although the strand scission by bi-functional glycosylases occur in biochemical experiments, the 
prevalence of the strand scission in live cell BER by DNA glycosylases is uncertain (32).  This is 
because several bi-functional DNA glycosylases, including NTHL1 and OGG1, are inhibited 
because they bind tightly to their abasic product (32).  The addition of APE1 increased the bi-
functional glycosylase catalytic activity, but did so while generating predominantly 5’-lyase 
products, not 3’-lyase products (32).  The bi-functional glycosylase would yield a 3’-lyase 
product, while APE1 strand cleavage results in a 5’-lyase product, indicating under physiological 
conditions of abundant APE1, some bi-functional glycosylases may act as mono-functional 
glycosylases (32).   
The DNA glycosylases have a wide range of DNA substrates, from multiply oxidized 
DNA bases to the unique case of mutY homolog (MUTYH) which can remove the normal 
adenine across from an 8-oxoG DNA lesion (15).  A more complete list of glycosylase names, 
subcellular localization, and substrates can be found below (Table 2, Table 3, and Table 4).   
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Table 2. Summary of human bi-functional DNA glycosylases (with associated β-elimination) 
Gene Symbol Gene Name Gene ID 
Uniprot 
Accession 
Number 
Organelle 
expressed 
Known Substrate
a
 
OGG1 
8-oxoguanine DNA 
glycosylase 
4968 O15527 
Nucleus and 
Mitochondria 
8-oxoG:C/T/G; me-FapyG:C; FapyG:C (32) 
8-oxoA:C (33) 
urea (34) 
NTHL1 
(NTH1) 
Nth endonuclease III-
like 1 (E.coli) 
913 P78549 
Nucleus and 
Mitochondria 
T or C-glycol; FapyA (32) 
5,6-dihydro-U:G/A (34) 
5-formyl-U (34) 
5,6-dihydroxy-C (34) 
5,6-dihydro-T (34) 
urea (34) 
5-OH-U:G (34) 
5-OH-C:G>A (34) 
5-hydroxy-5,6,-dihydro-T (34) 
8-oxoG:G (35) 
NEIL3 
nei endonuclease 
VIII-like 3 (E. coli) 
55247 Q8TAT5 Nucleus 
spiroiminodihydantoin (Sp):C (36) 
guanidinohydantoin (Gh):C (36) 
FapyA (36) 
FapyG (36) 
5-OH-U (36) 
5-OH-C (36) 
Tg (36) 
a
Target base on left in mismatches.   
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Table 3. Summary of human monofunctional DNA glycosylases 
Gene 
Symbol 
Gene Name Gene ID 
Uniprot 
Accession 
Number 
Organelle 
expressed 
Known Substrate
a
 
UNG 
Uracil DNA 
glycosylase 
7374 P13051 
Nucleolus 
(UNG2) and 
Mitochondria 
(UNG1) 
ssU; U:G; U:A; 5-fluorouracil (32) 
5,6-dihydroxy-U:G (34) 
5-OH-U:G (34, 37) 
Isodialuric acid; Alloxan (37) 
SMUG1 
Single-strand-
selective 
monofunctional 
uracil-DNA 
glycosylase 1 
23583 Q53HV7 Nucleolus 
ssU; U:G; U:A (32) 
5-chlorouracil:G, 5-fluorouracil:G,  (38) 
5-carboxyuracil:G (38) 
5-hydroxyuracil; 5-formyl-U (34) 
5-(hydroxymethyl)-U (34, 39) 
TDG 
Thymine DNA 
glycosylase 
6996 Q13569 Nucleus 
U:G; T:G; ethenoC:G (32) 
5-fluorouracil; 5-fluorouracil (ss)  (40) 
5-hydroxymethyluracil; 5-bromouracil (40) 
hypoxanthine:G; εC:A (40) 
5-formyl-U (34) 
Tg:G (41) 
MBD4 
Methyl-CpG 
binding domain 
protein 4 
8930 O95243 Nucleus 
U or T in U/TpG; 5-meCpG (32) 
5-formyluracil; 5-(hydroxymethyl)-U (34) 
Tg:G (41) 
MPG 
(AAG) 
N-methyl DNA 
glycosylase 
4350 P29372 
Cytoplasm  
and Nucleus 
3-meA; 7-meA; 3-meG; 7-meG; 
hypoxanthine; ethenoA; ethenoG (32) 
1,N2-εG:C; U:G; ethanoadenine (42) 
1-methylguanine; etheno-A(ss) (42) 
hypoxanthine(ss); ssU (42) 
8-oxoG:C (Mouse) (43) 
cyanuric acid:CT>GA (34) 
MUTYH 
(MYH) 
mutY homolog 
(E. coli) 
4595 Q9UIF7 
Nucleus  and 
Mitochondria 
A:G; A:8-oxoG; C:A; 2-OH-A (32) 
8-oxoA:G (44) 
a
Target base on left in mismatches.   
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Table 4. Summary of human bi-functional DNA glycosylases (with associated ß,δ-elimination) 
Gene 
Symbol 
Gene Name Gene ID 
Uniprot 
Accession 
Number 
Organelle 
expressed 
Known Substrate
a
 
NEIL1 
nei endonuclease 
VIII-like 1 
(E. coli) 
79661 Q96FI4 
Nucleus, 
Cytoplasm  
and 
Mitochondria 
(Mouse) 
TgG; 5-OH-C; 5-OH-U:AT>G 12(32) 
guanidinohydantoin (45) 
guanidinohydantoin (ss) (45) 
iminoallantoin (45) 
iminoallantoin (ss) (45) 
spiroiminodihydantoin (45) 
spiroiminodihydantoin (ss) (45) 
5,6-dihydro-T (34) 
5,6-dihydro-U:G/C/A>T (34) 
fapyG:C (34) 
8-oxo-G:C/G>T>A (34) 
fapyA:T (34) 
(5'R)-8,5'-cyclo-2'-deoxyadenosine (46) 
(5'S)-8,5'-cyclo-2'-deoxyadenosine (46) 
8-oxo-A:C (47) 
NEIL2 
 
nei endonuclease 
VIII-like 2  
(E. coli) 
252969 Q969S2 
Nucleus and 
Cytoplasm 
5-OH-U:G>T>A; 5-OH-C (32) 
5,6-dihydro-U:G/A (34) 
8-oxo-G:C/A (34) 
5,6-dihydrothymine (34) 
guanidinohydantoin (45) 
guanidinohydantoin (ss) (45) 
iminoallantoin (45) 
iminoallantoin (ss) (45) 
spiroiminodihydantoin (ss) (45) 
a
Target base on left in mismatches.   
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The glycosylases are most well known for their role in initiating BER by recognizing and 
removing DNA lesions.  However, recently there have been a series of reports on several 
glycosylases demonstrating essential functions of outside repair of DNA damage to prevent 
DNA mutations or cytotoxic DNA lesions.  The glycosylases MBD4 and TDG have been 
implicated as having important roles in organism development by affecting DNA methylation, 
particularly 5-methyl-cytosine (48, 49).  The mouse knockout of TDG was embryonic lethal, but 
likely not due to its role in BER from exogenous damage (48).  The authors presented a model 
for TDG and other glycosylases, particularly SMUG1, to be responsible for DNA methylation 
status of 5-methyl-cytosine (48).  The model predicts that 5-methyl-cytosine is present in nascent 
DNA and is specifically damaged by an oxidant-producing complex that includes the DNA 
glycosylase, TDG.  This local damage is then recognized by the TDG present in the complex.  
The lesion is then removed and replaced by a normal cytosine (48).  The specific types of 
damage to the 5-methyl-cytosine would dictate which glycosylases are required for methylation 
removal.  This is not the first time that investigators have hypothesized local endogenous DNA 
damage is essential for normal DNA metabolism and function.  Several reports have documented 
that the DNA glycosylase OGG1 is essential for transcriptional activation of v-myc 
myelocytomatosis viral oncogene homolog (MYC) and lysine (K)-specific demethylase 1A 
(KDM1A or LSD1) targeted proteins (50-52).  The proposed OGG1-dependent model is similar 
to the model described for TDG removal of 5-methyl-cytosine from DNA.  LSD1 demethylates 
histone H3 using its flavin containing catalytic site (50-52).  Removal of the methyl marks 
generates H2O2 as a byproduct of the demethylation reaction (50-52).  The locally produced 
H2O2 can damage the nearby DNA, creating oxidative DNA lesions.  These oxidative DNA 
lesions are recognized by the DNA glycosylases and of particular importance are the lesions 
  14 
recognized by OGG1.  OGG1 primarily removes one of the most studied oxidative DNA lesions, 
8-oxoguanine (8-oxodG) (15).  Removal of the 8-oxodG lesion by OGG1 and APE1 dependent 
cleavage of the DNA backbone yields a single strand break in the DNA, with the cleavage of the 
DNA backbone removing the physical constraints on the DNA giving access to the 
transcriptional machinery and initiating transcriptional activation of LSD1 target genes (50, 51).   
OGG1, TDG, and MBD4 are not the only DNA glycosylases with functions outside of 
BER.  Uracil-DNA glycosylase (UNG) plays a critical role in class switch recombination and 
somatic hypermutation (53).  Class switch recombination (also called isotype switching or 
immunoglobulin class switching) is the process by which a B-cell changes the constant version 
of the heavy chain (for example IgM to IgG), while keeping the same variable section of the 
heavy chain.  The switching of the isotype/class of antibodies from IgM to IgG yields the 
process’s name.  Although not fully explained, UNG is essential for this process and UNG 
knockout mice do not undergo class switch recombination and only express IgM antibodies (53).  
It was originally thought that Activation-Induced Deaminase (AID), which is also required for 
this process, deaminates many cytosines on the DNA where the class switch is to occur (53).  
Deaminating cytosines yields 2’-deoxyuridine as the product base recognized and removed from 
the DNA by UNG.  The resulting cluster of abasic sites are then hydrolyzed by APE1 leaving a 
double strand break (DSB).  The DSB is a substrate for repair by non-homologous end joining, 
which completes the class switch recombination by fusing the new constant heavy chain to the 
old variable heavy chain.   
This paradigm has been challenged by a series of elegant experiments demonstrating 
UNG’s catalytic activity is not required for class switch recombination and instead an unknown 
function of the glycosylase is required for the event (54).  To test if UNG’s glycosylase function 
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is required the uracil-DNA glycosylase inhibitor (Ugi), a specific peptide inhibitor of UNG from 
the bacteriophage Bacillus subtilis, was used to prevent uracil removal and DNA binding of 
UNG in human B-cells (54, 55).  These cells did have reduced ability to perform class switch 
recombination, but DNA cleavage was not prevented, as determined by the appearance of 
gamma-H2AX foci, suggesting an important aspect of UNG not related to its DNA binding and 
glycosylase activity is essential for the recombination (54).  The most convincing experiments 
were a series of separation of function point mutants that contained no glycosylase activity, but 
still had robust class switch recombination (54, 56).  There were several point mutants with 
undetectable catalytic activity, but still retained rates of class switch recombination comparable 
to wild-type protein (54, 56).  Further there were separation of function mutants with some UNG 
mutants which maintained glycosylase activity, but had the same class switch recombination 
rates as knockout cells (56).  Thus the N-terminal portion of UNG is essential for class switch 
recombination to fulfill an unknown function, while the glycosylase activity of UNG is 
dispensable, demonstrating an important purpose of UNG outside of BER (56).   
Another glycosylase BER independent function of UNG was reported to promote 
changes in chromatin structure (57).  The protein centromere protein A (CENP-A) is a histone 3 
variant, which is an essential protein due to its role in mitotic segregation.  CENP-A assembly 
was prevented by inhibiting UNG or reducing protein levels, while increasing UNG protein 
levels promoted CENP-A assembly (57).  While reducing UNG protein levels is not a lethal 
event, because UNG knockout mice are viable, it diminishes cellular replication, potentially due 
to delay in CENP-A assembly (57).  UNG also co-localizes to sites of DNA damage, gamma-
H2AX, and CENP-A, which is not surprising because it is a DNA repair protein (47).  It is 
intriguing to speculate that UNG can sense the DNA damage, since it has an affinity to damaged 
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DNA, and signal downstream repair via chromatin interactions.  The increase in CENP-A 
assembly and chromatin modifications could be the requirement of UNG for class switch 
recombination as both processes are independent of glycosylase activity.  The double strand 
break ends may require UNG dependent chromatin modification signaling to either signal for 
repair and recruitment of proteins or allow access of proteins to the recombination site.  While 
the DNA glycosylases are most well known for their function in BER, it is possible that all the 
glycosylases have other unknown functions important for organism survival independent of BER 
and discovering these functions remains an area of great interest.   
1.1.6 siRNA-Mediated Knockdown 
The ability to specifically target genes with interfering RNA to mediate knockdown has 
drastically changed our scientific capabilities.  There are several possible interfering RNA 
approaches such as short-interfering RNA (siRNA) or short-hairpin RNA (shRNA) that are 
exogenously introduced, or microRNA (miRNA) that are endogenously made by the cell.  The 
different RNA interference approaches have different starting points, but eventually merge 
pathways to share a common mechanism with several conserved steps.  For endogenously 
produced interfering RNAs, the initial pri-miRNA is transcribed before being processed by 
drosha, ribonuclease type III (DROSHA) to a shorter pre-miRNA in the nucleus.  This pre-
miRNA is then exported to the cytoplasm.  Once in the cytoplasm the pre-miRNA steps merge 
with that of exogenously introduced shRNAs.  The pre-miRNA or shRNA is then processed by 
dicer 1, ribonuclease type III (DICER1) to yield a twenty-one nucleotide double-stranded RNA 
that no longer contains a hairpin.  After this step, the pre-miRNA and shRNA steps merge with 
that of exogenously introduced siRNAs.  The subsequent siRNA is then incorporated into the 
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RNA-Induced Silencing Complex (RISC), which incorporates one of the siRNA strands into the 
complex.  Using the single stranded RNA, the RISC searches for complementary mRNAs to 
either inhibit their translation or to degrade the mRNAs.  An mRNA is targeted for degradation if 
it contains perfect complimentary sequence, while only partial complementation of the siRNA to 
the mRNA will inhibit the mRNA translation without being degraded.  Both mRNA degradation 
and inhibition of translation will decrease protein levels of the targeted gene.  Different mRNAs 
can be targeted by varying the siRNA sequence.  By using an siRNA containing 21 nucleotides 
and having 4 possible bases at each site yields a possible 4
21
 targeting sequences.  Although lack 
of perfect complimentary sequence still inhibits translation, it is still possible to create siRNAs 
targeting specific genes to limit off target possibilities and effects due to sequence specificity 
created by the siRNA sequence.  Thus large siRNA libraries targeting the entire genome can be 
designed and used to query if knockdown of specific genes impact a studied response.  To ensure 
off-target effects are not responsible for the phenotypic effects of siRNA-mediated knockdown, 
it is common to use at least two different sequences targeting the same gene and to generate the 
same phenotype.  The likelihood that two different siRNA sequences contain the same off-target 
gene to generate the desired phenotype is small.  Another method to eliminate studying siRNA 
off-target effects is to rescue the siRNA knockdown cells by expressing an siRNA resistant 
transcript to express the protein of interest.  This should diminish the phenotype observed by 
knockdown of the protein and demonstrate that specific knockdown of the gene is causing the 
studied phenotype.   
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2.0  MATERIAL AND METHODS 
2.1.1 Chemicals and Reagents 
DharmaFECT 2 transfection reagent and the siGENOME Non-Targeting siRNA #1 were 
from Dharmacon (Lafayette, CO). CellTiter-Blue Cell Viability Assay and CellTiter 96 
AQueous One Solution Cell Proliferation Assay were from Promega (Madison, WI). The 
Silencer Druggable Genome siRNA Library (Version 1.1) and 5x siRNA resuspension buffer 
were from Ambion (Austin, TX). Tissue culture-treated 384-well microtiter plates were from 
Greiner Bio-One (GmbH, Frickenhausen, Germany). OptiMEM, EMEM, phosphate buffered 
saline (PBS) and Hoechst 33342 were from InVitrogen (Carlsbad, CA). The shRNA vectors used 
for stable KD cell creation were obtained in glycerol stocks from Sigma-Aldrich. Temozolomide 
was from National Cancer Institute Developmental Therapeutics Program (Bethesda, MD). 
Puromycin was from Clontech Laboratories (Mountain View, CA) and gentamicin was obtained 
from Irvine Scientific (Santa Ana, CA). We used the following primary antibodies: UNG 
antibody (#MBS200056) was from MyBioSource (San Diego, CA) and PCNA antibody (#sc-56) 
was from Santa Cruz (Santa Cruz, CA). Secondary antibodies: GAM-HRP conjugates were from 
Bio-Rad (Hercules, CA). Signal generation substrates were from Bio-Rad (Hercules, CA) and 
Thermo Fisher Scientific (Waltham, MA). All electrophoresis reagents were from Bio-Rad 
(Hercules, CA). 
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2.1.2 Cell lines and culture conditions 
Cell line and culture conditions were as previously described (58). Briefly, T98G cells 
were cultured in EMEM with 10% heat-inactivated FBS, non-essential amino acids, sodium 
pyruvate, antibiotic/antimycotic and gentamicin.  The LN428 cells were cultured in alpha MEM 
(InVitrogen, Carlsbad, CA), 10% fetal bovine serum (Atlanta Biologics, Lawrenceville, GA), 
antibiotic/antimycotic (Sigma), gentamicin, L-glutamine (Sigma).  The LN428/XRCC1-KD and 
the LN428/GFP glioblastoma cell lines were cultured in the same media as the LN428 cells 
described above supplemented with 1 µg/mL puromycin (Sigma). The LN428/MPG cell line 
(LN428 cells modified for elevated expression of MPG) was cultured in the same media as the 
LN428 cells and supplemented with 600 µg/mL Geneticin (InVitrogen) and the 
LN428/MPG/XRCC1-KD glioblastoma cell line (LN428 cells modified for elevated expression 
of MPG and loss of XRCC1 expression) was cultured in the same media as the LN428 cells and 
supplemented with 600 µg/mL Geneticin (InVitrogen) plus 1 µg/mL puromycin (Sigma).   The 
HCT116 and SAOS-2 cells were cultured in McCoy’s 5A media (CellGro #10-050-CV) 
supplemented with 10% FBS and penicillin/streptomycin.  The MDA-MB-231 cells were 
cultured in RPMI 1640 (BW #12-702F) supplemented with 10% FBS and gentamicin.  The 
MCF-7 cells were cultured in EMEM (Invitrogen #11095-080) supplemented with 10% FBS, 
sodium pyruvate (Invitrogen), insulin (Invitrogen) and non-essential amino acids (Invitrogen).  
The U2OS cells were cultured in DMEM (CellGro# 10-013-CV) supplemented with 5% FBS, 
penicillin/streptomycin and L-glutamine.  The A-172, M059J and M059K cells were cultured in 
D-MEM-glucose (Invitrogen #11960-044) with 10% FBS, penicillin/streptomycin and Glutamax 
(Invitrogen# 35050-061).  The DBTRG5-MG cells were cultured in RPMI (CellGro # MT10-
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040-CV) supplemented with 10% heat-inactivated FBS, glutamine, penicillin/streptomycin, 
Hepes buffer solutions (Invitrogen # 15630-080) and non-essential amino acids.   
2.1.3 Screen siRNA transient transfection and temozolomide treatment 
Transient transfection by siRNA was as previously described (58, 59). Briefly, T98G 
cells were wet-reverse transfected with the Ambion Silencer Druggable Genome siRNA library. 
The library consisted of siRNAs targeting 5,520 different genes. Three unique siRNA duplexes 
targeting the same gene were pooled into a single well. Therefore, the siRNA knockdown 
targeted one gene in each well. The siRNA were prepared with DharmaFECT2 and OptiMEM 
and split evenly into two, 384-well plates. T98G cells were added directly to the siRNA 
complexes. The plates were incubated for five hours at 37ºC with 5% CO2 before the media was 
removed and replaced with fresh complete media.  
Cells were incubated at 37ºC with 5% CO2 for 48 hr after siRNA transfection in a 
humidified incubator to allow for gene silencing before addition of TMZ or vehicle. After 
incubation, the media was removed from the cells and replaced with fresh media containing 
either dimethyl sulfoxide (DMSO) vehicle (final concentration 1.0%) or the approximate EC10 of 
TMZ (final concentration 1 mM in 1% DMSO). Cells were incubated at 37ºC with 5% CO2 in 
the presence of TMZ for 48 hrs in a humidified incubator. Cell viability was measured 96 hours 
after siRNA transfection with the CellTiter-Blue viability assay according to manufacturer’s 
protocol. 
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2.1.4 Data analysis 
The siRNA screen was performed 3 times over 6 separate weeks. Fluorescence units from 
each well were normalized to plate negative controls (scrambled siRNA) enabling cell viability 
comparisons between different plates. Data was analyzed by creating a high confidence hit list as 
described previously (60). Briefly, cell viabilities for each targeting gene from the three 
screening replicates were averaged and data was analyzed using two statistical analysis methods. 
For each gene, a two-sample t-test was performed to determine if there was a sensitization effect 
on cellular survival between ‘siRNA plus vehicle’ treated cells as compared to ‘siRNA plus 
TMZ’ treated cells.  We selected targeting siRNAs with a p-value less than or equal to this 
threshold.  
Also, viability ratios (ratio of survival of ‘siRNA plus TMZ’ to ‘siRNA plus vehicle’) 
were calculated for each targeting siRNA to determine the magnitude of response between the 
two screening conditions (Equation 1). 
Equation 1: (siRNA+TMZ)/(siRNA+vehicle) = viability ratio 
The viability ratios were sorted in descending order and targeting siRNAs with a viability 
ratio in the lowest 5th percentile were selected for further analysis. The targeting siRNAs 
identified by both methods (p-value ≤ 0.05 and viability ratio in the lowest 5th percentile) were 
included in the final high-confidence hit list for further analysis and validation.   These methods 
produced an overlap of approximately 10%.   
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2.1.5 Pathway analysis and network visualization 
The hit list created from the screening data was further analyzed for pathway enrichment 
and network visualization. Several different programs were used to analyze and visualize the 
data including NIH DAVID (DAVID), Princeton GO term finder and Ingenuity Pathway 
Analysis (IPA). DAVID and Princeton GO term finder both classify genes based on their gene 
ontology (GO) (61-63). Each gene can have multiple classifications that are dependent on the 
gene’s molecular function, biological process, or cellular compartment and are referred to as 
“GO terms” (62). These classifications enable one to determine if certain GO terms are over 
represented or enriched in the hit list (61, 62). Groups of genes with the associated GO terms that 
are enriched are more likely to be true hits because multiple genes affecting the same process all 
yield sensitization and lend insight into which pathways are most affected since many genes with 
similar functions impact response (61, 64). The gene enrichment calculations used the 5,520 
genes screened as the background, due to the relatively small number of genes screened, instead 
of the entire human genome. The analysis with NIH DAVID was performed using multiple 
classification stringencies, gene ontology hierarchies, protein interaction databases and pathways 
to obtain insight into the biological pathways involved in TMZ resistance. The hit list was also 
analyzed with IPA (Ingenuity
®
 Systems, www.ingenuity.com), utilizing a proprietary, manually 
curated, interaction database. The Functional Analysis identified the biological functions that 
were most significant to the data set. Right-tailed Fisher’s exact test was used to calculate a p-
value determining the probability that each biological function assigned to that data set is due to 
chance alone. Because IPA utilizes a different scheme and algorithm to organize proteins into 
networks not based on GO terms, it was used as a separate method to analyze the hit list for 
enriched protein functions and networks. Fisher’s exact test was used with α = 0.05 to compute 
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the probability of correct functional assignment for the genes in the hit list. The enriched 
networks created by IPA were visualized with genes serving as nodes and edges representing 
known interactions. Genes colored green modulate toxicity to alkylating agents as determined in 
the screen. 
2.1.6 Generation of lentiviral single knockdown cell lines 
The shuttle vectors for expression of shRNA were from Sigma (St. Louis, MO). 
Lentiviruses were prepared in collaboration with the UPCI Lentiviral facility. Lentiviral particles 
were generated by co-transfection of 4 plasmids [the shuttle vector plus three packaging 
plasmids: pMD2.g(VSVG), pVSV-REV and PMDLg/pRRE] into 293-FT cells (65, 66) using 
FuGene 6 Transfection Reagent (Roche, Indianapolis, IN), as described previously (67). Forty-
eight hours after transfection, lentivirus-containing supernatant was collected and passed through 
0.45µM filters to isolate the viral particles. Lentiviral transduction was performed as described 
earlier (67). Briefly, 6.0  104 cells were seeded into a 6-well plate 24 hours before transduction. 
Cells were transduced for 18 hours at 32˚C and then cultured for 72 hours at 37˚C. Cells were 
then selected by culturing in growth media with 1.0 μg/mL puromycin, as previously described 
(67). 
2.1.7 Generation of lentiviral double knockdown cell lines 
The dual targeting of UNG and UBE3B by different lentiviral shRNA was done by first 
creating a stable UBE3B knockdown cell lines as described above.  This cell line was then 
transduced using the above procedure, with a lentivirus expressing GFP or a lentivirus 
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expressing GFP and  shRNA against UNG.  The cells were incubated for 4 days after 
transduction before selecting for cells expressing GFP or GFP with UNG shRNA using 
Fluorescence Activated Cell Sorting (FACS).  The isolated GFP-expressing cells were incubated 
at 37°C for 48 hours before being analyzed for UBE3B and UNG mRNA expression.   
To create double knockdowns using UBE3B knockdown single cell clones, the 
population of the UBE3B knockdown cell line was single cell cloned by limiting dilution.  
UBE3B knockdown cells were seeded at a concentration of 3 cells per mL of media into 96 well 
plates at a volume of 100 µL of cell solution per well.  The plates were incubated at 37°C for a 
week before single cell colonies were determined by visual inspection.  Single cell colonies were 
expanded before quantifying UBE3B mRNA levels.  Clones with low levels of UBE3B were 
transduced with lentivirus GPF control or GFP and UNG shRNA virus as described above.  Cells 
were FACS sorted for GFP expression and incubated for 48 hours before quantification of UNG 
and UBE3B mRNA levels.   
2.1.8 Quantitative RT-PCR analysis 
Expression of mRNA for each of ten glycosylases and five protein modification genes 
(OGG1, SMUG1, MBD4, UNG, MYH, NTHL1, MPG, NEIL1, NEIL2, NEIL3, UBE3B, ICMT, 
B4GALT7, CHRM3, and PADI1) after shRNA-mediated knockdown was measured by 
quantitative RT-PCR (qRT-PCR) using an Applied Biosystems StepOnePlus system as described 
previously (67). Applied Biosystems TaqMan® Gene Expression Assays used are as follows: 
human OGG1: Hs00213454_m1; human SMUG1: Hs00204820_m1; human MBD4: 
Hs00187498_m1; human UNG: Hs00422172_m1; human MYH: Hs01014856_m1; human 
NTHL1: Hs00267385; human MPG: Hs01012594_m1; human NEIL1: Hs0022637_m1; human 
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NEIL2: Hs00376746_m1; human NEIL3: Hs00217387_m1; human UBE3B: Hs00296200_m1; 
Human ICMT: Hs00202655_m1; Human B4GALT7: Hs01011258_m1; Human CHRM3: 
Hs00265216_s1; Human PADI1: Hs00203458_m1. Gene expression of each gene was 
normalized to the expression of human ß-actin (part #4333762T).  When comparing qRT-PCR 
data across multiple cell lines, the mRNA was normalized to T98G or T98G/GFP mRNA 
expression.   
2.1.9 Cell extract preparation and immunoblot 
Nuclear extracts were prepared and protein concentrations were determined as described 
previously (67). Fifteen micrograms of protein was loaded on a pre-cast 4-20% Tris-Glycine gel 
(InVitrogen, Carlsbad, CA). The following primary antibodies were used in immunoblot assays: 
anti-human UNG from MyBioSource.com (#MBS200056), anti-human MPG (Mab; clone 506-
3D) (67), anti-XRCC1 (Bethyl Labs; Montgomery, TX) and anti-human proliferating cell 
nuclear antigen (PCNA; Santa Cruz Biotechnology). Immunoblot membranes were stripped 
before re-probing for PCNA. The membranes were stripped with Restore PLUS Western Blot 
Stripping buffer (#46430) from Thermo Fisher Scientific (Waltham, MA) per the manufacturer’s 
instructions.  Immunoblots quantified by densitometry analysis were scanned and quantified 
using NIH ImageJ and the associated analysis software package, normalizing the expression 
across the four cell lines to the LN428/MPG cell line and to the expression of PCNA within each 
sample.   
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2.1.10 DNA glycosylase molecular beacon activity assay and design 
All oligodeoxyribonucleotides in the molecular beacon assay were purchased from 
Integrated DNA Technologies (Coralville, USA) as shown below (Table 5, Table 6, Table 7). 
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Table 5. Initial Design of Molecular Beacons 
Name 3’ Modifier Sequence Modified Base 5’ Modifier Target 
FD-Con 6-FAM 
GCACTATTGAATTGACACGCCATG
TCGATCAATTCAATAGTGC 
- Dabcyl Control Oligo 
FD-UNG1 6-FAM 
GCACTXAAGAATTGACACGCCATG
TCGATCAATTCTTAAGTGC 
2'-deoxyUridine Dabcyl UNG 
FD-MPG1 6-FAM 
GCACTXTTGAATTGACACGCCATG
TCGATCAATTCAATAGTGC 
Ethenoadenine (εA) Dabcyl MPG 
FD-MPG2 6-FAM 
GCACTXTTGAATTGACACGCCATG
TCGATCAATTCAATAGTGC 
Hypoxanthine (Inosine) Dabcyl MPG 
FD-THF 6-FAM 
GCACTXTTGAATTGACACGCCATG
TCGATCAATTCAATAGTGC 
THF, tetrahydrofuran (Abasic site 
mimic) 
Dabcyl APE1 
6-FAM is carboxyfluorescein and Dabcyl is 4-(4’-dimethylaminophenylazo) benzoic acid.  Target base is labeled bold and 
underlined and base opposite target base is labeled with bold and italics.  MYH removes A opposite 8oxoG while OGG1 removes the 
8oxoG lesion.   
 
Table 6. Molecular beacons designed for measuring DNA repair rates in vivo.   
 
Name 3’ Modifier Sequence Modified Base 5’ Modifier Target 
FD-Con3-
Cy5 
6-FAM 
CCACTATTGAATTGACACGCC/Cy5
/ATGTCGATCAATTCAATAGTGG 
-, also contains a Cy5 in hairpin Dabcyl Control Oligo 
FD-dU/A-
Cy5 
6-FAM 
CCACTXTTGAATTGACACGCC/Cy5
/ATGTCGATCAATTCAAAAGTGG 
2'-deoxyUridine, also contains a Cy5 
in hairpin 
Dabcyl UNG, SMUG1 
6-FAM is carboxyfluorescein and Dabcyl is 4-(4’-dimethylaminophenylazo) benzoic acid.  The target base is bold while the base 
opposite the target base is bold and underlined.  MYH removes A opposite 8oxoG while OGG1 removes the 8oxoG lesion.   
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Table 7. Improved Molecular Beacon design and structure. 
Name 3’ Modifier Sequence Modified Base 5’ Modifier Target 
FD-Con2 6-FAM 
CCACTATTGAATTGACACGCCATGT
CGATCAATTCAATAGTGG 
- Dabcyl Control Oligo 
FD-THF2 6-FAM 
CCACTXTTGAATTGACACGCCATGT
CGATCAATTCAATAGTGG 
THF, tetrahydrofuran (Abasic site 
mimic); opposite a 'T' 
Dabcyl APE1 
FD-THF2/G 6-FAM 
CCACTXTTGAATTGACACGCCATGT
CGATCAATTCAAGAGTGG 
THF, tetrahydrofuran (Abasic site 
mimic); opposite a 'G' 
Dabcyl APE1 
FD-THF2/A 6-FAM 
CCACTXTTGAATTGACACGCCATGT
CGATCAATTCAAAAGTGG 
THF, tetrahydrofuran (Abasic site 
mimic); opposite a 'A' 
Dabcyl APE1 
FD-THF2/C 6-FAM 
CCACTXTTGAATTGACACGCCATGT
CGATCAATTCAACAGTGG 
THF, tetrahydrofuran (Abasic site 
mimic); opposite a C' 
Dabcyl APE1 
FD-8oxoG/C 6-FAM 
CCACTXTTGAATTGACACGCCATGT
CGATCAATTCAACAGTGG 
8-oxoguanine (8-oxo-7,8-dihydro-
2’-deoxyguanosine ); opposite C 
Dabcyl OGG1 
FD-8oxoG/A 6-FAM 
CCACTXTTGAATTGACACGCCATGT
CGATCAATTCAAAAGTGG 
8-oxoguanine (8-oxo-7,8-dihydro-
2’-deoxyguanosine ); opposite A 
Dabcyl 
OGG1 and 
MYH 
FD-C/8oxoG 6-FAM 
CCACTCTTGAATTGACACGCCATGT
CGATCAATTCAAXAGTGG 
C opposite 8-oxoguanine (8-oxo-
7,8-dihydro-2’-deoxyguanosine ) 
Dabcyl OGG1 
FD-A/8oxoG 6-FAM 
CCACTATTGAATTGACACGCCATGT
CGATCAATTCAAXAGTGG 
A opposite 8-oxoguanine (8-oxo-
7,8-dihydro-2’-deoxyguanosine ) 
Dabcyl 
OGG1 and 
MYH 
FD-Tg/A 6-FAM 
CCACTXTTGAATTGACACGCCATGT
CGATCAATTCAAAAGTGG 
Thymine glycol (5,6-dihydroxy-
5,6-dihydrothymine ); opposite A 
Dabcyl NEIL1 
FD-5FU 6-FAM 
CCACTXTTGAATTGACACGCCATGT
CGATCAATTCAAAAGTGG 
5-fluoro-uracil (5FU) Dabcyl 
UNG,TDG, 
SMUG1 
FD-5HMDU 6-FAM 
CCACTXTTGAATTGACACGCCATGT
CGATCAATTCAAAAGTGG 
5-hydroxymethyl-2'-deoxyuridine Dabcyl SMUG1 
FD-Hx 6-FAM 
CCACTXTTGAATTGACACGCCATGT
CGATCAATTCAATAGTGG 
Hypoxanthine (Inosine) Dabcyl MPG 
FD-dU/A 6-FAM 
CCACTXTTGAATTGACACGCCATGT
CGATCAATTCAAAAGTGG 
2'-deoxyUridine Dabcyl UNG, SMUG1 
6-FAM is carboxyfluorescein and Dabcyl is 4-(4’-dimethylaminophenylazo) benzoic acid.  Target base is labeled bold and 
underlined and base opposite target base is labeled with bold and italics.  MYH removes A opposite 8oxoG while OGG1 removes 
the 8oxoG lesion.   
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The molecular beacon design underwent several changes during optimization and testing.  
The basic design was similar, including the carboxyfluorescein (6-FAM) fluorophore and 4-(4’-
dimethylaminophenylazo) benzoic acid (Dabcyl) quencher used.  All the molecular beacons are 
designed to form a stem-loop structure containing a 13-nucleotide loop and a 15 base pair stem 
forcing the 6-FAM fluorophore (at the 5’ end) and the Dabcyl quencher (at the 3’ end) into close 
proximity.   The close proximity of 6-FAM and Dabcyl enables quenching of the 6-FAM signal 
in a non-fluorescent manner via Fӧrster Resonance Energy Transfer (FRET) (68, 69).  However, 
if the base lesion (in Figure 1 this is ethenoadenine) is removed by a DNA glycosylase (in 
Figure 1 this is MPG) and the DNA backbone is hydrolyzed by APE1, the 6-FAM containing 
oligonucleotide (5 bases in length) will dissociate from the hairpin at 37˚C (Figure 1).  The 6-
FAM dissociation from the DNA hairpin prevents the quenching by Dabcyl. The increase in 6-
FAM-mediated fluorescence is proportional to base lesion (e.g. ethenoadenine) removal.  Any 
increase in fluorescence in control beacon containing a normal base is the result of non-specific 
DNA backbone cleavage. 
 
Figure 1. Model of Molecular Beacon mechanism.   
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The molecular beacon forms a DNA hairpin bringing the 6-FAM fluorophore near the Dabcyl quencher, enabling 
efficient quenching of 6-FAM.  The DNA lesion can be recognized and removed by a DNA glycosylase leaving an 
abasic site.  The abasic site is a substrate for APE1 that cleaves the DNA backbone enabling dissociation of the 6-
FAM fluorophore containing oligonucleotide from the other DNA strand.  The increase in distance of 6-FAM from 
Dabcyl eliminates the quenching of Dabcyl.  The increase in 6-FAM fluorescence is measured and is proportional to 
the amount of DNA lesion removed by the DNA glycosylase.   
 
To ensure that the beacons correctly adopted a stem-loop structure, each was incubated at 
95°C for 3 min.  The beacons were removed from the heat and allowed to slowly cool overnight 
to room temperature in an insulated container. Once the hairpin was formed, minimal measurable 
fluorescence was detected (Figure 2) and the hairpin was stable at 37°C for greater than 120 
min.  However, when heated, the hairpin unfolds, resulting in maximum fluorescence intensity 
(Figure 3). Nuclear protein extracts were prepared as described above.   
  
 
Figure 2. Background normalized fluorescence values for molecular beacons stay constant.   
After annealing the beacons overnight, we incubated the beacons in the absence of lysate at 37°C and graphed 
normalized fluorescence values.  The fluorescence values vary little during the duration of the experiment, 
demonstrating the stability of both the DNA structure and the dye/quencher pair contained in the beacons at 37°C.  
There is some photobleaching at later time points, but this is expected when taking rapid fluorescent measurements 
and why we subtract out this background from the experimental wells.   
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Figure 3. Melt curve data for FD-Con2 molecular beacon. 
After annealing the beacons overnight, we performed at melt curve on the beacons to ensure they adopted the same 
secondary structure.  The melt curve was done by heating various concentrations of the beacons in 0.5°C increments 
and measuring 6-FAM fluorescence at each 0.5°C step.  The 6-FAM was measured because as the beacon is heated 
the DNA will dissociate from its stem-loop structure, increasing the distance between the 6-FAM fluorophore and 
Dabcyl quencher yielding an increase in fluorescence.  The maximum fluorescence is obtained when all the beacons 
are no longer in a stem-loop structure.  The beacons have a temperature dependent decrease in fluorescence.  This is 
seen after 75°C for this beacon and is believed to be from the high heats affecting the dye, not from stem-loop 
formation at higher temperatures.   
 
Approximately 500 μL of nuclear protein extracts were dialyzed twice using the 7,000 
molecular weight cut-off Slide-A-Lyzer Dialysis Cassette (Pierce; Rockford, IL).  The samples 
were dialyzed for 90 min at 4°C in the following buffer: 50 mM Hepes pH7.5, 100 mM KCl, 0.5 
mM EDTA, 20% Glycerol and 1 mM DTT.  The reaction solution, samples and beacons were 
chilled to 4°C and mixed on ice to prevent initiation of the reaction before beginning to record 
data.  Reactions were performed at 37°C using 10 μg of dialyzed protein extract and beacon 
substrate (final conc. = 40 nM) in the following buffer: 25 mM HEPES-KOH pH7.8, 150 mM 
KCl, 0.5 mM EDTA, 1% Glycerol, 0.5 mM DTT. For initial experiments, fluorescence was 
measured every 20 seconds for 60 minutes, using a StepOnePlus real-time PCR system and 
expressed as arbitrary units (AU).  When normalizing the molecular beacons, several steps were 
added. After measuring fluorescence every 20 seconds for 60, 90 or 120 min at 37°C to 
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determine DNA repair rate, the beacons were incubated sequentially at 60°C, 65°C, 70°, 75°C, 
80°C for 5 min at each temperature.  The fluorescence was measured every 20 sec at each step to 
determine the maximum possible fluorescence for each beacon in each individual well.  The 
temperatures selected for these measurements encompassed the maximum fluorescence possible 
for each beacon as determined by previous melting assay experiments.     
2.1.11 Molecular Beacon Data Analysis 
2.1.11.1 Initial Analysis Methodology 
The fluorescence data were analyzed to enable comparisons across cell lines and for 
comparison of control and lesion-containing BER beacons. We eliminated the background 
fluorescence due to incubation of the beacon alone by subtracting the fluorescence values of a 
control well containing no protein extract from all wells using that molecular beacon. An 
example of the background fluorescence values is seen in Figure 2.  To enable comparisons 
across different cell lines, molecular beacons, and trials, we selected the fluorescence value of 
the 5-min time point as the zero value for each well. We subtracted this value from all other time 
points in that well so all graphs begin from zero AU and 5 min after initiating the reaction. Five 
minutes was selected as the point from which to begin comparisons, because time points earlier 
than 4 min contained variations in absolute fluorescence measurements independent of the 
molecular beacon and cell line (not shown). Five minutes was selected to eliminate the variable 
measurements and to facilitate valid comparisons between trials and conditions.  The mean of 3 
separate trials was plotted, with error bars representing the standard error of the mean. 
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2.1.11.2 Molecular Beacon Analysis by normalizing each well 
After measuring fluorescence every 20 seconds for 60, 90 or 120 min to determine DNA 
repair rates, the beacons were incubated sequentially at 60°C, 65°C, 70°, 75°C, 80°C for 5 min at 
each temperature.  The average fluorescence at each temperature was determined.  The 
maximum average fluorescence intensity in each well was used to normalize the beacon 
fluorescence in each corresponding well to account for pipetting error, well-to-well variability of 
measurements in the machine and machine-to-machine variability in fluorescence measurements.  
Under the likely assumption that maximum fluorescence intensity corresponds to the maximal 
possible fluorescence value when fully incised, these normalized data represent % free FAM (= 
% BER incised beacon).  The normalized fluorescence values were plotted as the mean of three 
independent experiments with error bars representing the SEM.   
2.1.12 Cell cytotoxicity assays 
2.1.12.1 Short-term MTS assay 
TMZ induced cytotoxicity was determined as described previously (12). Briefly, cells 
were seeded into 96-well plates at a density of 2,000 cells per well. Cells were treated with TMZ 
for 48 hours at 37˚C before determining the relative amount of metabolically active cells by an 
MTS assay. Results were the average of three separate experiments and normalized to vehicle 
treated control cells with error bars representing the standard error of the mean. 
MMS induced cytotoxicity was determined essentially as previously described (70).  
Briefly, cells were seeded into a 96-well plate at a density of 2,000 cells per well.  Cells were 
treated with MMS for 4 hours at 37°C.  MMS containing media was then removed and replaced 
with fresh media.  Cells were incubated for a total of 48 hours at 37˚C before determining the 
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relative amount of metabolically active cells by an MTS assay. Results were the average of three 
separate experiments and normalized to vehicle treated control cells with error bars representing 
the standard error of the mean. 
2.1.12.2 Long-term CyQuant assay 
Cells were grown until approximately 50-75% confluence before being trypsinized and 
counted using a CASY counter per the manufacturer’s instructions.  Cells were seeded into 96-
well plates at a density of 125cells/well and incubated at 37˚C for 24 hrs.   The cells were treated 
with vehicle, TMZ or MNNG and incubated for nine days at 37˚C.  Plates were removed and 
fluorescence was determined using the CyQuant kit (InVitrogen, #C7026) following the 
manufacturer’s instructions.  Results were the average of two separate experiments and 
normalized to vehicle treated control cells with error bars representing the standard error of the 
mean. 
2.1.13 Cross species analysis of alkylation screens 
The enriched biological process information associated with our TMZ screen was 
compared to other alkylation screens reported for S. cerevisiae and E. coli.  Our cross species 
analysis was performed similar to as reported (71).  Briefly, to determine if the same gene 
ontology biological processes were enriched in the alkylation sensitive hit lists from all three 
organisms, representing X number of genes, we aligned GO-terms from each organism.  To 
identify GO-terms significantly enriched for alkylation sensitive genes from all three organisms 
we randomly sampled X genes from the complete search space for each screen and identified 
associated GO functional terms.  Random sampling was performed over two hundred iterations 
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and the average number of hits in each GO category and the standard deviation were determined. 
These values were than compared to the actual values to identify GO terms significantly (P < 
0.05) enriched for alkylation sensitive genes from all three organisms.  The molecular functions 
and the corresponding genes, which were significantly enriched in all three alkylation screen data 
sets, were then visualized using Cytoscape (72). Genes which modulate alkylator toxicity from 
E. coli (dark blue), S. cerevisiae (light blue) and human (light green), all served as protein nodes, 
with enriched GO terms serving as central nodes. The edges between GO terms and genes 
demarcate which genes are annotated to that biological process. 
2.1.14 Generation of yeast knockout and viability analysis 
Media preparation and other yeast manipulations were performed using standard 
methods.  Mutants were made using a G418 knockout cassette from the S. cerevisiae Gene 
Deletion Project and were selected on Yeast Peptone Dextrose (YPD) plates containing G418 
(200 mg/ml).  A mag1Δ mutant was also made using a URA3 based strategy, with selection 
occurring on Synthetic Defined media lacking uracil (SD-URA).  Mutants were confirmed by 
PCR. Plate based MMS viability studies were performed as previously reported (73). 
2.1.15 Transient siRNA knockdown for validation studies 
We performed a wet-reverse transfection of the T98G cells in six-well plates using 
siPORT NeoFX (Applied Biosystems) per the manufacturer’s instruction.  Briefly, the siRNA 
was diluted to a working concentration of 2µM before being used.  The siPORT NeoFX was 
mixed with OptiMEM and incubated at room temperature for 15 min.  The siRNA was then 
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mixed with the OptiMEM and siPORT NeoFX solution and incubated at room temperature for 
another 10 min.  The siRNA mixture was then plated into the wells.  Cells were added to the 
plates for a concentration of 300,000 cells per well and an siRNA final concentration of 90nM.  
The cells were incubated for 24 hrs at 37°C before replacing transfection media with fresh 
media.  Forty-eight hours after transfection cells were trypsinized and seeded for mRNA 
quantification and MTS cytotoxicity assays as described above.  For knockdown of UNG and 
UBE3B the following Silencer Select siRNAs from Applied Biosystems were used: UNG: 
s14679; UBE3B: s40200; Silencer Negative control v2: am4613. 
2.1.16 Cloning of UBE3B 
The LN428 cells were seeded at 2x10
6
 cells per 100 mm dish and incubated until they 
reached approximately 70% confluence.  The RNA was purified using the RNeasy Mini Kit 
(Qiagen, #217004) as per the manufacturer’s instructions.  The RNA concentration was 
measured using a NanoDrop spectrophotometer.  Three μg of RNA was reverse transcribed to 
create cDNA using the SuperScript III first-Strand synthesis kit (Invitrogen, #18080-400) and an 
Oligo(dT)20 primer in a 20 μl reaction following the manufacturer’s instructions.  The product 
cDNA was diluted tenfold before being used for cloning.   
The primers were designed using the published UBE3B sequence from PubMed and 
guidelines provided in the pENTR cloning kit.  The primers were tested for self-annealing, 
hairpin formation, and primer-dimers using the MacVector program.  The PCR reaction was run 
as per the manufacturer’s instructions.  The PCR product was quantified using a NanoDrop 
spectrophotometer, before being run on a 1% agarose gel.  PCR products with an expected base 
pair size (3200 base pairs) were cloned into the pENTR plasmid.  The resulting plasmid was then 
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used to transform E. coli bacteria that were plated onto kanamycin plates.  Four clones were 
picked and grown to purify the plasmid DNA.  The plasmid DNA purified using a Qiagen 
miniprep kit from all four clones were then sent for double coverage sequencing using 
sequencing primers that were independent of initial cloning primers.  The sequences obtained 
were then compared to the published PubMed sequence.  The sequence of the primers used for 
cloning and sequencing can be found below (Table 8).   
Table 8. Cloning and Sequencing Oligonucleotides for UBE3B 
Cloning Oligonucleotides 
Oligo Name Sequence 
UBE3B-1-37 CACCATGTTCACCCTGTCTCAGACCTCGAGAGCATGG 
UBE3B-3192-3155-R CTAGGAGAGTTCAAAGCCCGTGTTCATGCTGATGGCG 
Sequencing Oligonucleotides 
UBE3B-503-522 CCTTCACAGACACTTCAACG 
UBE3B-983-1002 AGGAGGAGACAGATGGGTTC 
UBE3B-1478-1497 CCAAACTGTGGGCATTTATC 
UBE3B-1736-1754 TTGTAGAGAACGCCAAGGG 
UBE3B-2251-2274 AAGACAACCAGTGGGGATGAGAGG 
UBE3B-2714-2732 CCATTATCAAACCCGAGTG 
UBE3B-354-334-R CACATACCACACCTTAGGCTC 
UBE3B-772-753-R TGATGTGGATGAGGAACGGC 
UBE3B-1112-1094-R TCCACAGATTGGGAGAACC 
UBE3B-1477-1457-R GAAGCAGGTCATCAAGGTAAG 
UBE3B-1999-1980-R TCTCCTTCTCCTTGGTAACC 
UBE3B-2415-2397-R AAGCAGTTGGCTCAGGAAG 
UBE3B-2840-2821-R TGGAAACCACCGTAGTAGAC 
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3.0  SYNTHETIC LETHAL SCREEN OF T98G CELLS USING TEMOZOLOMIDE 
AND SIRNA 
3.1 INTRODUCTION 
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain 
tumor (6). Temozolomide (TMZ), radiation and surgery are currently used for treatment of 
GBM, yet median survival is still less than 2 years (3-5).  Chemotherapy resistance and 
difficulties in surgical removal contribute to poor prognosis (6).  TMZ methylates several bases 
in DNA, including the O
6
 position of guanine (O
6
-MeG), the N7 position of guanine (N7-MeG) 
and the N3 position of adenine (N3-MeA).  Two of the lesions (N7-MeG and N3-MeA) account 
for greater than 80% of the DNA lesions induced by TMZ, yet result in negligible clinical 
toxicity due to robust repair mechanisms (13). These lesions are predominantly repaired by the 
base excision repair (BER) pathway, a DNA repair mechanism that involves as many as 20 
different proteins (26). BER is initiated by one of eleven lesion specific DNA glycosylases (28). 
For example, methylpurine DNA glycosylase (MPG) recognizes and removes the N7-MeG and 
N3-MeA lesions that are induced by TMZ (15). The resulting abasic site is a substrate for AP 
endonuclease (APE1), which cleaves the sugar phosphate backbone, leaving a 3’OH and a 5’-
deoxyribose-phosphate moiety (15). Poly (ADP-ribose) polymerase 1 (PARP1) recognizes and 
binds the nick or single strand break (SSB), which activates PARP1 to recruit downstream 
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proteins such as X-ray repair cross complementing group 1 (XRCC1) and DNA polymerase ß 
(Polß) (26). Polß is recruited by XRCC1 and PARP1 to hydrolyze the 5’-deoxyribose-phosphate 
and fill the nucleotide gap, followed by ligation mediated by the XRCC1/DNA ligase III 
heterodimer (26) or DNA ligase I (74).  
Virtually all of TMZ’s clinical cytotoxicity is attributable to the O6-methylguanine (O6-
MeG) lesion, which accounts for approximately 5% of TMZ induced lesions (13). The O
6
-MeG 
lesion is repaired via a direct reversal mechanism by the protein O
6
-methylguanine-DNA 
methyltransferase (MGMT), which transfers the O
6
-methyl group from the guanine base onto a 
Cys residue in the MGMT protein (16). If the O
6
-MeG lesion is not removed by MGMT, during 
cellular replication the mis-pairing of O
6
-MeG with thymine is detected by the mismatch repair 
enzymes, triggering apoptosis signaling and cytotoxicity (13, 17, 18). However, 5-year survival 
rates still remain low in TMZ treated patients (4, 5), and TMZ resistance and/or recurrence with 
chemotherapy resistant tumors is common.  Resistant cells can harbor mutations in mismatch 
repair proteins such as the mutS homolog 6 (MSH6) (19) or have elevated expression of MGMT 
(as in the T98G cell line) (20).  Earlier endeavors to enhance TMZ efficacy by using MGMT 
inhibitors to prevent the repair of O
6
-MeG lesions have not shown an increase in sensitivity or 
efficacy in clinical trials (21, 23), especially in TMZ-resistant GBM (22, 24, 25).   
 Because GBM tumors can be resistant to TMZ therapy and recurring tumors may 
acquire resistance to the O
6
-MeG lesion, we explored novel mechanisms of TMZ resistance in 
tumor cells independent of the O
6
-MeG lesion (17, 75). To discover genes that sensitize cells to 
TMZ, we undertook a synthetic lethal screen using Ambion’s Silencer® Human Druggable 
Genome siRNA library, the chemotherapeutic agent TMZ and the T98G cell line, a TMZ 
resistant cell line derived from a GBM tumor (76).  We determined that several biological 
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pathways were enriched for TMZ sensitizing genes, including proteins involved in BER, 
response to DNA damage, cellular proliferation, and protein modification.  Many similar 
biological processes were also highly enriched in DNA alkylation screens performed in 
Saccharomyces cerevisiae and Escherichia coli (77, 78).  We combined the selected hits from all 
three species and performed a functionome analysis to identify significantly enriched biological 
processes conserved across all three organisms (71). We created a cross-species network 
representing the shared alkylation response from bacteria, yeast and humans and suggest that this 
network represents an Alkylation Functionome that includes many novel proteins not previously 
thought to impact TMZ or MMS resistance.  Our identification of evolutionarily conserved 
mechanisms affecting TMZ sensitivity suggests that although many proteins and processes 
impact sensitivity to alkylators, several critical survival pathways can be targeted to improve 
chemotherapy efficacy.  Simultaneous inhibition of both DNA repair and protein modification 
processes in yeast yielded greater sensitivity to alkylating agents than inhibition of either process 
alone. However, knockdown of both protein modification and DNA repair genes did not have an 
increased effect on alkylation-induced toxicity in human cells.  This potential epistatic 
interaction between the ubiquitin protein ligase E3B (UBE3B) and the DNA repair protein 
uracil-DNA glycosylase (UNG) suggests they may be in the same survival pathway.  Many DNA 
repair genes are regulated by ubiquitylation and several crucial DNA repair proteins are E3 
ligases such as BRCA1 (79-82).  UBE3B previously has not been implicated in DNA repair or 
alkylation survival and elucidating its role and substrates will be important to discover how it 
improves alkylation survival.  The highly conserved functionome enriches for essential genes in 
critical biological processes, thus also enriching for possible gene interactions in these crucial 
processes.  Importantly, the biological processes and corresponding genes identified in our 
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functionome analysis represent novel potential drug targets to increase TMZ efficacy 
independent of O
6
-MeG mediated toxicity as well as potential epistatic relationships that would 
provide mechanistic insight into the function of specific activities. 
3.2 RESULTS 
3.2.1 Synthetic lethal siRNA screen and generation of high confidence hit list 
To identify genes that when silenced confer sensitivity to the alkylating agent TMZ we 
conducted a synthetic lethal screen (in triplicate) on a TMZ-resistant GBM cell line (T98G) 
using TMZ and an siRNA library (Figure 4A). A concentration of 1 mM TMZ was selected due 
to minimal (~10%) toxicity measured at 48 hrs via an MTS assay. Further, T98G cells were 
treated with varying concentrations of DMSO to determine the impact of DMSO on cell survival 
(Figure 4B). No toxicity was observed at 1% DMSO after 48 hrs; this was the percentage of 
DMSO used for both vehicle and TMZ treatment in the screen.  
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Figure 4. Screen methodology, vehicle effects to verify screening conditions, and selection criteria.  
(A) A wet-reverse transfection was used to knockdown genes with siRNA.  Transfection consisted of 3 siRNAs 
targeting the same gene in every well.  Transfection reagents were mixed and split into two different plates before 
the addition of T98G cells to the plates.  After 48hrs one plate was treated with 1mM TMZ in DMSO (1% DMSO, 
final concentration) while the other was treated with 1% DMSO. (B) The vehicle (1%DMSO) is nontoxic after 48hrs 
of incubation before determining growth inhibition by an MTS assay. C) Methodology used to create high 
confidence hit list from two distinct methods 
 
The transfection conditions used in the screen maximized knockdown, similar to previous 
screens using these conditions (58). We first calculated viability ratios (ratio of survival of 
‘siRNA plus TMZ’ to ‘siRNA plus vehicle’) and normalized to vehicle-treated scrambled 
siRNA, enabling cross plate comparisons.  We then statistically analyzed the viability ratios and 
determined a group of gene targets that sensitized cells to TMZ by performing a two-tail sample 
t-test on each gene to determine the effect of siRNA and TMZ on cellular survival.  Targeting 
siRNAs were selected with a p-value of less than or equal to ≤ 0.05. The high confidence hit list 
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contained targets that satisfied both criteria: a p-value ≤ 0.05 and a viability ratio in the lowest 5 
percent (Figure 4C). By using these two methods, we created a hit list of 172 genes (Dataset 
S1). While most of the viability ratios on the hit list were between 0.4 and 0.65, these genes 
significantly modulated the toxicity of TMZ, yielding many new potential targets to increase 
response to alkylation chemotherapy.  All hits were analyzed for pathway and network 
enrichment to determine the potential biological pathways that modulated alkylation toxicity. 
3.2.2 Analysis of screen results for pathway and network enrichment 
The genes contained in the hit list were analyzed with NIH DAVID, Princeton GO term 
finder and Ingenuity Pathways Analysis (Ingenuity® Systems, www.ingenuity.com) (IPA) for 
pathway and network enrichment.  The analysis with DAVID and Princeton GO term finder was 
performed to search for gene enrichment in molecular functions, cellular compartments, or 
biological processes based on the associated gene ontology terms.  Each gene is linked to 
different terms based on their gene ontology in a hierarchical manner and gene enrichment was 
determined based on the probability of selecting proteins with similar terms. By focusing on the 
5,520 "druggable" genes we inherently expected a small but presumably more relevant and 
smaller gene enrichment dataset compared to probing the entire human genome as background. 
Several different thresholds for viability ratio percentiles were initially analyzed for gene 
enrichment, including 2.5%, 5%, 7.5% and 10% percentiles (Datasets S2-S4). The 5% group 
was selected for a more detailed analysis because it contained many of the gene enrichment 
groups seen in both the 7.5% and 10% datasets, but was more focused with higher gene 
enrichment scores.  
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The enriched genes from the NIH DAVID analysis contained several different groups 
including DNA repair, response to DNA damage stimulus, cell proliferation, amino acid 
glycosylation and biopolymer glycosylation (Table 9).  The most enriched groups have specific 
DNA repair functions including BER activity, hydrolase activity and DNA N-glycosylase 
activity. Surprisingly, four genes belonging to the three most enriched groups were DNA 
glycosylases that do not recognize alkylation damage (15, 27, 28, 34, 37, 40, 45). Interestingly, 
these genes (TDG, OGG1, NEIL1 and UNG) are known to recognize and repair multiple types 
of oxidative DNA damage (Table 10). 
Table 9. Top gene enrichment groups determined by NIH DAVID 
Gene Ontology Term p-value Genes Fold Enrichment FDR 
Base-excision repair 2.92E-05 
OGG1, NEIL1, 
POLD1, TDG, UNG 
14.7 0.054348 
Hydrolase activity, 
Hydrolyzing N-
glycosyl compounds 
4.71E-05 
CD38, OGG1, TDG, 
UNG, NEIL1 
13.48214 0.083124 
Glycosidase 9.54E-05 
SPAM1, SMPDL3A, 
OGG1, TDG, TREH, 
CTBS, UNG, NEIL1 
5.992216 0.148149 
DNA N-glycosylase 
activity 
1.07E-04 
OGG1, TDG, UNG, 
NEIL1 
17.47685 0.188687 
DNA repair 1.73E-04 
LIG4, OGG1, TDG, 
ATR, TREX1, LIG1, 
UNG, NEIL1 
5.522238 0.269107 
DNA damage 1.99E-04 
LIG4, OGG1, TDG, 
ATR, TREX1, LIG1, 
UNG, NEIL1 
5.416041 0.309503 
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Table 10. Sensitizing DNA glycosylases, their known substrates and viability ratios 
Gene Symbol Gene Name Known Substrate* 
Screen Viability 
Ratio 
OGG1 
8-oxoguanine DNA 
glycosylase 
8-oxoG:C=T=G; me-FapyG:C; 
FapyG:C; 8-oxoA:C; urea 
0.648 
UNG 
Uracil DNA 
glycosylase 
ssU; U:G; U:A; 5-fluorouracil; 5,6-
Dihydroxy-U:G; 5-OH-U:G; 
Isodialuric acid; Alloxan 
0.446 
TDG 
Thymine DNA 
glycosylase 
U:G; T:G and ethenoC:G; 
5-Fluorouracil; 5-fluorouracil (ss); 
5-Hydroxymethyluracil; 
hypoxanthine:G; 5-bromouracil; 
εC:A 
Tg:G; 5-formyl-U 
0.541 
NEIL1 
Nei endonuclease 
VIII-like 1 (E. coli) 
TgG; 5-OH-C; 5-OH-U:AT>G; 
Guanidinohydantoin; 
guanidinohydantoin (ss); 
Iminoallantoin; Iminoallantoin (ss); 
Spiroiminodihydantoin; 
Spiroiminodihydantoin (ss); 
5,6-Dihydro-T; 5,6-Dihydro-
U:G=C=A>T; FapyG:C; 
8-Oxo-G:C=G>T>A; FapyA:T; 
(5’R)-8,5’-Cyclo-2’-
deoxyadenosine; (5’S)-8,5’-Cyclo-
2’-deoxyadenosine; 8-Oxo-A:C 
0.559 
*
 
Target base on left in mismatches  
 
There were large overlaps of enriched genes from DAVID and Princeton GO term finder 
analyses (Figure 5 and Dataset S5). The oxidative DNA glycosylases, which sensitized cells to 
TMZ, were identified in the most significantly enriched networks determined by both DAVID 
and Princeton GO term finder (Table 9 and Dataset S6). Data were also analyzed through the 
use of IPA. IPA uses a manually curated proprietary interaction database and a right‐tailed 
Fisher’s exact test to calculate a p‐value determining the probability that each biological function 
assigned to that network is due to chance alone.  By using a distinct database to evaluate gene 
enrichment, which also returned similar biological processes, pathways and functions, we 
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validated our results from the previous analysis methods. IPA identified several of the DNA 
glycosylases in a statistically significant network, with a network value of twenty-four (Figure 
6).  The network score is the negative logarithm of the p-value (p-value =10
-24
).  This network is 
very similar to the biological processes and corresponding genes overrepresented in the DAVID 
and Princeton GO analysis.  Further, IPA returned several highly enriched molecular functions 
including DNA repair (p-value=5.31 x 10
-4
), excision repair (p-value=8.87 x 10
-4
), ligation of a 
DNA fragment (p-value= 2.84 x 10
-3
), ligation of DNA (p-value= 9.07 x 10
-3
) and nicking of 
DNA (p-value=1.83 x 10
-2
), very similar to the functions returned by DAVID.   
 
Figure 5.  Different methods of analysis yield similar gene enrichments.   
The diagram demonstrates the large overlap of gene enrichment groups determined by NIH DAVID and Princeton 
GO term finder. 
 
  47 
 
Figure 6. Analysis with NIH DAVID, Princeton GO term finder and Ingenuity Pathway Analysis 
yield similar gene enrichments, biological processes and pathways.   
The high confidence hit list was also analyzed by IPA for biological pathway enrichment.  One highly significant 
network generated by Ingenuity Pathway Analysis containing similar biological processes with other analysis 
methods is shown. The network is composed of many overlapping genes with genes in the high confidence hit list 
colored green.  The top functions in the network are nucleic acid metabolism, small molecule biochemistry and 
metabolic disease with a network score of 24.  The network score is the negative logarithm of the p-value. 
 
Other highly enriched molecular functions included post-translational modifications (p-
value= 2.98 x 10
-3 
- 3.12 x 10
-2
), carbohydrate metabolism (p-value= 5.56 x 10
-3
 - 4.57 x 10
-2
), 
nucleic acid metabolism (p-value= 9.65 x 10
-4
 - 3.12 x 10
-2
), and small molecule biochemistry 
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(p-value= 9.49 x 10
-4
 - 4.7 x 10
-2
).  Within these different functional groups, a conserved theme 
was the ability of the genes to modify DNA or proteins.  The modifications of DNA most 
significantly contained the excision of uracil (p-value = 9.65 x 10
-4
), while the many protein 
modifications included metabolism of proteoglycan (p-value = 5.56 x 10
-3
), metabolism of 
polysaccharide (p-value = 7.29 x 10
-3
), metabolism of carbohydrate (p-value = 8.05 x 10
-3
), 
generation of diacylglycerol (p-value = 5.56 x 10
-3
) and the release of acetylcholine (p-value = 
9.07 x 10
-3).  The “Protein Modification” theme was in our DAVID and Princeton GO results, 
and included protein amino acid glycosylation, bipolymer glycosylation, glycoprotein 
biosynthetic process, glycoprotein metabolic process and cellular carbohydrate metabolic 
process. These processes contained genes whose corresponding proteins are involved in protein 
modifications and we were intrigued by our result that when silenced the corresponding cells are 
sensitive to TMZ.  However, because of the highly significant enrichment of DNA repair 
processes in all three programs, genes associated with the DNA Repair pathway category were 
selected for initial biological validation. 
3.3 DISCUSSION  
To discover “druggable” targets that contribute to TMZ sensitivity, independent of the 
O
6
-MeG lesion, we conducted a synthetic lethal siRNA screen against 5,520 genes in a TMZ-
resistant cell line that has elevated expression of MGMT (T98G), uncovering enriched biological 
processes independent of MGMT and O
6
-MeG lesion induced cell death. The vehicle control did 
not have any cytotoxicity effects observed in the dose or duration used in the screening assay, 
thereby limiting the cytotoxicity results to that of TMZ and siRNA interactions.  The synthetic 
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lethal siRNA screen used similar screening conditions and selection criteria to obtain maximal 
knockdown of T98G mRNA and to determine positive screening hits (58, 60).  After selection of 
genes that significantly sensitize T98G cells to TMZ when knocked down, these hits were 
analyzed for pathway, network and gene enrichment using several programs.  By using NIH 
DAVID, Princeton GO term finder and IPA, with distinct methods of categorizing genes, 
organizing them into groups and determining probability of gene enrichment, we are more 
confident the biological processes and their corresponding genes enriched in all three programs 
are true hits with biological impact on survival from alkylation damage.  Importantly, the three 
programs contained considerable overlap in not only the genes that were enriched, but they also 
corresponded to similar biological processes and functions.  The increase in biological processes 
and functions enable interrogation of related genes not used in the screen that contain similar 
biological processes and functions to determine if they are also suitable targets.  By performing 
the enrichment analysis, we not only focus our workup efforts on the most likely positive hits, 
but also uncover the essential processes and functions for alkylation survival.  These processes 
possibly can be inhibited at several different steps.  Learning the essential alkylation survival 
processes yields not only many possible drug targets, but also a potential increase in therapeutic 
window for TMZ treatment.  This can result from inhibition of alkylation survival pathways that 
may be partially compromised in tumors due to spontaneous mutations or tumorigenisis.  An 
example of potential tumor selectivity by inhibiting alkylation survival pathways was 
demonstrated in a recent publication from our lab (70).  Although DNA alkylator treatment is not 
selective, by concurrently targeting the NAD
+
 biosynthesis pathway it may be possible to 
selectively induce tumor cytotoxicity from alkylation damage due to prevalent defects in tumor 
NAD
+
 biosynthesis (70).  Therefore, it is crucial to not only discover genes essential for 
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alkylation survival, but to also uncover if cancers are selectively defective in these pathways.  
With the defects in DNA repair and cellular responses to the many mutations that cancers 
undergo during transformation, it is possible to selectively target tumor DNA repair pathways.  
The recent development of PARP inhibitors and their synthetic lethal interaction with 
homologous recombination deficient cells suggests other synthetic lethal DNA repair defect 
combinations are possible (83, 84).  Determining how normal and cancer cells differ in their 
repair and response to TMZ genotoxic lesions is central to uncovering potential synthetic lethal 
interactions and cancer specific repair mechanisms to target to selectively kill tumors.   
The initial computational analysis contained some expected gene enrichment groups and 
networks, particularly those that focused on BER, as it is known to repair TMZ induced DNA 
lesions.  When mining deeper into the role of BER in TMZ survival, we discovered that several 
BER proteins not previously thought to be involved in alkylation repair or survival greatly 
sensitized the cells to TMZ.  Of particular interest were the four sensitizing DNA glycosylases 
(UNG, TDG, OGG1 and NEIL1) that remove oxidative DNA damage and not alkylation DNA 
lesions (15).  Further, cancer cells appear to be under greater oxidative stress compared to 
normal cells and impairment of oxidative DNA damage repair may yield tumor selective 
cytotoxicity (85).  With this initial pathway, network and gene enrichment determined, we then 
biologically validated several genes with the most significant enrichment findings from the three 
programs.   
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4.0  VALIDATION OF SIRNA SCREEN 
4.1 INTRODUCTION 
In the previous chapter the screening protocol was vetted and the screen was carried out.  
There was initial computational analysis of the selected genes to determine pathway, network 
and gene enrichment to increase our understanding of the important biological processes in 
alkylation survival, but to also increase the likelihood of identifying a true positive result.  After 
computational analysis, we sought to biologically validate our screen using distinct methods to 
eliminate the possibilities of siRNA off-target effects in the screening procedure and verify our 
results.  Further, we wanted to determine how our screen in human cells corresponded with that 
of previous alkylation screens done in other organisms.  Overlap of conserved proteins or 
functions would support our screen results and lend importance to the conserved proteins and 
functions in alkylation survival.  These conserved proteins and functions would be of great 
interest due to their conserved nature and likely fulfill essential roles in alkylation survival.  With 
these functions uncovered, we could focus our efforts on novel essential mechanisms for 
alkylation survival with the associated proteins as new potential therapeutic targets.   
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4.2 RESULTS 
4.2.1 Knockdown of oxidative DNA glycosylases sensitize cells to TMZ 
In our analysis, we discovered that the DNA repair category was enriched for TMZ 
sensitizing genes.  This category contained four DNA glycosylases (UNG, OGG1, TDG and 
NEIL1), each specific for the repair of oxidative DNA damage (27, 28, 34, 86). To determine if 
other DNA glycosylases also sensitize cells to TMZ and to validate the siRNA synthetic lethal 
screen results, seven of the eleven DNA glycosylases were knocked down using a lentiviral 
system to create stable T98G-derived cell lines. Knockdown of glycosylase mRNA was 
validated by qRT-PCR (Figure 7A).  The stable cell lines were then tested for sensitization to 1 
mM TMZ in a 96-well plate format using a modified MTS assay (67). As confirmation of our 
siRNA screen analysis, the newly developed UNG-KD cell line was also sensitive to TMZ 
(Figure 7B). Furthermore, knockdown of the DNA glycosylases MYH and MPG also sensitized 
cells to TMZ (Figure 7B). 
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Figure 7. Glioma cells with shRNA knockdown of DNA glycosylases are more sensitive to the clinical 
alkylator TMZ.  
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(A) Quantification of DNA glycosylase mRNA knockdown in cells as determined by qRT-PCR.  TaqMan probes 
were used to quantify mRNA levels on an Applied Biosystems StepOnePlus machine.  The qRT-PCR data was 
analyzed using the ΔΔCt method and was normalized to GFP infected plate controls.  Gene expression of each gene 
was normalized to the expression of human ß-actin.  The mean of three independent experiments is plotted ± SEM.  
(B) Validation of TMZ sensitization with knockdown of specific DNA glycosylases.   T98G DNA glycosylase 
knockdown cell line sensitivity to TMZ was determined by an MTS assay 48 hr after exposure to 1 mM TMZ.  The 
viability ratio is double normalized to account for both vehicle treated shRNA mediated growth defects and toxicity 
of control cells to TMZ.  The mean viability ratio of three independent experiments is plotted ± SEM.  (C) 
Knockdown of UNG mRNA corresponds with decreased UNG protein levels.  Control and UNG-KD cell line 
nuclear extracts were resolved in a 4-20% SDS/PAGE gel and immunoblotted for UNG.  The blot was stripped and 
re-probed for PCNA, which was used as a loading control. (D) Molecular beacon model for real-time detection of 
uracil removal at 37°C in nuclear extracts.  (E) Knockdown of UNG abolishes ability to remove uracil from DNA as 
determined by DNA Glycosylase Molecular Beacon Activity Assay.  Specific activity of DNA glycosylase activity 
for the uracil lesion was measured in nuclear extracts from T98G-SCR (control-beacon, red circles; uracil-beacon, 
blue squares) and T98G/UNG-KD (control-beacon, green diamonds; uracil-beacon, yellow triangles).  The mean 
fluorescence response unit of three experiments is plotted ± SEM. 
4.2.2 UNG knockdown eliminates removal of uracil in glioma cells 
Although UNG mRNA knockdown sensitized the T98G cells to TMZ in the validation 
study, we were uncertain if the mRNA knockdown affected UNG protein levels and DNA repair 
activity because other DNA glycosylases have a similar lesion spectrum (Table 3).  First, we 
tested UNG protein expression via immunoblot and determined that UNG protein levels were 
decreased in T98G/UNG-KD cells as compared to T98G-GFP control cells (Figure 7C).  
However, we were interested in ascertaining if the decrease in UNG protein levels affects the 
DNA repair capacity of the cells, because there is a large functional overlap of UNG with the 
three DNA glycosylases SMUG1, TDG and MBD4 (27, 28, 34, 86).  We were concerned that 
depletion of one of these DNA glycosylases would not have a functional DNA repair defect due 
to compensation by the other glycosylases. We therefore developed a DNA glycosylase 
molecular beacon assay to quantify the functional loss of uracil removal by UNG knockdown, 
similarly to what we have previously described for the analysis of MPG activity (87, 88).  The 
assay uses a molecular beacon composed of a single stranded DNA molecule with a 5’ 
fluorophore (6-FAM) and a 3’ quencher (Dabcyl).  The oligonucleotide also contains a uracil 
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lesion, a substrate for UNG.  We selected uracil as the lesion because it is removed by UNG, 
SMUG1, TDG and MBD4 (27, 28, 34, 86).  Therefore, we could determine if UNG-KD impacts 
uracil removal and if compensation by other DNA repair proteins occurred.  A similar 
oligonucleotide with a normal base was used as a control substrate.  Removal of the uracil lesion 
by UNG and hydrolysis of the DNA backbone by APE1 results in separation of the 6-FAM 
fluorophore from the Dabcyl quencher and the increase in 6-FAM fluorescence is proportional to 
uracil removal (Figure 7D).  The T98G-SCR lysate incubated with control beacon (Figure 7E, 
red circles) had a minimal increase in fluorescence, signifying the control beacon is intact.  
However, the T98G-SCR lysate incubated with the beacon containing uracil (Figure 7E, blue 
squares) exhibited a large increase in fluorescence (17.69 fold at 60 min) compared to the control 
beacon, indicative of robust uracil removal from the molecular beacon.  The T98G/UNG-KD 
lysates incubated with either the control beacon (Figure 7E, green diamonds) or the uracil-
containing beacon (Figure 7E, yellow triangles) contained no difference in fluorescence and 
exhibited low fluorescence, supportive of loss of UNG activity. 
These results support our conclusion that the T98G/UNG-KD cells have impaired uracil 
removal due to UNG knockdown as compared to the T98G-SCR control.  The scrambled shRNA 
control was used instead of the GFP control for the activity assay due to the interference of GFP 
fluorescence with the molecular beacon fluorophore 6-FAM.  Although uracil can also be 
removed by SMUG1, TDG and MBD4, UNG-KD alone was sufficient to deplete uracil removal 
activity (27, 28, 34, 86). 
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4.2.3 Cross-species functionome analysis creates a network of conserved processes 
important for survival after alkylation damage 
After biological validation, we then compared our T98G siRNA screen results to other 
alkylation screens conducted in S. cerevisiae and E. coli, comparing the outcome data using GO 
molecular function terms (77, 78).  This was done by compiling the sensitizing genes from all the 
screens and linking them to their specific Gene Ontology Biological Process. The list of 
sensitizing genes from E. coli, S. cerevisiae and human was then computationally analyzed to 
identify GO-functional categories over-represented with genes from human and either E. coli or 
S. cerevisiae (Table 11). The molecular functions enriched in all three alkylation screen datasets 
were then visualized using Cytoscape to create a cross species functionome of proteins which 
modulate toxicity to alkylating agents in S. cerevisiae, E. coli and human (Figure 8). This 
network of proteins has several “GO-hubs” of proteins from all three species clustered around a 
conserved biological process (node) that significantly impacts the survival of correspondingly 
depleted cells after exposure to alkylating agents.  These include proteins involved in global 
processes such as response to drugs or changes in pH.  There was also a collection of processes 
involved in macromolecule biosynthesis and modifications including fatty acid biosynthetic 
processes, transcription, regulation of transcription, transcription initiation, negative regulation 
of translation, protein modification process, protein processing and protein targeting to 
membrane.  These results suggest that synthesis of new RNA, protein, and fatty acids are 
essential for survival to alkylation. 
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Table 11. Significantly conserved biological processes as determined by cross-species Functionome Analysis. 
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Figure 8. Biological processes necessary for survival after alkylation damage are conserved and when compiled generate a cross-species functionome.  
The conserved biological processes with their corresponding genes were visualized using Cytoscape. Red nodes denote conserved biological processes. The remaining nodes are 
alkylation-modulating proteins belonging to E. coli (dark blue), S. cerevisiae (light blue) and humans (light green). The edges connect specific biological processes to each protein 
belonging to the processes.  Many proteins are involved in more than one biological process which affects alkylation exposure survival and therefore are connected to several 
biological processes nodes. 
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4.3 DISCUSSION 
A conserved theme involved DNA metabolism and included the GO hubs of DNA 
metabolic process, DNA replication, negative regulation of DNA replication, response to DNA 
damage stimulus, DNA repair, DNA recombination, mismatch repair, nucleotide excision repair, 
base excision repair and DNA dealkylation. The conserved processes affect several different 
layers of DNA metabolism with many genes involved in DNA replication and repair.  The 
prevalence of DNA replication and DNA recombination genes emphasize the importance of new 
DNA synthesis and repairing damaged DNA via recombination mechanisms.  Many genes 
involved in other DNA repair pathways including nucleotide excision repair, mismatch repair 
and base excision repair are present in the DNA repair hub.  The base excision repair subset from 
all three organisms was predominantly composed of DNA glycosylases that recognize and 
remove base lesions.    This subset contained several known alkylation resistance genes such as 
the 3-methyl-adenine DNA glycosylases alka and MAG1, in E. coli and S. cerevisiae, 
respectively.  Also included were human DNA glycosylases that recognize and repair oxidative 
base lesions including UNG, OGG1, TDG and NEIL1 (27, 28, 34, 86).  The alkA gene product 
has diverse substrate specificity and also removes oxidative lesions such as xanthine, oxanine, 5-
formyluracil and hypoxanthine (89-92).  The ability of AlkA to remove oxidation induced 
lesions correlates with the results seen in the human screen and may affect the sensitivity of alkA 
mutants to alkylation damage.  We obtained complimentary results in a different study using 
another glioblastoma cell line (LN428) with the DNA alkylating agent MMS, where decreased 
DNA repair activity as measured by the molecular beacon assay and comet assay inversely 
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correlated with cell survival (Page 112, Figure 22) (88).  The emphasis on proteins that 
recognize and remove DNA lesions, and correlation to cell survival, suggests the DNA lesions 
themselves are cytotoxic, with removal of both alkylation and oxidative lesions being important 
for survival following alkylation exposure.   
Unfortunately, we could not create stable knockdowns of three of the DNA glycosylase 
hits, likely because the knockdown of OGG1, TDG and NEIL1 created cells with a growth 
disadvantage compared to cells expressing normal levels of the corresponding protein. Cells 
lacking oxidative DNA glycosylases may be more sensitive to reactive oxygen species (ROS) 
because repair of oxidative lesions is compromised. For example, cells lacking NEIL1 are more 
sensitive to gamma-irradiation (93) and NEIL1
-/-
 mice have decreased expansion of germinal 
center B cells (94).  However, we could effectively reduce UNG mRNA, protein and the cell’s 
ability to repair uracil lesions in the T98G/UNG-KD cell lines.  Further, the UNG-KD 
sensitization was validated using a separate shRNA targeting sequence and experimental design, 
eliminating the role of RNAi off-target effects or screening artifacts in UNG-KD sensitization. 
Although UNG has not been reported to repair alkylation damage, knockdown of UNG 
sensitizes T98G cells to TMZ. It is possible that TMZ induces toxic oxidative lesions by 
increasing ROS levels as seen with MMS treatment in yeast (95, 96).  TMZ may directly alkylate 
the electron transport chain proteins and mitochondrial DNA, which could impair electron flow 
through the chain by direct alkylation damage of the protein and decreased functional protein 
expression due to replication blocking lesions or mutated DNA.  It is possible that mitochondrial 
alkylation damage induces an increase in ROS formation. Mitochondrial ROS production can 
increase from defects in electron transport chain proteins, such as complex I (97). This increase 
in ROS creates lethal oxidative lesions that UNG and other oxidative DNA glycosylases must 
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repair to prevent cell death after alkylation exposure.  NAD kinase, which phosphorylates NAD 
to form NADP
+
, was also a hit in our screen.  Cells maintain NADP
+
 in its reduced state, 
NADPH, to use NADPH’s reducing potential in many different pathways including glutathione 
regeneration for oxidant defense, reduction of RNA to DNA, and synthesis of fatty and amino 
acids.  New synthesis and repair of macromolecules are essential for alkylation survival (73, 78, 
98).  NAD kinase may affect alkylation survival via NADPH production by its positive effect on 
DNA and RNA synthesis and also for its central role in creating reducing equivalents for 
antioxidant defense.  Support for a potential role of ROS in alkylation sensitivity was also shown 
by others using mouse embryonic fibroblasts and several human cancer cell lines, which were 
treated with the alkylating agent MNNG and contained greater ROS production from both 
NADPH oxidase and mitochondria sources (99, 100). MNNG cytotoxicity could be completely 
abrogated by pretreatment with N-acetylcysteine, demonstrating that increased ROS formation 
may contribute to alkylation toxicity and is a likely source of cytotoxic DNA lesions (100).  
Although N-acetylcysteine could also prevent MNNG cytotoxicity by being an alkylation target 
of MNNG and thereby reducing the effective MNNG dose when used as a pretreatment, multiple 
organisms and cell lines suggest that alkylation exposure can increase ROS formation.  Cells 
expressing UNG may be less sensitive to TMZ because the increase in ROS produces cytotoxic 
oxidative DNA lesions removed by UNG, promoting cellular survival.   
 UNG was not the only DNA glycosylase to sensitize cells to alkylation exposure 
in the validation experiments. MPG and MYH knockdown also sensitized T98G cells to TMZ. 
This was unexpected because MPG did not sensitize in the siRNA screen, perhaps due to lack of 
knockdown. Our results are consistent with previous reports from several labs, as MPG-KD led 
to either an increase or decrease in cell death after alkylation exposure depending on the system 
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under study (101-104).  Further, MPG status alone does not adequately predict response to 
alkylators, but instead the balance of the entire BER pathway must be investigated to predict 
sensitivity to DNA damage (87, 88, 105).  The ability of MYH-KD to sensitize cells to alkylators 
was not anticipated since expression of MYH had been previously shown to promote cell death 
after alkylator exposure (106).  In that study, however, the authors used a clonogenic cell 
survival assay to interrogate cell death related to the O
6
-MeG lesion, measuring surviving cells 
after at least two replication cycles (106).  In contrast, in our initial validation experiments, cell 
survival was determined after 48 hours post TMZ treatment, too short for two replication cycles 
to occur (107). Therefore, the role of MYH in O
6
-MeG mediated cell death is likely very 
different than its role in cell survival after 48hr exposure to TMZ as described in this study.  
MYH is primarily known for the removal of the mismatched A opposite 8-oxodG lesions (34) 
and MYH deficiency does not sensitize cells to H2O2, IR, or cis-platinum (34, 86, 108). 
Therefore, the sensitization of MYH depletion to TMZ treatment may be the result of an increase 
in ROS induced lesions, although less likely due to MYH depletion insensitivity to H2O2, and 
instead could be the result of inhibiting a novel glycosylase function.   
After biological validation of the screen, we conducted a cross-species functionome 
analysis that illustrated that many biological processes are conserved in E. coli, S. cerevisiae and 
humans, with multiple proteins from each organism belonging to the different processes.  We 
have used this approach to discover a network of proteins that constitutes a cross-species 
functionome of evolutionarily important processes essential for survival after alkylation 
exposure. The functionome analysis affirms that our TMZ screen results from human cells are 
consistent with previous alkylation studies in other species.  Importantly, the analysis distils the 
crucial processes and corresponding proteins for alkylation survival in humans.  The targets 
  63 
found in the screen may not be possible targets for adjuvant therapy due to adverse cytotoxicity 
or difficulties in drug development.  However, the essential pathways contain other proteins that 
were not tested in the screen and may also be viable targets to improve sensitivity to alkylating 
agents.  Mining the pathways for genes essential for the biological processes may yield the best 
targets for improving DNA alkylator therapy.  Additionally, the conserved processes and 
corresponding genes are excellent candidates to investigate using the new large cancer datasets 
such as the Cancer Genome Atlas and REMBRANDT to determine if patient tumors have 
varying expression of the genes and if the gene expression correlates with treatment outcome.  
The differential expression of these crucial genes may serve as important biomarkers to predict 
outcome of alkylation treatment and which patients would derive most or least benefit from 
treatment.  It would yield possible personalized medicine and potential tumor-specific effects in 
certain cancers due to decreased activity and expression of these genes.  This network links 
seemingly disparate genes that may prevent cell death after alkylation damage through their 
crucial biological processes and represent novel targets for adjuvant chemotherapy. 
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5.0  TARGETING NOVEL BIOLOGICAL PROCESSES TO IMRPOVE 
TEMOZOLOMIDE SENSITIVITY  
5.1 RESULTS 
5.1.1 Disruption of protein modification processes sensitizes human cells to alkylators 
Based on the functionome network we identified, we chose to further validate another 
node of proteins to improve sensitivity to alkylators.  The protein modifications node was chosen 
due to enrichment in the cross-species analysis, good sensitization in the screening studies and 
the observation that this node had multiple genes in both human and yeast cells.  The human 
knockdown cell lines were generated using lentivirus shRNA vectors as described above.  
Knockdown levels of mRNA were determined using qRT-PCR (Figure 9A).  The cell lines with 
mRNA knockdown were then tested for sensitivity to TMZ treatment using a modified MTS 
assay.  The knockdown of UBE3B and ICMT significantly sensitized the glioblastoma cells to 
TMZ resulting in viability ratios of 0.6 and 0.7, respectively (Figure 10B), as compared to the 
control.  We then tested each knockdown cell line for sensitivity to TMZ in a long-term assay 
similar to a clonogenic cell survival assay. The CyQuant assay utilizes a highly sensitive 
fluorescent intercalating DNA dye to determine relative DNA content and cell number nine days 
after TMZ or vehicle treatment. The UBE3B-KD cell lines were approximately 45% more 
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sensitive compared to control cells in the CyQuant assay at concentrations as low as 50μM TMZ 
(Figure 10C). 
 
Figure 9. Lentivirus and siRNA mediated knockdown of UNG, UBE3B, and ICMT.   
The mRNA was quantified by qRT-PCR. A) Quantification of protein modification processes mRNA knockdown in 
lentiviral-infected cells as determined by qRT-PCR.  TaqMan probes were used to quantify mRNA levels on an 
Applied Biosystems StepOnePlus machine.  The qRT-PCR data was analyzed using the ΔΔCt method and was 
normalized to GFP infected plate controls.  Gene expression of each gene was normalized to the expression of 
human ß-actin.  The mean of three independent experiments is plotted ± SEM.  B) Quantification of UBE3B and 
UNG mRNA knockdown in siRNA transfected cells as determined by qRT-PCR.  Dark gray bars denote UBE3B 
mRNA levels while light gray bars denote UNG mRNA levels.  TaqMan probes were used to quantify mRNA levels 
as described above.  The qRT-PCR data was normalized to scrambled siRNA controls. 
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Figure 10. Knockout or depletion of protein modification genes sensitizes S. cerevisiae and human 
glioma cells to alkylating agents.   
(A) A dilution series of yeast single and double knockouts were tested in YPD and YPD + MMS containing media.  
(B) Knockdown of protein modification genes sensitizes glioma cells to TMZ.  The T98G cell lines with protein 
modification gene knockdown were treated with 1mm TMZ to determine sensitivity by an MTS assay 48 hours after 
exposure.  The mean viability ratio of three independent experiments is plotted ± SEM. (C) Knockdown of UBE3B 
sensitizes glioma cells to TMZ at clinically achievable doses. The T98G/UBE3B-KD cell line was treated with 
50μM of TMZ and survival was determined by CyQuant assay 9 days after exposure.  The percent survival of two 
independent experiments is plotted ± SEM.  (D) Sensitivity to TMZ via knockdown of UNG and UBE3B are not 
independent.  T98G cells transiently transfected with siRNA that was scrambled, targeting UNG, UBE3B or both 
UNG and UBE3B.  Forty-eight hours after transfection cells were seeded to determine sensitivity to TMZ by MTS 
assay.  Both individual knockdowns of UNG and UBE3B sensitized glioma cells to TMZ, but dual knockdown did 
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not have a greater effect than either single knockdown, suggesting an epistatic relationship between UNG and 
UBE3B. 
5.1.2 Protein modification gene knockout sensitizes yeast to alkylators, while 
simultaneous knockout of protein modification genes and an alkylbase DNA glycosylase 
yields the greatest sensitivity 
Our collaborators have previously reported that aim22Δ, lip22Δ, pby1Δ and stp22Δ cells 
from S. cerevisiae, which belong to the protein modification node, are sensitive to the alkylating 
agent MMS (77).  In addition, it has been firmly established that mag1Δ cells are sensitive to 
MMS because of their alkylbase DNA glycosylase deficiency and inability to repair damaged 
DNA.   We assayed all individual knockouts to further validate our previously reported screening 
results (Figure 10A) and demonstrate decreased growth after MMS treatment for all five 
mutants.  Based on our functionome results, we reasoned that there would be increased 
alkylation sensitivity when deficiencies in protein modification and base excision repair were 
combined.  We generated double knockouts in the four protein modification associated mutants, 
using a mag1Δ deletion cassette.  We demonstrate that there is increased sensitivity in all of the 
double mutants tested, relative to the individual parent or mag1Δ knockout strains.  The protein 
modification genes correspond to activities involved in the modification of mitochondrial 
enzymes by the attachment of lipoic acid groups (Lip2), a protein that works with Lip2 (Aim22), 
a tubulin tyrosine ligase associated with P-bodies (Pby1) and a component of the ESCRT 
complex that is involved in ubiquitin-dependent sorting of proteins into the endosome (Stp22).   
We note that Pby1 is homologous to the mouse and human Tsg101 tumor susceptibility genes, 
which are homologs of ubiquitin-conjugating enzymes implicated in being involved in cell cycle 
regulation and genome maintenance.  The mag1Δstp22Δ double mutant is the most sensitive to 
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MMS, but there also appears to be a growth defect in these strains on untreated media, 
suggesting some synthetic lethal interaction outside of alkylation damage.  Nonetheless, our 
results with combined protein modification and BER mutants in budding yeast supports the idea 
that similar dual knockouts in humans may confer increased sensitivity to TMZ. 
5.1.3 Dual disruption of both DNA repair and protein modification nodes reveals a 
potential epistatic relationship between UNG and UBE3B 
Although the UNG-KD and UBE3B-KD cell lines were both more sensitive to TMZ 
when compared to control cells, we were interested in determining if the double-KD cells would 
have an increased TMZ sensitivity, as was seen for the double KO lines in S. cerevisiae (Figure 
10A). To this end, we investigated if simultaneous inhibition of both DNA repair and protein 
modification genes increased sensitivity compared to either inhibition alone.  Our initial strategy 
for dual inhibition of DNA repair and protein modification genes used a dual lentivirus approach.  
The stable UBE3B-KD cell lines were transduced with either a control GFP virus or a virus 
expressing both GFP and shRNA specific for UNG.  Four days after transduction the cells were 
sorted for GFP expression using Fluorescence Activated Cell Sorting (FACS).  The isolated cells 
were expanded then tested for UBE3B and UNG mRNA expression.  Although UBE3B was 
knocked down at earlier passage numbers, the double knockdown cell lines contained reduced 
levels of UNG mRNA, but did not have a reduction in UBE3B mRNA (Figure 11).  
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Figure 11. UNG mRNA levels are reduced in the cells containing GFP expression and shRNA against 
UNG, while UBE3B knockdown is absent in double lentivirus infected cell lines.     
(A) Quantification of UNG and (B) UBE3B in the double lentivirus infected cell lines as determined by qRT-PCR 
described above. 
 
However, we noticed during long-term passaging of the UBE3B-KD cell line that 
sensitivity and knockdown levels diminished, suggesting outgrowth of WT cells in a pooled 
population.  To prevent the loss of UBE3B knockdown we single cell cloned the UBE3B-KD 
population by limiting dilution.  The cells were seeded into 96-well plates and incubated for a 
week before determining colonies derived from single cells by visual inspection.  The clones 
were expanded before being tested for UBE3B mRNA expression levels.  Two clones (clones 1 
and 12, shown in gray) had significantly low levels of UBE3B and were selected for lentivirus-
mediated knockdown of UNG (Figure 12).  
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Figure 12. Single cell clones contain significant knockdown of UBE3B compared to GFP controls. 
The T98G/UBE3B-KD cell line was cloned by single cell dilution and tested for UBE3B mRNA expression levels 
as previously described.  Clones 1 and 12 (gray bars) were selected for double infection with UNG shRNA 
lentivirus.   
 
The two clones that were double infected were then tested for both UBE3B and UNG 
mRNA levels.  Surprisingly, even though the T98G/UBE3B-KD clones had measurable 
knockdown before UNG lentivirus transduction, the mRNA validation studies again showed loss 
of UBE3B-KD (Figure 13).   
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Figure 13. T98G/UBE3B-KD clones lose knockdown of UBE3B with time in culture. 
(A) Quantification of UNG and (B) UBE3B in the T98G/UBE3B-KD clones 1 and 12 infected with GFP or shRNA 
against UNG, as determined by qRT-PCR described above. 
 
Because long-term culture of UBE3B-KD cells lost UBE3B knockdown levels, even 
when derived from single cell clones, we returned to using an siRNA transient transfection 
approach to knockdown both UNG and UBE3B.  We reasoned that only short-term loss of 
UBE3B is possible in the T98G cell lines since previous methods for stable knockdown had 
failed.  Therefore, we transfected parental T98G cells with a scrambled control siRNA, UNG 
siRNA, UBE3B siRNA, or UNG plus UBE3B siRNA before determining mRNA levels by qRT-
PCR (Figure 9B). Cells were seeded for qRT-PCR and sensitivity determination by MTS assay 
at the same time.  Wells with less than 35% mRNA for either UNG or UBE3B remaining were 
analyzed for sensitivity to TMZ.  We expected the dual knockdown of UNG and UBE3B to 
confer at least an additive effect to TMZ sensitivity, suggesting that the sensitivity observed after 
knockdown of the proteins resulted from independent mechanisms.  However, although UNG 
and UBE3B knockdown alone both confer sensitivity to TMZ, when they are simultaneously 
knocked down there is no significant increase in sensitivity to TMZ below the level of either 
single knockdown (Figure 10D).  Thus, TMZ sensitivity to knockdown of UNG and UBE3B are 
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not independent events, demonstrating a possible epistatic relationship between the UNG and 
UBE3B genes. The conserved biological processes also enrich for possible alkylation sensitivity 
gene interactions as seen with UNG and UBE3B.  The activity of many DNA glycosylases are 
regulated by post-translational modifications (26).  SUMOylation of TDG promotes its catalytic 
activity by increasing catalytic turnover by decreasing TDG’s affinity for the abasic site product 
(109).  Although it is more likely UBE3B has an indirect role in UNG sensitivity, it is possible 
that ubiquitylation of UNG by UBE3B can modify protein localization, abundance or activity as 
it has been suggested that UNG is targeted for ubiquitin-mediated proteolysis during the S phase 
of the cell cycle (110, 111). 
5.2 DISCUSSION 
Many genes in yeast and humans whose corresponding activities are involved in protein 
modifications are required for protection from TMZ or methyl methanesulfonate (MMS) 
exposure, suggesting conservation of gene activation via post-translational modifications to 
alkylation damage. Several different types of protein modifications including ubiquitylation, 
methylation, glycosylation and deimination are present in the hub (Figure 8).  These include two 
of the four known human peptidyl arginine deiminases, type I and type IV (PADI1 and PADI4) 
(112).  Petidyl arginine deiminases catalyzes the post-translational deimination of proteins by 
converting arginine residues into citrullines (112). The PADs have distinct substrate specificities 
and tissue-specific expression patterns (113, 114).  The enzymatic reaction is highly dependent 
on pH and calcium concentrations, with the different PAD isoforms containing different activity 
profiles (113).  The differential expression patterns, substrates and activity profiles all contribute 
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to the distinct functions of the PAD genes.  Currently, the most prevalent function of PADI1 is 
its role in epidermal differentiation, where it deiminates filaggrin and keratin (113, 114).  
However, its role in DNA repair or survival to alkylation exposure has not been determined.  In 
contrast, PADI4 is likely involved in DNA repair and cell death signaling as it can modulate p53 
signaling and p53 gene target expression levels (115, 116).  PADI4 can also antagonize histone 
methylation by arginine deimination to citruline, thus removing the methylation mark (117).  
PADI4 also regulates gene expression by associating with histone deacetylase 2 (HDAC2) (118).  
HDAC2 is known to modulate the DNA damage response and cells depleted of HDAC2 are 
hypersensitive to DNA damaging agents (119).  Further, glioblastoma cells pretreated with the 
HDAC inhibitor MS275 were sensitized to TMZ (120).  These data suggests that PADI4 
sensitivity may result from interference with multiple steps in the DNA damage response, likely 
through deregulation of HDAC2, but PADI4’s interaction with p53 likely contributes to 
alkylation survival as well.   
One of the human genes in the node is isoprenylcysteine carboxyl methyltransferase 
(ICMT), a gene that is ubiquitously expressed and encodes the last of three steps for 
isoprenylation (121, 122).  Methylation of isoprenylcysteine allows movement of the protein 
from the endoplasmic reticulum to the plasma membrane (122).  ICMT has been of interest to 
cancer researchers because ICMT inhibition can disrupt RAS signaling in several model systems 
(123-125).  Knockout of ICMT prevented oncogenic transformation of cells with oncogenic K-
RAS or B-RAF in soft agar and mice models (124).  Although there is interest in creating potent 
and selective ICMT inhibitors, there has been no link for ICMT to DNA repair or response to 
alkylation exposure (126).  ICMT may play a role downstream of the DNA damage cascade and 
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regulate signaling for cell death, as it has been linked with both autophagic and apoptotic cell 
death (127).   
Another gene in the protein modification group is the human ubiquitin protein ligase E3B 
(UBE3B), which may play a role in the repair of alkylated DNA. The activity of many DNA 
repair proteins can be affected by ubiquitylation such as FANCD2 (79) and PCNA (80).  
Monoubiquitylation of FANCD2 is used as a marker of intra-strand crosslink (ICL) repair 
activity, while ubiquitylation of PCNA determines polymerase switching (81).  Furthermore, the 
E3 ubiquitin ligase activity of BRCA1, CUL4A and CUL4B is critical for their function in DNA 
repair (82, 128).  The E3 activity of BRCA1 is crucial for its role in cell cycle checkpoint 
activation and sensitivity to DNA damage, while CUL4A and CUL4B E3 activity is required to 
regulate chromatin structure and access of DNA repair proteins to the DNA in nucleotide 
excision repair (NER) (82, 128, 129).  The potential role of UBE3B and its substrates in DNA 
repair are of great interest, but have yet to be defined. 
We sought to create greater sensitivity to alkylators by simultaneously knockdown of 
both UNG and UBE3B.  We expected an additive effect on sensitivity to TMZ that would denote 
independent effects of UNG and UBE3B knockdown.  To our surprise, the double knockdown 
cell line had no increase in sensitivity compared to the single knockdown cell lines, suggesting 
that UNG and UBE3B knockdown do not have independent effects on TMZ sensitivity and 
represent an epistatic interaction.  This is likely an indirect interaction with downstream targets 
of UBE3B modulating TMZ cytotoxicity through a UNG dependent pathway.  However, a direct 
interaction is possible, since UNG is a known target of ubiquitylation (111, 130, 131), although 
these data would not implicate UBE3B in the cell cycle-regulated proteolysis of UNG.  Further, 
the activity of many DNA repair proteins are modulated by ubiquitylation and several essential 
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DNA repair proteins are E3 ubiquitin ligases (79-82, 128).  The epistatic interaction between the 
two genes supports the possibility of UBE3B playing a role in modulating DNA repair or 
survival to DNA damage.  Determining how UBE3B and UNG regulate alkylation survival and 
their mechanism of interaction is an area of interest.   
Any kind of functional interaction between UBE3B and UNG was unexpected because 
the probability of selecting two genes from the alkylation functionome that have a functional 
interaction to impact alkylation survival appeared small.  The lack of independence on UNG and 
UBE3B mediated alkylation cytotoxicity is likely due to the enrichment analysis that selected for 
proteins that could be members of the same essential pathway for alkylation survival, thereby 
eliminating independent events.  The analysis of the three screens revealed that many biological 
processes that modulate survival after alkylation damage are conserved through evolution and 
supports the validity of the screen, which suggests that novel processes are involved in repairing 
alkylation damage.  The conserved biological processes importance to alkylation survival is 
underscored by the sensitivity of the cell lines depleted of various protein modification genes. 
These yeast and human cell lines were more sensitive to alkylating agents in both short-term and 
long-term clonogenic-like assays. Both DNA repair and protein modification gene depletion 
enhanced TMZ efficacy in glioma cells; however, the greatest alkylator toxicity in yeast cells 
were generated by dual inhibition of both processes.  With multiple avenues to develop 
alkylation resistance, simultaneous inhibition may be required to achieve a clinically significant 
sensitization for chemotherapies.   
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6.0  UBIQUITIN LIGASE E3B AND URACIL DNA GLYCOSYLASE AS TARGETS 
FOR CANCER THERAPEUTICS 
6.1 RESULTS 
6.1.1 UBE3B is differentially expressed in various tumor types  
Expression of UBE3B affected GBM sensitivity to TMZ and may impact response of 
various cancers to other chemotherapeutic alkylating agents such as cyclophosphamide, 
chlorabucil and dacarbazine. With little known on the function or expression of UBE3B in 
normal and cancerous tissue, we wanted to determine if UBE3B expression levels vary in 
different cancer cell lines.  To determine if UBE3B is differentially expressed in different cancer 
types we quantified relative expression levels of UBE3B mRNA by qRT-PCR.  We discovered 
that UBE3B mRNA expression varies by approximately 7-8 fold in the tumor cell lines tested 
(Figure 14).  Although this is a small sample size, it reveals that levels of UBE3B can vary 
dramatically in different cancers and may lead to an increase in therapeutic index in certain 
cancers.  We were then interested in determining of variations in UBE3B and UNG also vary in 
patient primary tumors and if these levels correlated with outcome or response to therapy.     
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Figure 14. UBE3B is differentially expressed with a seven-fold difference in cancer cell lines. 
The UBE3B mRNA levels were determined in the different cancer cell lines using qRT-PCR as described above 
(Page 24).  The UBE3B mRNA levels from the cancer cell lines were normalized to the T98G cell line.  The cell 
lines used were a collection of glioblastoma (MO59K, MO59J, T98G, DBTRGO-5MG, A172, LN428), 
osteosarcoma (SAOS-2, U2OS), breast cancer (MCF7, MDA-MB231) and colon cancer (HCT116) cell lines.   
 
6.1.2 UNG is over expressed in GBM, while UBE3B maintains similar levels of expression 
in GBM compared to normal controls 
The change in UBE3B expression in our different cancer cell lines intrigued us and we 
sought to determine if UBE3B and UNG levels vary in the LN428 and T98G cancer cell lines 
and in clinical samples when compared to normal controls.  In a separate project, we have run 
Affymetrix microarrays on our different cell lines to measure mRNA expression levels and we 
determined our GBM cell lines had levels of UNG which varied considerably from that of 
normal primary human astrocytes, while the UBE3B mRNA levels were similar to that of the 
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normal astrocytes (Table 12).  The increased UNG expression for both LN428 and T98G cell 
lines was significant, as evidenced by very small p-values.   
Table 12. Relative expression of UNG and UBE3B mRNA in cell lines used compared to normal 
human astrocytes using an Affymetrix microarray.   
 Relative Gene Expression 
Cells UNG UBE3B 
Normal Human Astrocytes 1 1 
LN428 
5.17776 
p-value = 3.44972x10
-7
 
0.816376 
p-value = 0.216969255 
T98G 
3.354535 
p-value = 2.84847x10
-6
 
0.85976429 
p-value = 0.302796239 
 
We were interested in determining if similar increases in UNG expression levels are 
present in primary patient tumors.  We investigated this by interrogating The Cancer Genome 
Atlas (TCGA) dataset on GBM.  GBM was one of the pilot cancers for the TCGA and is 
completed with publically available data (132).  The frequency of two-fold decrease or increase 
in expression of UNG and UBE3B is shown in Table 13.  UNG expression is two-fold greater in 
over 14% of the GBMs studied in the TCGA while UBE3B has two-fold less expression in 
greater than 19% of samples.  Interestingly, there are no samples with either a decrease in UNG 
expression or an increase in UBE3B expression in TCGA files.  We also queried the Rembrandt 
database for UNG and UBE3B gene expression data and found that similar to the TCGA, the 
levels of UNG tended to be higher in glioblastoma compared to normal controls and that UBE3B 
tended to be lower in GBM compared to normal controls (133, 134).  These results from a 
separate database reinforced our conclusion that expression levels of our proteins of interest 
varied significantly in tumors.  Importantly, the directionality of the changes are important as it 
appears over-expression of UNG is beneficial for GBM, particularly in the absent of any samples 
with decreased expression in either tumor database.  We also graphed the change in UNG 
expression for all different brain tumors and observed that all brain tumors had higher median 
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expression of UNG, with GBM having the highest expression of all brain tumors, compared to 
normal controls (Figure 15).  The expression data on UBE3B is less impressive due to the 
smaller amount of samples that deviate from the normal tissue in Rembrandt, although several 
samples do contain significantly less UBE3B compared to controls in TGCA.   
Table 13. Frequency of UNG and UBE3B relative expression differences compared to normal 
controls in The Cancer Genome Atlas and REMBRANDT databases.   
The frequency of 2-fold decrease or increase in UNG and UBE3B gene expression data is recorded below.  This 
data was collected from the Rembrandt Database (133). 
 
 UNG UBE3B 
 2x Decrease 2x Increase 2x Decrease 2x Increase 
The Cancer Genome Atlas 0% 14% 19% 0% 
Rembrandt Database 0% 33.77% 1.1% 0% 
 
 
Figure 15. UNG is expressed at higher levels in all brain tumors, but particularly in GBM, when 
compared to non-tumor controls.   
The Rembrandt brain tumor database expression data was queried for expression of UNG based on tumor types and 
normal controls.  The median expression intensity was plotted against the cell of origin and all brain tumors 
contained higher levels of UNG median expression intensity, with GBM the highest of all measured tumor types.  
This data was collected from the Rembrandt Database (133). 
 
 
Knowing that the expression levels of UNG and UBE3B fluctuate in primary tumor 
samples, we desired to determine if expression levels of UNG and UBE3B correlated with 
  80 
response to therapy or survival.  We would predict the increase in UNG expression levels would 
correlate with reduced survival due to the ability of the cells to repair their DNA more 
efficiently, especially TMZ induced lesions.   
6.1.3 UNG expression correlates with a worse prognosis in brain tumors  
We then queried the Rembrandt database for patients with GBM tumors and over-
expression of UNG and plotted a Kaplan-Meier survival curve to determine if over-expression of 
UNG correlated with decreased survival (Figure 16).  Surprisingly, the over-expression of UNG 
did not correlate with decreased survival as expected, although we believe this was due to the 
small sample size of GBM tumors in the database, as there appeared to be a trend of decreased 
survival, particularly around 2000-4000 days in the study.  Therefore, we plotted a Kaplan-Meier 
survival curve of all glial tumors over-expressing UNG compared to tumors containing an 
intermediate level of UNG (Figure 17).  We determined that two-fold over-expression of UNG 
correlated with a decrease in probability of survival compared to intermediate expression of 
UNG, with a log-rank p-value, calculated using the Mantel- Haenszel procedure, of 1.0177x10
-4
.  
This correlation matches our prediction based on our in vitro data, suggesting that increased 
expression of UNG negatively impacts brain tumor survival, possibly from increased resistance 
to chemotherapeutic treatment.   
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Figure 16. The over-expression of UNG in GBM tumors does not significantly impact patient 
survival.   
The Kaplan-Meier survival curve in GBM tumors reveals reduced survival for patients with over expression of UNG 
(Red trace) compared to that of intermediate expression of UNG (Yellow trace) with a log-rank p-value, calculated 
using the Mantel- Haenszel procedure, of 0.2389423205.  This data was collected from the Rembrandt Database 
(133). 
 
 
Figure 17. The over-expression of UNG negatively impacts survival of all glioma tumor patients.   
The Kaplan-Meier survival curve in all glial tumors reveals reduced survival for patients with over expression of 
UNG (Red trace) compared to that of intermediate expression of UNG (Yellow trace) with a log-rank p-value, 
calculated using the Mantel- Haenszel procedure, of 1.0177x10-4.  This data was collected from the Rembrandt 
Database (133). 
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6.1.4 Cloning of UBE3B 
To learn more about the function of these proteins in response to alkylation treatment we 
began to clone them from our LN428 glioblastoma cell line.  We were successfully able to 
isolate four different sequences of UBE3B.  One of the clones matched the wild-type published 
sequence found in PubMed.  However, the other three clones contained point mutations, with 
some of them conserved across the different clones, suggesting the point mutants were not the 
result of the cloning reaction.  One of the clones also contained a stop codon fifty amino acids 
into the HECT domain of UBE3B.  The HECT domain contains the E3 ubiquitin ligase domain 
of UBE3B and deletion of almost the entire HECT domain likely creates an inactive protein.  
The other mutations have unknown effects due to the little information known on UBE3B 
structure and function.  The sequences of the different UBE3B sequences that we cloned are 
found in Appendix B (Page 120).  Complementation experiments with inactive UBE3B would 
be possible using the clone missing the HECT domain and would determine if the ubiquitin 
ligase activity is required for UBE3B’s role in alkylation survival.   
6.2 DISCUSSION 
We have demonstrated that expression of UBE3B and UNG correlate with tumor cell line 
survival when treated with the clinical alkylator TMZ.  We were interested in determining if 
these two proteins are differentially expressed in different cancers.  We found that expression of 
UBE3B can vary as much as eight fold in the cancer cell lines we studied.  Using the Cancer 
Genome Atlas (TCGA) and the Repository for Molecular Brain Neoplasia Data 
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(REMBRANDT) data sets we discovered that UBE3B and UNG expression vary in GBM when 
compared to normal controls.  Although, UBE3B was only found to be either down regulated or 
contain similar expression to controls, the expression pattern of UNG in brain tumors supported 
it as a potential target in GBM.  UNG was over expressed in brain tumors in general when 
compared to normal controls.  However, it was interesting to note that over expression of UNG 
was highest in GBM when being compared to even other brain tumor types.  Over expression of 
UNG correlated with a decrease survival in all glioma, suggesting that UNG expression is 
deleterious to brain tumor treatment or increases tumor growth.  These clinical data correlate 
with the screening results and pre-clinical testing.   
How UNG is playing a role in patient survival is still unknown.  The pre-clinical data 
suggests it may be due to increased resistance to chemotherapeutics such as TMZ.  However, this 
is not certain.  How UNG impacts alkylation survival is still uncertain.  UNG appears to play a 
role in cellular proliferation because of its involvement with CENP-A in mitosis.  It is possible 
that UNG over-expression enables increased tumor growth as decreased expression of UNG 
decreased proliferation in cell models (57).  While UNG’s role in repair of oxidative DNA 
lesions is a plausible explanation for contributing to alkylation survival, there are still 
experiments needed to prove this relationship.  Adding back separation of function point 
mutants, such as those used in studying class-switch recombination, to the knockdown cell lines 
and testing sensitivity on these cells would be very informative.  The mutants used would be 
deficient in DNA glycosylase activity to determine if repair of DNA is crucial, or have mutations 
in the N-terminal domain as that is required for class-switch recombination for unknown reasons.  
If the unknown function of the N-terminal domain is required, a new function potentially relating 
UNG and double strand break repair would be an interesting avenue to pursue.   
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7.0  MEASUREING REAL-TIME DNA REPAIR RATES WITH MOLECULAR 
BEACONS  
7.1 RESULTS 
7.1.1 Using different DNA lesions to probe catalytic activity of specific DNA glycosylases 
After validating the molecular beacons with either over-expression (MPG) (Figure 20, 
Figure 21) or knockdown of glycosylases (UNG) (Figure 7), we were interested in determining if 
a variety of well studied base lesions were repaired in unaltered control cells.  We used our new 
beacon design to improve the fluorescence signal (Table 7) and varied the base opposite the THF 
lesion, to determine if the base opposite the abasic mimic affected catalytic rate in the T98G 
nuclear extracts previously prepared.  To our surprise, the small differences in beacon design 
repeatedly revealed that the base opposing the THF lesion can drastically affect strand scission 
by APE1 (Figure 18).  The strand scission by APE1 was very similar when thymine, adenine and 
guanine bases were opposite the THF lesion, with a normalized maximum fluorescence 
approaching 1.0.  Strand scission was markedly reduced in molecular beacons with a cytosine 
opposite the THF lesion, as it obtained a maximum fluorescence of approximately 0.7 of 
normalized maximum fluorescence.  Although APE1 is not the rate limiting step for BER (135), 
the bases opposite the lesion may affect glycosylase lesion removal rates and must be considered 
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when comparing DNA repair rates and beacon designs.  The stand scission step of THF opposite 
cytosine bases in LN428 nuclear extract was similarly slower compared to adenine, thymine and 
guanine.   
 
Figure 18. The base opposite THF DNA lesions can affect APE1 strand scission.   
Using the molecular beacon assay we can sensitively measure DNA repair rates of several different enzymes.  The 
strand scission step mediated by APE1 is affected by the base opposite the lesion.  The molecular beacon assay was 
performed and analyzed as described above (Pages 26-33).  The control beacon with no lesion was used as a 
negative control and is the blue trace in all four graphs.  The positive control beacon containing the THF lesion was 
opposite a (A) cytosine, (B) thymine, (C) adenine or (D) guanine nucleotide.  The strand scission by APE1 was very 
similar when thymine, adenine and guanine bases were opposite the THF lesion, with a normalized maximum 
fluorescence approaching 1.0.  Strand scission was markedly reduced in molecular beacons with a cytosine opposite 
the THF lesion, as it obtained a maximum fluorescence of approximately 0.7 of normalized maximum fluorescence.   
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We then tested the repair capacity of the T98G nuclear extracts using all of our currently 
available molecular beacons (Table 7) to determine if we could measure repair activity to each 
lesion and if we could create a baseline to compare with the previously made glycosylase 
knockdown cell lines (Figure 19).   
 
Figure 19. T98G nuclear extracts endogenous proteins can remove several oxidative DNA lesions.  
The T98G nuclear extracts were used to test beacon design of several oxidative DNA lesions and endogenous 
protein levels were sufficient to remove the DNA lesions, but at drastically different rates.  (A) The removal of 2’-
deoxyuridine (orange) was the fastest lesion removed tested that required a DNA glycosylase.  The rates of (B) 
thymine glycol (red), (C) hypoxanthine (light blue), and (D) 5-fluorouracil (green) were much slower, but did 
appear to differ from that of the control beacon (blue trace in each panel), signifying repair of the molecular beacon.  
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Excluding the THF beacons that measure APE1 activity, the 2’-deoxyuridine beacon was 
the fastest repaired beacon.  Although uracil can be removed by UNG, SMUG1, TDG and 
MBD4, the uracil removal activity seen in the assay is likely from UNG as demonstrated 
previously using the T98G and T98G/UNG-KD cell lines (Figure 7).  The removal of thymine 
glycol (Tg) was not as robust as that of 2’-deoxyuridine yet it was still clearly elevated when 
compared to the control beacon.  The hypoxanthine and 5-fluorouracil had the lowest removal 
rates.  A low level of hypoxanthine repair was expected because we cannot detect MPG 
expression in the T98G cell lines by immunoblot.  However, the slow removal of 5-fluoruracil 
(5-FU) was interesting because several DNA glycosylases are able to remove that DNA lesion 
including UNG, SMUG1 and TDG (Table 3).  Although 5-FU was repaired, its repair was 
drastically slower than other beacon repair rates, even though 2-deoxyuridine is avidly removed.  
This is likely related to the rate of 5-FU removal in a cellular extract, as previous in vitro assays 
have incubated DNA incorporated with 5-FU for 20 hours before determining DNA lesion 
removal via electrophoresis (136).  Those experiments still had substantial substrate remaining 
after 20 hour incubating with 20 µg of nuclear proteins, which is 17 times longer and twice as 
much protein we used in the molecular beacon assay (136).   
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8.0  CONCLUSIONS AND DISCUSSION 
8.1 DISCOVERY OF TMZ SENSITIZING GENES BY SIRNA SCREEN 
GBMs are the most common and aggressive primary brain tumor with the current 
standard of care consisting of maximum surgical removal, radiation and TMZ (3-5). Many 
tumors are refractory to TMZ treatment with very poor outcomes. Difficulties in treating GBM 
make it a candidate for drug research since an increase in therapeutic options is necessary to 
improve survival rate. Because TMZ clinical efficacy is due to the O
6
-MeG lesion, much of the 
alkylation damage sensitization research has focused on this lesion. Unfortunately, previous 
attempts to improve efficacy of O
6
-MeG lesion cytotoxicity have been futile. The clinical trials 
testing the effectiveness of MGMT inhibitors (21, 23) do not show an increase in efficacy, 
particularly in TMZ-resistant GBM (22, 24, 25).  Due to the inherent difficulties and resistance 
of GBM to chemotherapies, any increase in cancer sensitization could impact patient outcomes.   
In these studies we investigated both new ways to improve cancer chemotherapy efficacy 
and ways to measure DNA repair which correlate with therapy resistance.  We sought to improve 
efficacy of TMZ, independent of the O
6
-MeG lesion.  By using a synthetic lethal siRNA screen 
toward “druggable” targets we biased the potential targets based on what genes are known to 
bind drug-like molecules, but otherwise we allowed the biology to direct our search for novel 
genes that modulate TMZ toxicity.  This enabled us to discover genes that impact DNA alkylator 
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survival, but have no known function related to DNA repair.  The approach allowed us to find 
the epistatic interaction between UNG and UBE3B that would not have been found by a 
candidate gene approach.   
Although we have learned much about essential biological processes for alkylation 
survival that are conserved from bacteria to humans, we have learned from the difficulties in the 
screen and would likely have modified our approach after obtaining more practical experience.  
One important adjustment would be the dose and duration of TMZ treatment.  Knowing more 
about alkylation survival, we would use a lower TMZ dose more likely to be found in patients, 
such as 100 µM, and measure cell survival after a longer duration such as the nine days used in 
the CyQuant assay.  The short time frame used in the screen precluded observation of many 
alkylation cytotoxicity effects as alkylators generally take several replication cycles to produce 
cytotoxic events.  This would be more challenging to undertake in the screen using 384-well 
plates due to the small area for growth, but modifications such as using stable cell lines to reduce 
days needed for siRNA transfection incubation or increasing well size by using 96-well plates 
could have made this possible.  One benefit of using the 384-well plates compared to 96-well 
plates was our ability to carry out the screen in triplicate to generate more reliable data for 
selection of positive hits, due to the lower cost of reagents when using a 384-well plate.  The 
increased replicates increased our statistical power and made our analysis more likely to 
represent true results. The inclusion of positive and negative controls for both transfection and 
TMZ dosing would have been helpful, since the screen only contained negative controls for both 
siRNA transfection and TMZ.  By transfecting a lethal siRNA we could have obtained a positive 
control for transfection efficiency.  Unfortunately, we were not aware of any genes that would 
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improve alkylation toxicity in the short-term when we began the screen, but by using a longer 
exposure to TMZ we could knockdown MGMT and increase T98G sensitivity to TMZ.   
To address the need for cancer selectivity, screening a normal control cell line in parallel 
to the T98G cell line would have been beneficial.  Although this would have doubled the cost of 
the screen, discovering the important genes and biological processes used in normal cells to 
survive alkylators is crucial.  With this information, essential sensitizing genes and biological 
processes from the T98G cell line could be compared to the normal control cell line, with 
overlapping genes and processes removed from further study.  This would focus target selection 
on genes that preferentially kill GBM cells when treated with TMZ or genes that selectively 
promote normal cell survival.  This would likely result in lower possible TMZ doses and 
enhanced tumor selectivity, which would reduce dose-limiting side effects and improve TMZ 
efficacy.  Selection of the correct normal control line for the comparison would be essential.  
TMZ’s cytotoxic effects on bone marrow cells causing myelosuppression, thrombocytopenia and 
neutropenia, can limit TMZ dosing (137).  Therefore, we propose that selecting a human bone 
marrow cell line, for the normal control would be critical for the comparison.  If practical 
constraints limit the control cell line to an immortalized cell line a myeloid precursor cell line 
such as the 32D cell line (138).  If the 32D cell line is not amenable to the screening procedure, 
Jurkat cells would be a possible, although less ideal control.  Jurkat cells are immortalized T-
cells derived from an acute T-cell leukemia patient and would yield baseline knowledge of bone 
marrow derived cells TMZ resistance mechanisms (139).  Current efforts to increase bone 
marrow resistance to TMZ induced O
6
-MeG lesion toxicity includes transplanting bone marrow 
overexpressing mutant MGMT protein (140).   The approach involves creation of bone marrow 
cells that stably express the MGMT protein with the P140K mutation, which render MGMT 
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insensitive to O
6
-benzyl-guanine inhibition (141).  Although the gene therapy methods have 
shown promise in pre-clinical trials, they have not yet entered clinical trials (142).  Studying 
TMZ resistance mechanisms in bone marrow-derived cell lines would yield potential targets to 
improve bone marrow survival and enable specific targeting of tumor resistance mechanisms, 
both resulting in increased TMZ efficacy.   
Even though the screen was not ideally prepared, we still discovered several important 
genes that contribute to TMZ sensitivity and uncovered some mechanistic insight into their 
survival mechanisms.  The genes we discovered to modulate DNA alkylator cytotoxicity were 
validated by using distinct shRNA vectors against the genes of interest and retesting sensitivity 
to TMZ.  This eliminated off-target effects of the siRNA and shRNA vectors and ensured we 
were pursuing true positive results.  We found that many genes and processes not previously 
thought to play a role in TMZ toxicity significantly impact alkylation sensitivity.  For example, 
UNG was previously known to remove uracil-based DNA lesions, interact with CENP-A and is 
required for class switch recombination.  However, UNG’s role in DNA alkylator survival was 
previously unknown.  Due to the multiple functions and pathways UNG is involved in, it is 
impossible to definitively determine from our experiments what function of UNG is responsible 
for alkylator sensitivity when UNG is depleted.  It is possible that the DNA repair activity of 
UNG is involved in removing cytotoxic oxidative lesions induced by TMZ and lack of UNG 
increases the amount of genotoxic lesions yielding increased cell death.  Also UNG is essential 
for class switch recombination, although this function is independent of UNG’s DNA 
glycosylase activity.  UNG is not required for stand break formation, but instead appears to be 
involved in resolution of the breaks to complete class switch recombination (54, 56).  Perhaps a 
mutant UNG can also confer a worse patient survival.  Over-expression of wild-type UNG may 
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not be essential, but instead UNG mutants that contain only glycosylase function, interaction 
with CENP-A or ability to perform class-switch recombination can also confer worse patient 
survival.  If this is true, it would emphasize one of the pathways UNG is involved for future 
study to determine what is important in this pathway that correlates with decreased patient 
survival with UNG over-expression.  Re-expression of shRNA resistant separation of function 
mutants in the T98G/UNG-KD cell line could delineate if UNG’s glycosylase activity or N-
terminal domain are required for alkylation sensitivity.  Determining the function of UNG in 
alkylation survival would be important to correlate with the decreased survival of brain tumor 
patients with tumors over-expressing UNG.   
We also determined that UNG expression varies in our tumor cell lines compared to 
normal human astrocytes, with UNG being highly over-expressed in both the T98G and LN428 
glioblastoma cell lines.  Although the over-expression varied in the two GBM cell lines, there 
was a 3-5-fold increase in mRNA expression when compared to normal human astrocyte 
controls.  This over-expression was statistically significant with p-values of 3.44972x10
-7 
for the 
LN428 cells and 2.84847x10
-6
 for the T98G cells.  To investigate whether clinical tumors also 
contain this over-expression, we mined TCGA and REMBRANDT data sets and discovered that 
UNG is upregulated in all brain tumors types compared to control tissues, with GBM having the 
highest expression level of all brain tumor types (133).  The frequency of two-fold UNG over-
expression varied from 14-33% of all GBM tumors in the two data sets.  Thus, UNG over-
expression occurs naturally in patient brain tumors.  Importantly, brain tumor over-expression of 
UNG has a strong negative correlation with patient survival when compared to brain tumors 
containing intermediate expression of UNG with a p-value of 1.0177x10
-4
 (133).  Why UNG up-
regulation is correlated with negative patient survival is not known.  UNG may have no direct 
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role in determining patient survival, but is merely a bystander marker useful for prognosis.  
Conversley, UNG may play a central role in patient survival and determining the important 
function of UNG in brain tumor patient survival would be important for brain tumor biomarker 
development.  Currently we assume that the DNA repair activity of UNG likely impacts 
cytotoxicity from TMZ treatment creating more resistant tumors.  However, UNG already has 
two known functions unrelated to its glycosylase activity and they could also be responsible for 
decreased patient survival.  Sequencing of UNG in the different patient tumors would lend 
insight into the required functions, with several “separation-of-function” mutants already 
described.  Testing of new mutants discovered in patient tumors for glycosylase activity, class 
switch recombination and assembly of CENP-A could easily be done in cell culture.  If mutants 
are not identified, we could also determine if UNG glycosylase activity is an important predictor 
of survival by using the molecular beacon assay.  Using the sensitive new molecular beacon 
design it may be possible to use small tumor samples to determine UNG catalytic rate.  This 
could be compared to normal controls and define the role of UNG’s glycosylase activity in 
patient survival and tumor resistance.  It would be interesting to determine if over-expression of 
UNG contributes to worse patient survival due to increased tumor resistance to alkylation 
treatment as predicted by our pre-clinical work.  However, much more work is required to 
determine how UNG over-expression impacts patient survival to brain tumor treatment.   
Although the discovery of UNG’s role in TMZ sensitivity in cell culture and its 
correlation to patient survival is exciting, other important observations made from the data 
analysis yield greater potential targets and biomarkers for TMZ response.  This stems from the 
analysis of our human screen results to similar alkylator sensitivity screens done in S. cerevisiae 
and E. coli (77, 78).  Many of the same biological processes significantly enriched in the human 
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screen were enriched in both screens from yeast and bacteria.  The conservation of these 
processes through evolution suggests these are the essential processes required for alkylation 
survival in bacteria, yeast and humans with non-essential or secondary processes lost during 
evolution.  There are a diverse collection of biological processes, ranging from DNA repair to 
modulation of transcription, translation, protein modifications and fatty acid biosynthesis that 
appear to be essential for survival after alkylation exposure. The many processes necessary for 
cellular survival after alkylation exposure likely stems from the alkylator’s ability to modify all 
macromolecules in a cell, thereby requiring repair of not only DNA, but also of RNA, proteins 
and fatty acids.  Contained in this diverse set of processes are the conserved processes in 
alkylator survival that could be potentially targeted anywhere in the pathway.  It is important to 
determine if inhibition of these processes by ablating other important proteins within the 
pathway also increase sensitivity to TMZ.   If more “druggable” genes in the conserved pathways 
are also essential for TMZ survival, this would yield a plethora of protein targets with potential 
tumor specific effects and generate a cadre of possible biomarkders to predict TMZ response and 
patient side-effect toxicity.  With personalized medicine being increasingly developed, 
determining the possible biomarkers to predict tumor response to therapy would be crucial.    We 
could potentially pre-determine who would derive the most benefit from treatment, diminish the 
costs of misguided treatments and reduce patient side effects in unresponsive patients.   
One of the enriched biological processes was protein modification processes that were 
validated using both the human and yeast system.  The knockdown of the human protein UBE3B 
significantly sensitized human cells to TMZ by approximately 45% in both short and long-term 
assays.  Notably, the concentration of TMZ used in the long-term assay was only 50 µM, well 
within the clinically achievable dose of TMZ.  This was unexpected because the mechanisms for 
  95 
short and long term survival to DNA alkylators are thought to be related, yet distinct.  Our lab 
has shown that short-term survival to alkylating agents is dependent on both BER status and 
NAD
+
 levels in the cell (67, 70).  Long-term survival to alkylators is usually dictated by 
resistance to the O
6
-MeG lesion since it is the most cytotoxic DNA lesion created by alkylators.  
However, over-expression of the MGMT protein in the T98G cells likely removes many of the 
O
6
-MeG lesions.  There are a myriad of methods for UBE3B to play a role to increase cell 
survival in response to TMZ, with several possibilities illustrated below.  The first is simplest, 
for UBE3B may promote MGMT expression or activity and lack of UBE3B decreases MGMT 
activity.  MGMT protein levels could be tested by immunoblot and MGMT activity can be 
measured using a fluorescence-based assay (143).  This mechanism is not likely because there is 
an increase in cell death in the short-term assay as well, which as previously described does not 
measure O
6
-MeG toxicity.  If this does occur, a separate function of UBE3B would have to 
promote cell survival in the short-term assay.  Second, UBE3B could modulate the MMR 
response and signaling to apoptosis for cell death mediated by O
6
-MeG lesions.  This could be 
determined by investigating UBE3B knockdown cells for MMR activity by measuring 
microsatellite instability.  This is also not likely because there is an increase in cell death in the 
short-term when UBE3B expression is inhibited.  If this does occur, a separate function of 
UBE3B would have to promote cell survival in the short-term assay.  Third, UBE3B could play a 
role in repair of BER substrates by modulating protein activity.  There is precedence for BER 
protein activity to be regulated by post-translational modifications such as phosphorylation, 
acetylation, methylation, ubiquitylation and SUMOylation (26, 144).  Many other DNA repair 
proteins are regulated by ubiquitylation.  Measuring BER activity in the wild-type and UBE3B-
KD cell lines could test this hypothesis.  BER activity can be measured using the molecular 
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beacon assay or traditional BER assays using 
32
P end labeling and denaturing gels (145, 146).  A 
fourth possibility is that UBE3B is regulating protein quality and turnover which impacts cell 
survival.  Fifth, UBE3B is involved in regulating DNA damage-mediated cell death.  This 
appears to be more likely since there is the epistatic relationship between UBE3B and UNG, 
another DNA repair protein, suggesting they are part of the same alkylation survival pathway.   
Investigating the epistatic relationship between UNG and UBE3B in DNA damage 
mediated cell death pathways to uncover potential drug targets would be an interesting next step.  
This relationship would be particularly interesting to study not only because UBE3B’s functions 
are essentially unknown, but also because it would identify other proteins in the survival 
pathway that may be potentially targeted to increase TMZ efficacy.  As mentioned previously, 
the known role of UBE3B in cellular processes is minimal and simple experiments such as 
tagging UBE3B with GFP to visualize sub-cellular localization is beneficial.  Using a 
fluorescently tagged UBE3B protein, it is possible to determine whether UBE3B changes 
locations, forms foci or associates with chromatin after TMZ treatment and would add to our 
basic understanding of the protein.  This would also improve our ability to predict potential 
interaction points between UBE3B and UNG in their survival pathway.  For example, if UBE3B 
is only located in the cytoplasm and never traffics to the nucleus, it likely is not involved in 
direct DNA repair like other ubquitin ligases. Instead it would more likely be involved in cell 
death signaling.  UBE3B likely has an indirect interaction with UNG that mediates their epistatic 
relationship and may regulate DNA repair activity in cells.  The BER activity can be measured 
by the molecular beacon assay or traditional repair assay methods.  Tagging of UBE3B for 
immunoprecipitation to discover possible substrates is also possible.  Another method for 
discovering UBE3B targets is transfecting tagged ubiquitin into wild-type and UBE3B 
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knockdown cells and immunoprecipitating the tagged ubiquitin.  Separating the tagged ubiquitin 
on a 2D gel to determine what proteins are ubiquitylated in the wild-type cells compared to the 
knockdown cell line.  We are also interested in determining if UBE3B knockdown sensitizes 
cells to other alkylating agents, such as cyclophosphamide, chlorabucil and dacarbazine, and 
other types of DNA damage induced by other chemotherapeutics, such as carboplatin, 
doxorubicin and etoposide.  This would help determine if UBE3B is involved in DNA repair and 
signaling of other genotoxic agents or sensitizes to TMZ in an alkylator specific manner.   
Critical to any TMZ adjuvant treatment would be introducing cancer selectivity to TMZ 
toxicity.  There are several methods available to confer tumor-selective killing.  One method is 
the creation of a compound that can enter all cells, but selectively kill tumor cells.  An example 
of a drug that employs this mechanism could be found in many of the targeted therapies such as 
the PARP inhibitor ABT-888 (Veliparib) or the Bcr-Abl inhibitor imatinib (Gleevec).  A second 
method would be to have a uniformly toxic compound, but selectively target the compound to 
cancer cells to minimize normal tissue exposure.  An example of this method is administration of 
radioactive iodine-131 for the treatment of thyroid tumors or the DNA alkylator streptozotocin 
for the treatment of metastatic pancreatic beta cell cancer.  The third method to selectively kill 
tumor cells would be local delivery of a toxic compound to tumor tissue, thereby limiting contact 
with normal tissue.  This is an extension of the second method to limit normal tissue exposure to 
a toxic agent.  An example of this method is the placement of Gliadel wafers in the tumor bed of 
GBM patients or tumor focused tumor radation therapy instead of whole body irradation.   
TMZ is a DNA alkylator that indiscriminately modifies macromolecules in all cells and is 
not easily adapted to the second and third methods stated above.  Although it may be possible to 
target TMZ specifically to cancers, as seen with the DNA alkylator streptozotocin, any 
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modifications to TMZ may disrupt the spontaneous breakdown required for conversion to the 
active methyldiazonium ion.  Local delivery of TMZ via wafer therapy is also possible, but 
GBM tumor resections are not always feasible, limiting frequency of wafer treatment.  Also, 
invasion of the tumor cells outside the tumor bed may not be effectively treated by the TMZ 
released via wafers.  The most promising methodology to improve TMZ selectivity is to target 
the resistance mechanisms that differ in cancer compared to normal tissue.  For example, PARP 
inhibitors selectively target cells and tumors defective in homologous recombination (83, 84).  
Although the PARP inhibitor mechanism of action in homologous recombination defective cells 
is controversial, the key idea is a specific mechanism of DNA repair is compromised in cancer 
cells and modulating parallel DNA repair pathways selectively induces cancer cell death (84, 
147).   
A deep understanding of all the required biological processes that modulate TMZ 
sensitivity will enable tumor specific targeting if sensitivity pathways or associated pathways are 
defective in cancers.  Discovering the overlapping TMZ sensitivity pathways in normal tissue 
and cancer will facilitate tumor selective target acquisition.  The large scale cancer sequencing 
and expression databases are beginning to uncover and quantify the genes and pathways 
disrupted in specific cancers.  The large datasets will generate targets for cancer therapy because 
of dysregulation of specific genes and pathways.  Equally important will be mapping 
chemotherapy sensitivity pathways to the datasets to discern if specific cancers or subsets of 
cancers are defective in repair pathways making them susceptible to current therapy or 
alternative treatment options.  For example, our lab has shown that although DNA alkylator 
treatment is not selective, by concurrently targeting the NAD
+
 biosynthesis pathway it may be 
possible to selectively induce tumor cytotoxicity from alkylation damage due to prevalent defects 
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in tumor NAD
+
 biosynthesis (70).  Likewise, it may be possible to inhibit TMZ sensitivity 
pathways and increase efficacy in a subset of glioma cases.  The UNG is up-regulated two-fold 
in approximately one-third of all GBM patients in the REMBRANDT database and UNG 
overexpression correlates with worse patient survival suggesting that UNG may be contributing 
to poor response (133).  Inhibiting UNG activity may increase TMZ efficacy in all tissue.  
However, the overexpression of UNG in the cancer tissue may make it more susceptible to 
chemical inhibition and yield a larger increase in TMZ sensitivity in tumors compared to normal 
tissue.  Chemical inhibition of UNG may increase TMZ’s specificity and efficacy.  More studies 
are necessary to characterize UNG’s role TMZ sensitivity and patient survival in GBM and 
glioma to validate UNG as an adjuvant drug target.   
 In summary, these studies suggest that alkylation resistance mechanisms are 
evolutionarily conserved. The collection of conserved biological processes in E. coli, S. 
cerevisiae and humans composes an Alkylation Functionome that includes many novel proteins 
not previously thought to impact TMZ or MMS resistance. We can now begin to appreciate the 
multiple processes that are required for cellular survival after alkylation damage and form an 
unbiased approach to discovering targets for adjuvant chemotherapy.  This is an important next 
step, so as to determine if genes that were not tested in the screen, but share conserved biological 
pathways, are also possible targets to enhance TMZ response.  Because the analysis enriched for 
the most essential pathways and genes, there may be functional overlap of the conserved genes 
and pathways.  The highly conserved nature of these biological processes should generate 
significant interest into studying potential gene and pathway interactions.  Investigating the 
relationships between these genes and biological processes is important in determining pathway 
redundancy.  Importantly, some of the targets studied have already been shown to be 
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significantly up-regulated in cancers and correlate with worse patient survival.  If targeted by 
adjuvant chemotherapies, this would potentially create tumor specific sensitivity, increase the 
therapeutic window and reduce side effects.  However, due to the plethora of resistance 
mechanisms it is possible that depletion or inhibition of one gene in a conserved biological 
process cannot overcome the drug resistance due to compensation by another gene or biological 
process.  By investigating multiple pathways and processes we can determine important 
interactions that promote tumor survival to be targeted for improved chemotherapy response.   
 
8.2 MOLECULAR BEACON ASSAY EXPERIMENTS 
The molecular beacon assay is a very versatile assay enabling sensitive and precise real-
time measurements of DNA repair activity in nuclear extracts.  One of the interests in the lab has 
been to move the assay into live cells using a modified beacon design (Table 6), which 
incorporates a Cy5 fluorophore in the loop of the hairpin.  This secondary fluorophore does not 
overlap with the absorbance/emission spectra of the 6-FAM dye or the Dabcyl quencher.  The 
Cy5 would be used as a normalization fluorophore.  The modified molecular beacon would be 
transfected into cells, similar to siRNA due to the similar structure and size, and the appearance 
of 6-FAM fluorescence would be monitored as molecular beacon repair rates and would be 
normalized to the Cy5 fluorophore.  The extra Cy5 not only eliminates any temperature 
adjustments to melt the hairpin after DNA repair readings, but also allows us to normalize for 
transfection efficiency in every cell measured.  We could use a confocal microscope to monitor 
both dyes simultaneously.  Furthermore, the development of our Microwell Comet Assay 
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dovetails nicely with measuring the beacons in real-time cells (88, 148).  The Microwell Comet 
Assay enables separation of each cell into single wells in defined locations on a 96-well plate.  
The gel works by having small wells, roughly 20 microns, which can only fit one cell in each 
well.  The well locations are preprogrammed into the computer that uses the individual cell 
location to quickly scan the plate for all cells to increase throughput of individual cell images 
without having to manually scan for isolated cells for measurements.  This would allow a large 
sample size of individual cells to be scanned for Cy5 dye, which would correspond to beacon 
uptake, and followed for 6-FAM fluorescence, corresponding with DNA repair activity.  
Furthermore, the ability to scan individual cells quickly and monitor their location and 
fluorescence would yield an interesting ability to correlate real-time DNA repair rates with 
genomic DNA damage.  For example, we could use the Microwell Comet Assay to separate our 
cells and treat them with molecular beacons to determine DNA repair rates of the individual 
cells.  Since these cells are now already in the wells we could then carryout a comet assay on the 
same wells.  With this in place we could monitor an individual cell’s ability to repair DNA and 
correlate that to incorporated genomic DNA damage.  This could be used with different DNA 
repair deficient knockdown cell lines, such as the isogenic cell lines being developed in the 
Sobol Lab, or known repair deficient cancer cell lines.  This would enable a direct correlation of 
how DNA repair rates in cells affect genomic lesions, because all the experiments are 
individually normalized and controlled.  This could be further used to discover if repair rates of 
alkylation damage correlates with genomic DNA damage.  For example, the Microwell Comet 
Assay and molecular beacons can be used to determine DNA repair rates of the individual cells 
and record their exact location.  Cells are then washed to remove the molecular beacons before 
treating the cells with a DNA alkylator such as MNNG.  The cell’s genomic DNA damage 
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measured via a Comet Assay would be measured.  Using the level of DNA repair measured by 
the molecular beacons and genomic DNA damage measured by comet assay, we could determine 
if robust DNA repair was inverselty correlated with levels of genomic DNA damage measured in 
a time dependent manner.  An alternative would be to plate cells in the Microwell Comet Assay, 
measure molecular beacon repair rates, treat with MNNG and monitor apoptosis or other forms 
of cell death.   By measuring DNA repair rates and cell death the correlation of increased DNA 
repair promotes or prevents cell survival after alkylation or any type of DNA damage exposure 
in different cell types would be elucidated.  This would determine if over-expression or 
knockdown of DNA repair proteins actually impact the rate of DNA repair, cell survival 
signaling or other methods of DNA damage tolerance that do not actually repair the DNA to the 
original sequence.  Our lab has already optimized MNNG cell treatment before measuring 
genomic DNA damage using the Microwell Comet Assay.  Although adding the molecular 
beacon step would increase the difficulty of the experiment, another washing procedure is 
possible before determining DNA damge via the Microwell Comet Assay.  By combining several 
novel methods in live cells we could learn mechanistic detail into not only rates of DNA repairs, 
but also have an easy method to determine what genes actually impact the rate of repair and 
correlate these to survival.   
The role of functional biomarkers would be another important avenue to investigate.  Due 
to the predominance of genotoxic chemotherapeutic drugs and cancers containing inherent 
defects in DNA repair, the development of functional DNA repair assays that can be used to 
monitor cancer biomarkers to predict outcome of treatment and predisposition to cancer would 
be important clinical tools.   The molecular beacon assay enables sensitive and precise 
measurements of DNA glycosylase activity.  Our lab has shown that MPG activity impacts 
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cancer cell line sensitivity to TMZ (148).  MPG expression and sensitivity to DNA alkylators has 
been a controversial topic.  Several papers show that in different biological systems, MPG 
expression can either increase or decrease sensitivity to alkylating agents (101, 105, 149).  
However the expression of MPG alone cannot accurately predict survival to DNA alkylators, 
because MPG is involved in a pathway which uses over 20 different proteins (26).  DNA 
polymerase β (Polβ) also plays a critical role in alkylating agent toxicity and is likely a 
confounding factor in some studies investigating MPG expression as many groups do not 
interrogate Polβ expression or activity.  Polβ expression and more importantly activity can 
compensate for high expression of MPG and the balance of BER needs to be considered when 
studying alkylation damage.  The need for functional DNA repair assays to ameliorate this 
confusion is critical.   
MPG clinical tumor cell expression has been reported to correlate with worse survival in 
clinical cases (149).  However, they used an antibody that does not recognize their protein of 
interest as their immunoblot recognized a 24 kDa protein, when MPG is actually a 34 kDa 
protein.  To clarify the outcomes, a functional assay would enable groups to accurately determine 
if MPG and Polβ tumor activity dictate alkylation sensitivity more accurately than expression.  
Towards these ends our lab is developing molecular beacons to accurately measure MPG activity 
in tumor lysates or primary tumor cells.  However, we have also been developing a similar 
molecular beacon approach to quantify Polβ polymerase activity in cell lysates and subsequently 
in live cells.  This approach would take advantage of pyrene deoxyriboside’s ability to be 
quenched by thymine and uracil DNA bases (150).  A single-stranded DNA that forms a hairpin 
structure, containing internal pyrene deoxyriboside fluorophore adjacent to a THF site would 
enable efficient detection of fluorescent signal (150).  However, when incubated with nuclear 
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lysates, the active proteins would recognize and repair the abasic site leaving an undamaged 
DNA strand.  The newly incorporated DNA base would efficiently quench the fluorescence and 
loss of signal would correspond with repaired DNA. The oligonucleotide will be larger than that 
already used for the molecular beacons to ensure the oligo that is cut by APE1 does not 
dissociate quickly from the other DNA strand.  Based on previous BER assay work using 
32
P 
end-labeling, a stem of 30 bases should be sufficient to maintain the stem-loop structure and 
allow BER proteins to correctly process the THF and subsequent DNA intermediates (146).  This 
would enable us to accurately measure Polβ polymerase activity in real-time and not only enable 
us to screen for inhibitors of Polβ, which is a wide interest in the field (151), but to also 
determine if the relationship between MPG and Polβ activity can accurately predict sensitivity to 
alkylating agents in clinical tumor samples.  The production of a functional biomarker assay 
would be a boon to the field as the current best assays only measure expression or promoter 
methylation to predict sensitivity to TMZ.  Polβ is known to have many mutations in cancer, but 
the functionality of many of these mutations is unknown (151).  Also the expression levels may 
not accurately predict protein activity, which would undermine correlative studies.  Thus, 
development of both DNA glycosylase and Polβ functional assays in clinical tumor samples is an 
important step to learn how to most accurately predict sensitivity to TMZ and to enable us to 
accurately measure the pathways to manipulate the proteins via chemical inhibitors for increased 
clinical benefit.   
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APPENDIX A.  OPTIMIZATION OF MOLECULAR BEACON AND CYQUANT 
ASSAYS 
A.1 MOLECULAR BEACON DEVELOPMENT AND OPTIMIZATION 
In the course of the project we needed to determine if DNA repair rates correlate with 
response to alkylating agents.  Therefore, we developed and optimized a DNA repair assay that 
enables us to measure real-time repair rates of nuclear cell extracts with enough accuracy to 
determine enzymatic kinetic parameters and to validate or screen inhibitors.  This highly 
sensitive and quantitative assay is also applicable to the analysis of purified proteins, enabling 
studies on substrate specificity by altering the molecular beacons accordingly. Finally, the assay 
is applicable to analysis of tumor and tissue lysates, providing an opportunity to measure 
functional DNA repair endpoints as biomarkers of response or therapeutic efficacy, as we have 
suggested for evaluating tumors for PARP1 inhibitor potentiation of the alkylating agent 
temozolomide (148).   
We first designed the molecular beacons as described above (Page 25, Figure 1) to 
determine rates of the DNA glycosylase MPG, because we had previously characterized repair 
rates of MPG in a glioblastoma cell line (LN428) with low levels of endogenous MPG and in the 
LN428 cell line over-expressing MPG (LN428/MPG) using the standard 
32
P-endlabeling 
methodology previously (152).  Using these cell lines we could prepare nuclear extracts from 
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both cell lines as described above (Page 25) and determine DNA repair rates of a control beacon 
(FD-Con, Table 5) and the MPG specific DNA lesion ethenoadenine (FD-MPG1, Table 5) (15, 
148).  The same BER-beacon structure with a normal adenine was used as the control substrate.  
Following removal of 1A by MPG and subsequent DNA strand excision by APE1 5′ to the AP 
site, the fluorophore 6-FAM is separated from the quencher (Dabcyl) and the increase in 
fluorescence signal (517 nm) is proportional to the level of MPG activity (Figure 1).  The 
LN428 lysate incubated with the control beacon (Figure 20D, red filled squares) had a minimal 
(if any) increase in fluorescence, indicating the control beacon is largely intact. The LN428 
lysate has little or no endogenous MPG activity, since when incubated with the beacon 
containing the MPG-specific substrate 1A, there was no observable change in fluorescence 
(Figure 20D, green open squares). The LN428/MPG lysate also did not have a negligible 
increase in fluorescence when incubated with the control beacon (Figure 20D, orange open 
circles), indicating that MPG over-expression does not increase cleavage of normal DNA.  
However, the LN428/MPG lysate exhibited robust MPG activity visible with a large increase in 
fluorescence when incubated with the molecular beacon containing the MPG substrate 1A 
(Figure 20D, filled blue circles). This corresponded to an overall 7.9-fold increase in MPG 
activity (measured at 60 min), as compared with the LN428 cells and an estimated rate of repair 
(based on the slope of the curve from 15 to 30 min) of 107.00 AU/min, whereas the background 
rate of repair in the LN428 cell lysate was similar to the background signal using the control 
beacon (14.64 AU/ min). This demonstrates that the LN428/MPG cell line has increased 
functional MPG and does not recognize normal DNA as a substrate. These data are in-line with 
our earlier report showing that over-expression of MPG results in an increase in DNA 
glycosylase activity (148).   
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Figure 20. Increased DNA glycosylase activity in MPG over-expressing LN428/MPG cells as 
determined by the DNA Glycosylase Molecular Beacon Activity Assay.  
DNA glycosylase activity specific for removal of the MPG substrate 1A was measured in nuclear lysates from the 
control cell line (LN428) and the MPG over-expression cell line (LN428/MPG), as described in the Materials and 
Methods section. Each lysate was analyzed using either the control-beacon or the 1A-beacon: LN428 lysates 
(control-beacon, red filled squares; 1A-beacon, green open squares) and LN428/MPG lysates (control-beacon, 
orange open circles; 1A-beacon, filled blue circles).  Results are reported as the mean fluorescence response unit of 
3 independent experiments + S.E.M. 
 
With this method in hand, we wanted to determine if DNA glycosylase repair rates 
correlated with cellular survival, if different lesions for the same glycosylase yields similar 
results and if knockdown of essential BER proteins, such as XRCC1, affected the DNA repair 
rate.  Therefore, we tested four different glioblastoma cell lines that had endogenous levels of 
protein (LN428), over-expressed MPG (LN428/MPG), had reduced XRCC1 via shRNA 
knockdown (LN428/XRCC1-KD), and both over-expressed MPG and had reduced XRCC1 
(LN428/MPG/XRCC1-KD), for sensitivity to the alkylator MMS and real-time repair rates of 
two DNA lesions (εA and Hx), which are substrates of MPG (15, 88).  Furthermore, εA inhibits 
DNA replication and is thus a toxic base lesion (153, 154).  We first determined that the MPG 
over-expression cell line did have elevated levels of MPG as the LN428 and LN428/XRCC1-KD 
cells had levels of MPG lower than our ability to detect (Figure 21A).  To compare the 
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expression levels of XRCC1 and MPG among the four cell lines, the immunoblot was scanned 
and quantified using NIH Image J and the associated analysis software package, normalizing the 
expression across the four cell lines to the MPG cells and to the expression of PCNA within each 
sample. As indicated in the plot of relative protein expression (Figure 21B), the MPG expression 
levels are very similar when comparing the LN428/MPG and LN428/MPG/XRCC1-KD cells. 
Similarly, the expression of XRCC1 is similar when comparing the LN428 and LN428/MPG 
cells. Importantly, no expression of XRCC1 was detected in the LN428/XRCC1-KD and 
LN428/MPG/XRCC1-KD cells.     
We assessed the ability of cell extracts from LN428WT, XRCC1-KD, MPG and 
MPG/XRCC1-KD cells to excise εA, Hx or tetrahydrofuran (THF), an abasic site analog (155).  
We observed minimal fluorescence when extracts were incubated with a control molecular 
beacon that contained no lesion (Figure 21C). Since the signal (fluorescence) is generated 
following base lesion removal and abasic site hydrolysis by APE1, we also tested each lysate 
using a THF beacon to ensure that all four lysates could similarly cleave an abasic site. As 
expected, a similar increase in fluorescence was observed by all four of the cell extracts when 
evaluated for APE1 activity using the THF beacon (Figure 21D). It should be noted that we did 
not observe any difference in activity between the XRCC1 expressing cells (LN428WT and 
MPG) and the XRCC1-KD cells (XRCC1-KD and MPG/XRCC1-KD); indicating that cleavage 
of the AP site by APE1 is not influenced by XRCC1. An earlier report using purified enzymes 
suggested that XRCC1 stimulates APE1-mediated 3’–5’ exonuclease activity but it is not likely 
that this activity of APE1 is measured in this assay (156). However, our data are in contrast to an 
earlier report suggesting that XRCC1 and APE1 interact and that XRCC1 stimulates APE1 
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activity (157). Clearly, such an XRCC1-dependent stimulation of APE1 activity is not observed 
here, at least for the hydrolysis of the THF abasic site analog.   
Conversely, a molecular beacon containing Hx resulted in a time-dependent increase in 
fluorescence when incubated with extracts from LN428WT, XRCC1-KD, MPG and 
MPG/XRCC1-KD cells, which is indicative of base release by the MPG glycosylase and 
cleavage of the resulting AP site (Figure 21E). As expected, cells over-expressing MPG (MPG) 
yielded the highest increase in fluorescence, which is consistent with these cells being the most 
efficient at excising the Hx lesion. However, when XRCC1 expression is knocked down in the 
MPG cells (MPG/XRCC1-KD), there is a decrease in the observed fluorescence (Figure 21E). 
The observed 25% reduction in glycosylase activity in the XRCC1-deficient cells (when 
measured at 40 min) indicates that XRCC1 facilitates MPG excision of Hx, which is consistent 
with a previous report using purified recombinant proteins [39]. In contrast to the cells over-
expressing MPG, the molecular beacon assay yields very little signal for the LN428WT or the 
XRCC1-KD cell extracts. The nominal increase in fluorescence is probably due to the 
exceptionally low amounts of MPG in the LN428WT parental cell line. Indeed, the levels of 
MPG in the LN428WT parental cell line and the XRCC1-KD cell line are so low as to preclude 
noticeable detection by western blot (Figure 21A). Thus, additional expression of MPG leads to 
a significant increase in the excision of εA and Hx.   
To learn if these observations are can be generalized to other MPG substrates we queried 
whether εA excision by MPG could be facilitated by XRCC1. We incubated cell extracts from 
the glioblastoma cells with a molecular beacon containing εA. Similar to the Hx molecular 
beacon, a time-dependent increase in fluorescence was observed following incubation with 
lysates from LN428WT, XRCC1-KD, MPG and MPG/XRCC1-KD cells. Of the cell lines 
  110 
examined, the MPG cells yielded the greatest increase in fluorescence and the MPG/XRCC1-KD 
cells yielded a significant (45% at 40 min) reduction in the kinetics of BER initiation (Figure 
21F). The difference in the observed fluorescence between the MPG cells and the MPG/XRCC1-
KD cells indicates that XRCC1 does indeed facilitate MPG excision of εA. Collectively, these 
data indicate that XRCC1 is capable of stimulating the MPG-mediated excision of two 
inflammation-associated base lesions, Hx and εA, in vitro.  
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Figure 21. XRCC1 facilitates MPG-mediated NO•-induced base lesion removal.  
(A) Immunoblot showing expression of MPG and XRCC1 protein in wild type (LN428), MPG over-expressing cells 
(MPG), XRCC1 knockdown cells (XRCC1-KD), and MPG over-expressing cells with XRCC1 knocked down 
(MPG/XRCC1-KD). (B) Bar graph showing the relative protein expression of MPG and XRCC1 in LN428, MPG, 
XRCC1-KD and MPG/XRCC1-KD cells. The immunoblot in (A) was scanned and quantified using NIH Image J 
and the associated analysis software package, normalizing the expression across the four cell lines to the MPG cells 
and to the expression of PCNA within each sample. (C–F) Fluorescent molecular beacon assay indicating XRCC1 
facilitated excision of NO•-induced base lesions by MPG from DNA double-stranded oligonucleotides containing 
(C) no lesion, (D) an abasic analog THF, (E) hypoxanthine (Hx) or (F) 1,N6-ethenoadenine (εA). 
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A.1.1 Molecular beacon DNA repair rates correlates with genomic DNA damage and 
survival to alkylating agents 
We wanted to confirm that XRCC1-KD not only affected DNA repair rates, but also 
impacted cell survival to alkylators.  In collaboration with Dr. Bevin Engleward, the genomic 
DNA damage of the LN428, LN428/MPG, LN428/XRCC1-KD and LN428/MPG/XRCC1-KD 
cells was determined using an alkaline buffer comet assay to measure not only DNA strand 
breaks, but also abasic sites, a BER intermediate.  They determined that the 
LN428/MPG/XRCC1-KD cells contained significantly more genomic DNA damage 4 hours 
after treatment with MMS when compared to controls.  This data fit with the decreased DNA 
repair rates seen in the molecular beacon assay and we sought to determine if survival to 
alkylators correlates with decreased DNA repair rates and increased genomic DNA damage.  We 
then treated the four different cell lines with vehicle or various doses of MMS for four hours, the 
same time frame that contained increased genomic damage in the comet assay, and measured 
survival via an MTS assay (Figure 22).  We found that as previously reported the LN428 cells 
were not sensitive; while LN428/MPG cells are sensitive to alkylating agents (67, 70, 148).  
However, the LN428 XRCC1-KD cell line was not sensitive, likely due to the undetectable level 
of MPG to initiate BER.  The most sensitive cell line was LN428/MPG/XRCC1-KD cell line, 
which was significantly more sensitive to MMS than the all three other cell lines, suggesting that 
once repair is initiated XRCC1 performs a critical survival function, likely related to the defect in 
DNA repair observed using the molecular beacon and comet assays.  The strong correlation 
between DNA repair rates, genomic DNA damage and cellular survival after alkylation treatment 
encouraged us to develop better methods to measure DNA repair rate, with the goal to measure 
DNA repair in vivo.   
  113 
 
Figure 22. Role of XRCC1 and MPG in human glioblastoma cells following exposure to MMS. 
MMS induced cytotoxicity in LN428, LN428/MPG, LN428/XRCC1-KD and LN428/MPG/XRCC1-KD cells. After 
treatment (4 h MMS followed by 48 h in normal media), viable cells were determined using a modified MTT assay. 
Plots show the % viable cells as compared to untreated (control) cells. Means are calculated from six values in each 
experiment. Results indicate the mean ± S.E. of three independent experiments. 
 
A.1.2 New molecular beacon design improves signal detection 
Upon further research into molecular beacon design, we discovered that 6-FAM 
fluorescence is partially quenched when in close proximity to a guanine base.  Our original 
design created a beacon with guanine adjacent to the 6-FAM fluorophore (Table 5).  We 
designed new molecular beacons by replacing the guanine abutting the 6-FAM with a cytosine to 
take advantage of the potential increase in fluorescence (Table 7).  The new THF (FD-THF2) 
beacon was tested in parallel with our old beacon designs (FD-Con and FD-THF) using nuclear 
lysates from the LN428 and LN428/MPG cell lines.  We expected identical results from the two 
different cell lines, as seen in Figure 21, due to the same levels of APE1 in each lysate.  
However, we did expect a modest increase in fluorescence with the new beacon design when 
  114 
compared to the old design.  To our surprise, the new beacon design yielded over a 300% 
increase in signal when compared to the old design (Figure 23).  This new design was 
incorporated into all our new molecular beacons and the increased signal potentially enables live 
cell imaging of the beacons to determine in vivo DNA repair rates.  Further, we determined that 
pre-chilling all the solutions and mixing the reactions on ice drastically reduced the initial 
variability of the measurements.  This reduces the amount of beacon that is cleaved while mixing 
the plate and before beginning measurement readings.   
 
Figure 23. The nucleotide adjacent to 6-FAM fluorophore impacts fluorescence signal. 
The substitution of a cytosine for the guanine adjoining the 6-FAM fluorophore yields a 300% increase in maximum 
signal, enabling more precise measurements of DNA repair rates.  The large increase in signal can be seen in both 
the LN428 and LN428/MPG cell lines when comparing the FD-THF1 to the FD-THF2 beacon.  As expected, using 
different cell lysates did not impact removal of the THF lesion, since both lysates have equal amounts of APE1.  
Results are the average of two independent experiments with error bars representing ± SEM.   
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A.1.3 Normalization analysis of molecular beacons 
Although the background levels of fluorescence were low and the results were very 
consistent, we noticed there was high variability in absolute fluorescence when using different 
qRT-PCR machines.  The relationships to the different beacons were the same, but plotting the 
absolute fluorescence was not possible if using different machines.  To enable comparisons 
across machines, we developed a different analysis method to normalize for well-to-well and 
machine differences.  This was done by adding several steps at the end of the beacon protocol to 
collect absolute fluorescence data that could be used for normalization.   
  We determined DNA repair rates by measuring fluorescence every 20 seconds for 60, 
90 or 120 min.  The beacons were then incubated sequentially at 60°C, 65°C, 70°, 75°C, 80°C 
for 5 min at each temperature.  The average fluorescence value at each temperature was 
determined.  The maximum average fluorescence value in each well was used to normalize the 
beacon fluorescence in each corresponding well to account for pipetting error, well to well 
variability of measurements in the machine and machine to machine variability in fluorescence 
measurements (Figure 24).   
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Figure 24. Raw and normalized data for LN428 and LN428/MPG cells extracts.   
AP endonuclease activity specific for hydrolysis of the abasic site analog tetrahydrofuran (THF) was measured in 
nuclear lysates from the control cell line (LN428) and the MPG over-expression cell line (LN428/MPG). Each lysate 
was analyzed using either the BER Molecular Beacon Control (LN428, green; LN428/MPG, purple) or the BER 
THF Molecular Beacon (LN428, blue; LN428/MPG, red). Results are reported as (A) the mean fluorescence 
response units and (B) the same data normalized as described above (Page 33) (THF = tetrahydrofuran).  DNA 
glycosylase activity specific for removal of the MPG substrate hypoxanthine (Hx) was measured in nuclear lysates 
from the control cell line (LN428) and the MPG over-expression cell line (LN428/MPG). Each lysate was analyzed 
using either the BER Molecular Beacon Control (LN428, green; LN428/MPG, purple) or the BER Hx Molecular 
Beacon (LN428, blue; LN428/MPG, red). Results are reported as (C) the mean fluorescence response units and (D) 
the same data normalized as described above (Page 33) (Hx = hypoxanthine). 
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A.2 CYQUANT ASSAY OPTIMIZATION AND DEVELOPMENT 
The CyQuant assay yields similar results to that of the clonogenic survival assay.  The 
clonogenic survival assay is the standard for cytotoxicity studies, but is dependent on the cells 
understudy to form good colonies that can be counted.  Because our cell lines studies do not for 
colonies, we needed to develop the CyQuant assay to generate long-term survival results.  The 
CyQuant assay uses a sensitive DNA intercalating dye, similar to ethidium bromide that 
fluoresces when bound to DNA.  Using the CyQuant dye, we can accurately measure the small 
amounts of DNA, which is proportional to the number of cells present.  Because the CyQuant 
dye is more sensitive than ethidium bromide, we can determine small number of cells, yielding 
similar results to that of a clonogenic survival assay.   
We first determined the correct number of cells to be seeded per well.  We seeded 
different concentrations of LN428 cells and measured the fluorescence at 8, 9 and 10 days after 
mock treatments.  We sought a concentration of cells that were within the linear range of the 
experiment (Figure 25).  We selected 9 days of treatment to maintain a minimum of five 
doubling times, to increase the dynamic range of the experiment, and because it enabled greater 
than 50 cells per well which decreases pipetting errors and increases the precision of the 
experiment.  We chose a concentration of 70 cells per well since the 100 cells per well appeared 
to have growth restriction, by comparing day 8 to day 9.   
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Figure 25. CyQuant cell seeding optimization for LN428 and T98G cells. 
The CyQuant cell seeding experiments were done for the LN428 and T98G cell lines due to their different doubling 
times. (A) The LN428 cell line was seeded at different cell densities and had their fluorescence measured either 8, 9 
or 10 days after mock treatment.  A cell density of 70 cells per well and 9 days of treatment was selected as seeding 
density to maintain fluorescence measurements in the linear range.  (B) The T98G cell line was seeded at different 
cell densities and measured 9 days after mock treatment.  The 9 days were chosen to stay consistent with the LN428 
cells.  A final concentration of 125 cells per well was selected for the T98G cells to maintain measurements in the 
linear range.   
 
We then validated the assay by using the LN428, LN428/MLH1-KD, LN428/MSH2-KD 
and LN428/MSH6-KD cell lines treated with the alkylating agent MNNG.  The parental LN428 
cells are resistant to alkylators in short-term cytotoxicity assays, but are sensitive to alkylators in 
long-term survival assays due to an intact mismatch repair and lack of MGMT expression (67, 
70, 148).  However, the LN428/MLH1-KD, and LN428/MSH2-KD and LN428/MSH6-KD cells 
are deficient in mismatch repair and are therefore resistant to alkylators (17, 19, 70).  The 
CyQuant assay was validated as the LN428 cells were very sensitive to MNNG at very low 
doses, while all three MMR defective cell lines maintained very high survival rates, indicative of 
very resistant cell lines (Figure 26).  With the CyQuant assay we can clearly determine 
alkylation survival similar to that of a clonogenic survival assay.   
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Figure 26. Parental LN428 cell line is sensitive to MNNG while cells defective in mismatch repair are 
resistant to DNA alkylating agents in long-term CyQuant assay.   
Cells were seeded at 70 cells per well and treated with various doses of MNNG.  The parental LN428 cells are 
sensitive to alkylators in a long-term assay due to a functional MMR pathway and lack of MGMT expression.  The 
LN428 knockdown lines tested are defective in key enzymes in MMR and are therefore resistant to alkylation 
cytotoxicity.   
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APPENDIX B. SEQUENCE OF UBE3B CLONED FROM LN428  
B.1 CLONE 2 – WILD-TYPE 
Clone 2 contained wild-type sequence and was identical to the published PubMed 
sequence.  The DNA sequence is below.   
ATGTTCACCCTGTCTCAGACCTCGAGAGCATGGTTCATCGATAGAGCCCGTCAGGCACGAGAAGAAAGGCTTGTGCA
GAAGGAACGGGAGCGGGCAGCTGTTGTGATCCAGGCCCATGTCCGGAGTTTTCTCTGTCGGAGTCGACTGCAGAGAG
ATATCAGGAGAGAGATTGATGACTTTTTTAAAGCAGATGACCCTGAGTCCACTAAAAGAAGTGCACTTTGTATTTTC
AAGATTGCCAGGAAACTGCTGTTCCTATTCAGAATCAAAGAGGATAATGAGAGATTTGAGAAGTTGTGTCGCAGCAT
CCTGAGCAGCATGGATGCTGAGAATGAGCCTAAGGTGTGGTATGTGTCCCTGGCTTGTTCTAAGGACCTCACCCTCC
TTTGGATTCAACAGATCAAGAACATTTTGTGGTACTGCTGTGATTTTCTCAAGCAGCTCAAGCCTGAAATCCTGCAG
GACTCCCGACTCATCACCCTGTACCTCACGATGCTTGTCACCTTCACAGACACTTCAACGTGGAAAATTCTTCGGGG
AAAAGGTGAAAGTCTTCGACCAGCGATGAACCACATTTGTGCAAATATAATGGGACATCTCAACCAGCATGGATTTT
ATTCTGTGCTGCAGATATTGTTAACCCGTGGCCTGGCAAGACCCCGTCCTTGTCTATCCAAAGGCACTTTAACAGCA
GCTTTTTCTCTAGCGTTACGCCCTGTGATTGCTGCACAGTTCTCAGACAATCTGATTCGGCCGTTCCTCATCCACAT
CATGTCTGTGCCTGCTCTGGTGACTCATCTCAGCACAGTGACCCCTGAGCGCCTCACTGTTTTAGAATCCCATGACA
TGCTTCGTAAATTCATCATATTTTTAAGAGACCAAGATCGATGCCGTGATGTATGTGAAAGTTTAGAAGGATGCCAT
ACGCTTTGTCTAATGGGCAACCTCCTACACTTGGGCTCCCTCAGCCCCAGAGTGTTAGAGGAGGAGACAGATGGGTT
CGTGAGTTTGCTCACCCAGACGCTGTGCTACTGTCGGAAGTATGTGTCTCAGAAGAAGTCCAACCTGACCCACTGGC
ATCCTGTCCTTGGCTGGTTCTCCCAATCTGTGGATTATGGCCTTAACGAGTCAATGCACTTGATCACCAAACAGCTG
CAGTTCTTGTGGGGGGTGCCTCTGATCCGGATCTTCTTCTGTGACATCCTGAGCAAGAAGCTACTGGAGAGCCAGGA
GCCAGCCCACGCACAGCCAGCATCCCCTCAGAATGTGCTCCCAGTGAAGAGTCTCCTAAAGCGTGCTTTTCAAAAGT
CGGCATCAGTCCGGAATATTCTCAGGCCTGTCGGGGGTAAACGGGTCGACTCTGCAGAAGTCCAGAAGGTTTGCAAC
ATCTGTGTCCTCTACCAGACCTCGCTGACAACTCTCACACAGATTCGGCTGCAGATACTCACAGGTCTCACTTACCT
TGATGACCTGCTTCCCAAACTGTGGGCATTTATCTGTGAGCTCGGGCCCCACGGAGGGTTAAAGCTCTTCTTGGAAT
GCCTGAACAATGACACTGAAGAGTCCAAGCAACTCTTGGCCATGCTGATGCTGTTCTGTGACTGTTCGCGGCACCTC
ATCACAATCCTTGATGACATTGAAGTTTATGAAGAACAGATTTCATTCAAACTGGAAGAGCTGGTCACTATCTCCTC
TTTCCTGAATTCTTTTGTGTTTAAGATGATCTGGGATGGAATTGTAGAGAACGCCAAGGGTGAGACCTTGGAGCTGT
TCCAGTCTGTCCACGGGTGGCTTATGGTGCTGTACGAGCGGGACTGCCGGCGGCGCTTCACCCCCGAGGACCACTGG
CTGCGAAAGGATCTCAAACCTAGCGTGCTCTTCCAAGAACTCGACAGGGACAGAAAACGGGCACAGTTGATCCTGCA
GTACATCCCACATGTCATCCCTCACAAAAACAGAGTTCTACTGTTTCGAACCATGGTTACCAAGGAGAAGGAGAAAC
TGGGGCTGGTGGAAACCAGCTCTGCCTCCCCGCATGTCACTCACATCACCATCCGCCGGTCCAGGATGCTGGAGGAC
GGCTACGAGCAGCTTAGGCAGCTCTCCCAGCACGCCATGAAGGGGGTCATCCGTGTGAAGTTTGTCAATGACCTCGG
GGTGGACGAAGCAGGGATTGATCAAGACGGTGTTTTTAAGGAGTTCTTGGAAGAGATCATCAAGAGAGTTTTTGACC
CAGCACTCAATCTGTTCAAGACAACCAGTGGGGATGAGAGGCTGTACCCCTCACCCACATCCTACATCCATGAGAAT
TACCTGCAGCTCTTCGAGTTTGTGGGGAAGATGCTGGGGAAGGCTGTGTATGAGGGAATTGTGGTGGACGTGCCATT
TGCATCCTTCTTCCTGAGCCAACTGCTTGGGCACCACCACAGCGTCTTCTATAGCTCGGTGGATGAACTGCCTTCTC
TGGACTCCGAGTTCTATAAAAACCTCACCTCCATCAAGCGCTATGATGGGGACATCACTGACCTGGGCCTGACGCTG
TCTTACGACGAGGACGTCATGGGTCAGCTTGTTTGCCATGAACTGATTCCTGGAGGGAAGACCATTCCTGTTACAAA
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TGAAAATAAAATTAGCTACATCCATCTGATGGCACATTTTCGAATGCACACTCAAATAAAAAACCAAACAGCTGCCC
TCATTAGCGGATTCCGTTCCATTATCAAACCCGAGTGGATCCGAATGTTCTCAACTCCTGAACTGCAGCGTCTCATC
TCTGGCGACAATGCTGAGATTGATCTGGAAGATTTAAAGAAGCACACAGTCTACTACGGTGGTTTCCATGGAAGTCA
CAGAGTCATCATCTGGCTCTGGGATATTCTGGCCTCCGACTTCACACCGGATGAGAGAGCTATGTTTCTGAAGTTCG
TGACCAGCTGCTCCAGACCCCCGCTCCTGGGATTCGCCTACCTCAAGCCTCCATTCTCCATCCGCTGCGTGGAGGTG
TCGGACGATCAGGACACCGGGGACACTCTGGGCAGCGTCCTCCGGGGCTTCTTCACCATCCGCAAGCGGGAGCCAGG
CGGCCGCCTGCCCACCTCCTCCACCTGCTTCAACCTGCTCAAGCTGCCCAACTACAGCAAGAAGAGCGTCCTCCGCG
AGAAGCTGCGCTACGCCATCAGCATGAACACGGGCTTTGAACTCTCCTAG 
B.2 CLONE 4  
Clone 4 contains two point mutants which change the amino acid sequence as follows 
Arg215Cys, Ile1059Phe.  The DNA sequence is below.   
ATGTTCACCCTGTCTCAGACCTCGAGAGCATGGTTCATCGATAGAGCCCGTCAGGCACGAGAAGAAAGGCTTGTGCA
GAAGGAACGGGAGCGGGCAGCTGTTGTGATCCAGGCCCATGTCCGGAGTTTTCTCTGTCGGAGTCGACTGCAGAGAG
ATATCAGGAGAGAGATTGATGACTTTTTTAAAGCAGATGACCCTGAGTCCACTAAAAGAAGTGCACTTTGTATTTTC
AAGATTGCCAGGAAACTGCTGTTCCTATTCAGAATCAAAGAGGATAATGAGAGATTTGAGAAGTTGTGTCGCAGCAT
CCTGAGCAGCATGGATGCTGAGAATGAGCCTAAGGTGTGGTATGTGTCCCTGGCTTGTTCTAAGGACCTCACCCTCC
TTTGGATTCAACAGATCAAGAACATTTTGTGGTACTGCTGTGATTTTCTCAAGCAGCTCAAGCCTGAAATCCTGCAG
GACTCCCGACTCATCACCCTGTACCTCACGATGCTTGTCACCTTCACAGACACTTCAACGTGGAAAATTCTTCGGGG
AAAAGGTGAAAGTCTTCGACCAGCGATGAACCACATTTGTGCAAATATAATGGGACATCTCAACCAGCATGGATTTT
ATTCTGTGCTGCAGATATTGTTAACCtGTGGCCTGGCAAGACCCCGTCCTTGTCTATCCAAAGGCACTTTAACAGCA
GCTTTTTCTCTAGCGTTACGCCCTGTGATTGCTGCACAGTTCTCAGACAATCTGATTCGGCCGTTCCTCATCCACAT
CATGTCTGTGCCTGCTCTGGTGACTCATCTCAGCACAGTGACCCCTGAGCGCCTCACTGTTTTAGAATCCCATGACA
TGCTTCGTAAATTCATCATATTTTTAAGAGACCAAGATCGATGCCGTGATGTATGTGAAAGTTTAGAAGGATGCCAT
ACGCTTTGTCTAATGGGCAACCTCCTACACTTGGGCTCCCTCAGCCCCAGAGTGTTAGAGGAGGAGACAGATGGGTT
CGTGAGTTTGCTCACCCAGACGCTGTGCTACTGTCGGAAGTATGTGTCTCAGAAGAAGTCCAACCTGACCCACTGGC
ATCCTGTCCTTGGCTGGTTCTCCCAATCTGTGGATTATGGCCTTAACGAGTCAATGCACTTGATCACCAAACAGCTG
CAGTTCTTGTGGGGGGTGCCTCTGATCCGGATCTTCTTCTGTGACATCCTGAGCAAGAAGCTACTGGAGAGCCAGGA
GCCAGCCCACGCACAGCCAGCATCCCCTCAGAATGTGCTCCCAGTGAAGAGTCTCCTAAAGCGTGCTTTTCAAAAGT
CGGCATCAGTCCGGAATATTCTCAGGCCTGTCGGGGGTAAACGGGTCGACTCTGCAGAAGTCCAGAAGGTTTGCAAC
ATCTGTGTCCTCTACCAGACCTCGCTGACAACTCTCACACAGATTCGGCTGCAGATACTCACAGGTCTCACTTACCT
TGATGACCTGCTTCCCAAACTGTGGGCATTTATCTGTGAGCTCGGGCCCCACGGAGGGTTAAAGCTCTTCTTGGAAT
GCCTGAACAATGACACTGAAGAGTCCAAGCAACTCTTGGCCATGCTGATGCTGTTCTGTGACTGTTCGCGGCACCTC
ATCACAATCCTTGATGACATTGAAGTTTATGAAGAACAGATTTCATTCAAACTGGAAGAGCTGGTCACTATCTCCTC
TTTCCTGAATTCTTTTGTGTTTAAGATGATCTGGGATGGAATTGTAGAGAACGCCAAGGGTGAGACCTTGGAGCTGT
TCCAGTCTGTCCACGGGTGGCTTATGGTGCTGTACGAGCGGGACTGCCGGCGGCGCTTCACCCCCGAGGACCACTGG
CTGCGAAAGGATCTCAAACCTAGCGTGCTCTTCCAAGAACTCGACAGGGACAGAAAACGGGCACAGTTGATCCTGCA
GTACATCCCACATGTCATCCCTCACAAAAACAGAGTTCTACTGTTTCGAACCATGGTTACCAAGGAGAAGGAGAAAC
TGGGGCTGGTGGAAACCAGCTCTGCCTCCCCGCATGTCACTCACATCACCATCCGCCGGTCCAGGATGCTGGAGGAC
GGCTACGAGCAGCTTAGGCAGCTCTCCCAGCACGCCATGAAGGGGGTCATCCGTGTGAAGTTTGTCAATGACCTCGG
GGTGGACGAAGCAGGGATTGATCAAGACGGTGTTTTTAAGGAGTTCTTGGAAGAGATCATCAAGAGAGTTTTTGACC
CAGCACTCAATCTGTTCAAGACAACCAGTGGGGATGAGAGGCTGTACCCCTCACCCACATCCTACATCCATGAGAAT
TACCTGCAGCTCTTCGAGTTTGTGGGGAAGATGCTGGGGAAGGCTGTGTATGAGGGAATTGTGGTGGACGTGCCATT
TGCATCCTTCTTCCTGAGCCAACTGCTTGGGCACCACCACAGCGTCTTCTATAGCTCGGTGGATGAACTGCCTTCTC
TGGACTCCGAGTTCTATAAAAACCTCACCTCCATCAAGCGCTATGATGGGGACATCACTGACCTGGGCCTGACGCTG
TCTTACGACGAGGACGTCATGGGTCAGCTTGTTTGCCATGAACTGATTCCTGGAGGGAAGACCATTCCTGTTACAAA
TGAAAATAAAATTAGCTACATCCATCTGATGGCACATTTTCGAATGCACACTCAAATAAAAAACCAAACAGCTGCCC
  122 
TCATTAGCGGATTCCGTTCCATTATCAAACCCGAGTGGATCCGAATGTTCTCAACTCCTGAACTGCAGCGTCTCATC
TCTGGCGACAATGCTGAGATTGATCTGGAAGATTTAAAGAAGCACACAGTCTACTACGGTGGTTTCCATGGAAGTCA
CAGAGTCATCATCTGGCTCTGGGATATTCTGGCCTCCGACTTCACACCGGATGAGAGAGCTATGTTTCTGAAGTTCG
TGACCAGCTGCTCCAGACCCCCGCTCCTGGGATTCGCCTACCTCAAGCCTCCATTCTCCATCCGCTGCGTGGAGGTG
TCGGACGATCAGGACACCGGGGACACTCTGGGCAGCGTCCTCCGGGGCTTCTTCACCATCCGCAAGCGGGAGCCAGG
CGGCCGCCTGCCCACCTCCTCCACCTGCTTCAACCTGCTCAAGCTGCCCAACTACAGCAAGAAGAGCGTCCTCCGCG
AGAAGCTGCGCTACGCCtTCAGCATGAACACGGGCTTTGAACTCTCCTAG 
 
B.3 CLONE 5 
Clone 5 contains 1 point mutant which change the amino acid sequence as follows, 
Arg346Gln.  The DNA sequence of the clone is below.   
ATGTTCACCCTGTCTCAGACCTCGAGAGCATGGTTCATCGATAGAGCCCGTCAGGCACGAGAAGAAAGGCTTGTGCA
GAAGGAACGGGAGCGGGCAGCTGTTGTGATCCAGGCCCATGTCCGGAGTTTTCTCTGTCGGAGTCGACTGCAGAGAG
ATATCAGGAGAGAGATTGATGACTTTTTTAAAGCAGATGACCCTGAGTCCACTAAAAGAAGTGCACTTTGTATTTTC
AAGATTGCCAGGAAACTGCTGTTCCTATTCAGAATCAAAGAGGATAATGAGAGATTTGAGAAGTTGTGTCGCAGCAT
CCTGAGCAGCATGGATGCTGAGAATGAGCCTAAGGTGTGGTATGTGTCCCTGGCTTGTTCTAAGGACCTCACCCTCC
TTTGGATTCAACAGATCAAGAACATTTTGTGGTACTGCTGTGATTTTCTCAAGCAGCTCAAGCCTGAAATCCTGCAG
GACTCCCGACTCATCACCCTGTACCTCACGATGCTTGTCACCTTCACAGACACTTCAACGTGGAAAATTCTTCGGGG
AAAAGGTGAAAGTCTTCGACCAGCGATGAACCACATTTGTGCAAATATAATGGGACATCTCAACCAGCATGGATTTT
ATTCTGTGCTGCAGATATTGTTAACCCGTGGCCTGGCAAGACCCCGTCCTTGTCTATCCAAAGGCACTTTAACAGCA
GCTTTTTCTCTAGCGTTACGCCCTGTGATTGCTGCACAGTTCTCAGACAATCTGATTCGGCCGTTCCTCATCCACAT
CATGTCTGTGCCTGCTCTGGTGACTCATCTCAGCACAGTGACCCCTGAGCGCCTCACTGTTTTAGAATCCCATGACA
TGCTTCGTAAATTCATCATATTTTTAAGAGACCAAGATCGATGCCGTGATGTATGTGAAAGTTTAGAAGGATGCCAT
ACGCTTTGTCTAATGGGCAACCTCCTACACTTGGGCTCCCTCAGCCCCAGAGTGTTAGAGGAGGAGACAGATGGGTT
CGTGAGTTTGCTCACCCAGACGCTGTGCTACTGTCAGAAGTATGTGTCTCAGAAGAAGTCCAACCTGACCCACTGGC
ATCCTGTCCTTGGCTGGTTCTCCCAATCTGTGGATTATGGCCTTAACGAGTCAATGCACTTGATCACCAAACAGCTG
CAGTTCTTGTGGGGGGTGCCTCTGATCCGGATCTTCTTCTGTGACATCCTGAGCAAGAAGCTACTGGAGAGCCAGGA
GCCAGCCCACGCACAGCCAGCATCCCCTCAGAATGTGCTCCCAGTGAAGAGTCTCCTAAAGCGTGCTTTTCAAAAGT
CGGCATCAGTCCGGAATATTCTCAGGCCTGTCGGGGGTAAACGGGTCGACTCTGCAGAAGTCCAGAAGGTTTGCAAC
ATCTGTGTCCTCTACCAGACCTCGCTGACAACTCTCACACAGATTCGGCTGCAGATACTCACAGGTCTCACTTACCT
TGATGACCTGCTTCCCAAACTGTGGGCATTTATCTGTGAGCTCGGGCCCCACGGAGGGTTAAAGCTCTTCTTGGAAT
GCCTGAACAATGACACTGAAGAGTCCAAGCAACTCTTGGCCATGCTGATGCTGTTCTGTGACTGTTCGCGGCACCTC
ATCACAATCCTTGATGACATTGAAGTTTATGAAGAACAGATTTCATTCAAACTGGAAGAGCTGGTCACTATCTCCTC
TTTCCTGAATTCTTTTGTGTTTAAGATGATCTGGGATGGAATTGTAGAGAACGCCAAGGGTGAGACCTTGGAGCTGT
TCCAGTCTGTCCACGGGTGGCTTATGGTGCTGTACGAGCGGGACTGCCGGCGGCGCTTCACCCCCGAGGACCACTGG
CTGCGAAAGGATCTCAAACCTAGCGTGCTCTTCCAAGAACTCGACAGGGACAGAAAACGGGCACAGTTGATCCTGCA
GTACATCCCACATGTCATCCCTCACAAAAACAGAGTTCTACTGTTTCGAACCATGGTTACCAAGGAGAAGGAGAAAC
TGGGGCTGGTGGAAACCAGCTCTGCCTCCCCGCATGTCACTCACATCACCATCCGCCGGTCCAGGATGCTGGAGGAC
GGCTACGAGCAGCTTAGGCAGCTCTCCCAGCACGCCATGAAGGGGGTCATCCGTGTGAAGTTTGTCAATGACCTCGG
GGTGGACGAAGCAGGGATTGATCAAGACGGTGTTTTTAAGGAGTTCTTGGAAGAGATCATCAAGAGAGTTTTTGACC
CAGCACTCAATCTGTTCAAGACAACCAGTGGGGATGAGAGGCTGTACCCCTCACCCACATCCTACATCCATGAGAAT
TACCTGCAGCTCTTCGAGTTTGTGGGGAAGATGCTGGGGAAGGCTGTGTATGAGGGAATTGTGGTGGACGTGCCATT
TGCATCCTTCTTCCTGAGCCAACTGCTTGGGCACCACCACAGCGTCTTCTATAGCTCGGTGGATGAACTGCCTTCTC
TGGACTCCGAGTTCTATAAAAACCTCACCTCCATCAAGCGCTATGATGGGGACATCACTGACCTGGGCCTGACGCTG
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TCTTACGACGAGGACGTCATGGGTCAGCTTGTTTGCCATGAACTGATTCCTGGAGGGAAGACCATTCCTGTTACAAA
TGAAAATAAAATTAGCTACATCCATCTGATGGCACATTTTCGAATGCACACTCAAATAAAAAACCAAACAGCTGCCC
TCATTAGCGGATTCCGTTCCATTATCAAACCCGAGTGGATCCGAATGTTCTCAACTCCTGAACTGCAGCGTCTCATC
TCTGGCGACAATGCTGAGATTGATCTGGAAGATTTAAAGAAGCACACAGTCTACTACGGTGGTTTCCATGGAAGTCA
CAGAGTCATCATCTGGCTCTGGGATATTCTGGCCTCCGACTTCACACCGGATGAGAGAGCTATGTTTCTGAAGTTCG
TGACCAGCTGCTCCAGACCCCCGCTCCTGGGATTCGCCTACCTCAAGCCTCCATTCTCCATCCGCTGCGTGGAGGTG
TCGGACGATCAGGACACCGGGGACACTCTGGGCAGCGTCCTCCGGGGCTTCTTCACCATCCGCAAGCGGGAGCCAGG
CGGCCGCCTGCCCACCTCCTCCACCTGCTTCAACCTGCTCAAGCTGCCCAACTACAGCAAGAAGAGCGTCCTCCGCG
AGAAGCTGCGCTACGCCATCAGCATGAACACGGGCTTTGAACTCTCCTAG 
B.4 CLONE 6 
Clone 6 contains two point mutants that would change the amino acid sequence as 
follows, Arg346Gln, Glu757Stop.  DNA sequence is below. 
ATGTTCACCCTGTCTCAGACCTCGAGAGCATGGTTCATCGATAGAGCCCGTCAGGCACGAGAAGAAAGGCTTGTGCA
GAAGGAACGGGAGCGGGCAGCTGTTGTGATCCAGGCCCATGTCCGGAGTTTTCTCTGTCGGAGTCGACTGCAGAGAG
ATATCAGGAGAGAGATTGATGACTTTTTTAAAGCAGATGACCCTGAGTCCACTAAAAGAAGTGCACTTTGTATTTTC
AAGATTGCCAGGAAACTGCTGTTCCTATTCAGAATCAAAGAGGATAATGAGAGATTTGAGAAGTTGTGTCGCAGCAT
CCTGAGCAGCATGGATGCTGAGAATGAGCCTAAGGTGTGGTATGTGTCCCTGGCTTGTTCTAAGGACCTCACCCTCC
TTTGGATTCAACAGATCAAGAACATTTTGTGGTACTGCTGTGATTTTCTCAAGCAGCTCAAGCCTGAAATCCTGCAG
GACTCCCGACTCATCACCCTGTACCTCACGATGCTTGTCACCTTCACAGACACTTCAACGTGGAAAATTCTTCGGGG
AAAAGGTGAAAGTCTTCGACCAGCGATGAACCACATTTGTGCAAATATAATGGGACATCTCAACCAGCATGGATTTT
ATTCTGTGCTGCAGATATTGTTAACCCGTGGCCTGGCAAGACCCCGTCCTTGTCTATCCAAAGGCACTTTAACAGCA
GCTTTTTCTCTAGCGTTACGCCCTGTGATTGCTGCACAGTTCTCAGACAATCTGATTCGGCCGTTCCTCATCCACAT
CATGTCTGTGCCTGCTCTGGTGACTCATCTCAGCACAGTGACCCCTGAGCGCCTCACTGTTTTAGAATCCCATGACA
TGCTTCGTAAATTCATCATATTTTTAAGAGACCAAGATCGATGCCGTGATGTATGTGAAAGTTTAGAAGGATGCCAT
ACGCTTTGTCTAATGGGCAACCTCCTACACTTGGGCTCCCTCAGCCCCAGAGTGTTAGAGGAGGAGACAGATGGGTT
CGTGAGTTTGCTCACCCAGACGCTGTGCTACTGTCaGAAGTATGTGTCTCAGAAGAAGTCCAACCTGACCCACTGGC
ATCCTGTCCTTGGCTGGTTCTCCCAATCTGTGGATTATGGCCTTAACGAGTCAATGCACTTGATCACCAAACAGCTG
CAGTTCTTGTGGGGGGTGCCTCTGATCCGGATCTTCTTCTGTGACATCCTGAGCAAGAAGCTACTGGAGAGCCAGGA
GCCAGCCCACGCACAGCCAGCATCCCCTCAGAATGTGCTCCCAGTGAAGAGTCTCCTAAAGCGTGCTTTTCAAAAGT
CGGCATCAGTCCGGAATATTCTCAGGCCTGTCGGGGGTAAACGGGTCGACTCTGCAGAAGTCCAGAAGGTTTGCAAC
ATCTGTGTCCTCTACCAGACCTCGCTGACAACTCTCACACAGATTCGGCTGCAGATACTCACAGGTCTCACTTACCT
TGATGACCTGCTTCCCAAACTGTGGGCATTTATCTGTGAGCTCGGGCCCCACGGAGGGTTAAAGCTCTTCTTGGAAT
GCCTGAACAATGACACTGAAGAGTCCAAGCAACTCTTGGCCATGCTGATGCTGTTCTGTGACTGTTCGCGGCACCTC
ATCACAATCCTTGATGACATTGAAGTTTATGAAGAACAGATTTCATTCAAACTGGAAGAGCTGGTCACTATCTCCTC
TTTCCTGAATTCTTTTGTGTTTAAGATGATCTGGGATGGAATTGTAGAGAACGCCAAGGGTGAGACCTTGGAGCTGT
TCCAGTCTGTCCACGGGTGGCTTATGGTGCTGTACGAGCGGGACTGCCGGCGGCGCTTCACCCCCGAGGACCACTGG
CTGCGAAAGGATCTCAAACCTAGCGTGCTCTTCCAAGAACTCGACAGGGACAGAAAACGGGCACAGTTGATCCTGCA
GTACATCCCACATGTCATCCCTCACAAAAACAGAGTTCTACTGTTTCGAACCATGGTTACCAAGGAGAAGGAGAAAC
TGGGGCTGGTGGAAACCAGCTCTGCCTCCCCGCATGTCACTCACATCACCATCCGCCGGTCCAGGATGCTGGAGGAC
GGCTACGAGCAGCTTAGGCAGCTCTCCCAGCACGCCATGAAGGGGGTCATCCGTGTGAAGTTTGTCAATGACCTCGG
GGTGGACGAAGCAGGGATTGATCAAGACGGTGTTTTTAAGGAGTTCTTGGAAGAGATCATCAAGAGAGTTTTTGACC
CAGCACTCAATCTGTTCAAGACAACCAGTGGGGATtAGAGGCTGTACCCCTCACCCACATCCTACATCCATGAGAAT
TACCTGCAGCTCTTCGAGTTTGTGGGGAAGATGCTGGGGAAGGCTGTGTATGAGGGAATTGTGGTGGACGTGCCATT
TGCATCCTTCTTCCTGAGCCAACTGCTTGGGCACCACCACAGCGTCTTCTATAGCTCGGTGGATGAACTGCCTTCTC
TGGACTCCGAGTTCTATAAAAACCTCACCTCCATCAAGCGCTATGATGGGGACATCACTGACCTGGGCCTGACGCTG
TCTTACGACGAGGACGTCATGGGTCAGCTTGTTTGCCATGAACTGATTCCTGGAGGGAAGACCATTCCTGTTACAAA
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TGAAAATAAAATTAGCTACATCCATCTGATGGCACATTTTCGAATGCACACTCAAATAAAAAACCAAACAGCTGCCC
TCATTAGCGGATTCCGTTCCATTATCAAACCCGAGTGGATCCGAATGTTCTCAACTCCTGAACTGCAGCGTCTCATC
TCTGGCGACAATGCTGAGATTGATCTGGAAGATTTAAAGAAGCACACAGTCTACTACGGTGGTTTCCATGGAAGTCA
CAGAGTCATCATCTGGCTCTGGGATATTCTGGCCTCCGACTTCACACCGGATGAGAGAGCTATGTTTCTGAAGTTCG
TGACCAGCTGCTCCAGACCCCCGCTCCTGGGATTCGCCTACCTCAAGCCTCCATTCTCCATCCGCTGCGTGGAGGTG
TCGGACGATCAGGACACCGGGGACACTCTGGGCAGCGTCCTCCGGGGCTTCTTCACCATCCGCAAGCGGGAGCCAGG
CGGCCGCCTGCCCACCTCCTCCACCTGCTTCAACCTGCTCAAGCTGCCCAACTACAGCAAGAAGAGCGTCCTCCGCG
AGAAGCTGCGCTACGCCATCAGCATGAACACGGGCTTTGAACTCTCCTAG 
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APPENDIX C. SIRNA SCREEN DATASETS 
Dataset 1.  
Accession No Gene Symbol Avg POC Ratio P-Value FDR 
NM_018324 THEDC1 0.429536424 0.0209992 0.1273799 
NM_004666 VNN1 0.429964133 0.0240549 0.1341246 
NM_080911 UNG 0.445720958 0.0154252 0.1129269 
XM_165973 USP24 0.454884119 0.0314827 0.1476503 
NM_021970 MAP2K1IP1 0.468591817 0.0403303 0.1595864 
NM_002933 RNASE1 0.469939834 0.0133807 0.109913 
NM_153189 SPAM1 0.486478025 0.0415279 0.1605281 
NM_138340 ABHD3 0.486532905 0.0067143 0.0919669 
NM_013251 TAC3 0.491722626 0.0279567 0.1404196 
NM_006327 TIMM23 0.501591174 0.0036578 0.0810883 
NM_003841 TNFRSF10C 0.512219543 0.0140413 0.1100968 
NM_172236 POFUT1 0.521360956 0.0160409 0.1146967 
NM_003799 RNMT 0.521827669 0.0118005 0.106785 
NM_003839 TNFRSF11A 0.521925008 0.0147432 0.111789 
NM_001025243 IRAK1 0.524453336 0.0053168 0.0860671 
NM_005718 ARPC4 0.526481464 0.0136158 0.1102038 
NM_002309 LIF 0.53479142 0.0026576 0.081955 
NM_173353 TPH2 0.535499705 0.0315239 0.1475927 
NM_012125 CHRM5 0.535566907 0.0201234 0.1250917 
NM_012360 OR1F1 0.540526776 0.0168029 0.1166694 
NM_003211 TDG 0.541857164 0.0034462 0.0806063 
NM_130767 CACH-1 0.544235702 0.0455433 0.1651768 
NM_005762 TRIM28 0.545059748 0.028319 0.1409565 
NM_001876 CPT1A 0.54638003 0.0023785 0.0805481 
NM_033181 CNR1 0.548978297 0.0084768 0.0972802 
NM_017686 GDAP2 0.549407967 0.0317187 0.1478776 
NM_145910 NEK11 0.551522047 0.0006802 0.0682706 
NM_014465 SULT1B1 0.552146948 0.0173686 0.118951 
NM_012387 PADI4 0.552576488 0.0187445 0.1220159 
NM_001702 BAI1 0.556730459 7.658E-05 0.0528393 
NM_199040 NUDT4 0.557359244 0.0072567 0.0949217 
NM_024608 NEIL1 0.559400704 0.0324636 0.1483438 
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NM_003227 TFR2 0.559841619 0.0059989 0.0878351 
NM_012214 MGAT4A 0.560188918 0.0103896 0.1038964 
NM_001184 ATR 0.5610753 0.0363013 0.1534327 
NM_003268 TLR5 0.563577132 0.0043176 0.085424 
NM_003071 SMARCA3 0.564168075 0.0291905 0.1438677 
NM_002934 RNASE2 0.564991995 0.001158 0.0718247 
NM_002572 PAFAH1B2 0.565111742 0.0373269 0.1552708 
NM_001866 COX7B 0.565778198 0.0222086 0.1302777 
NM_003272 TM7SF1 0.569465132 0.0455148 0.1652907 
NM_005508 CCR4 0.569924369 0.0006306 0.0740637 
NM_006714 SMPDL3A 0.571885333 0.0153518 0.1132911 
NM_153446 GALGT2 0.57287254 0.0011754 0.0705242 
NM_001024592 UNG2 0.573614706 5.972E-05 0.0470927 
NM_001002019 PUS1 0.574720416 0.0017126 0.0807981 
NM_024342 GRLF1 0.575297825 0.0034254 0.080804 
NM_000814 GABRB3 0.575759866 0.0415214 0.1606154 
NM_000536 RAG2 0.575804467 0.0125883 0.1080676 
NM_007255 B4GALT7 0.575961939 0.0005847 0.0733561 
NM_177552 SULT1A3 0.577010219 0.000668 0.0695751 
NM_003650 CST7 0.579687602 0.0174241 0.1190359 
NM_023018 FLJ13052 0.581448317 0.0020006 0.0824126 
NM_000961 PTGIS 0.58160867 0.0199218 0.1245393 
NM_000150 FUT6 0.582777658 0.0218182 0.129641 
NM_001775 CD38 0.583916315 0.0497526 0.1706863 
NM_170706 NMNAT2 0.586556927 0.015877 0.114116 
NM_014058 DESC1 0.586739966 0.0331931 0.1496942 
NM_000926 PGR 0.587029255 9.715E-05 0.0446905 
NM_138578 BCL2L1 0.587481551 0.0149647 0.1123878 
NM_145207 SPATA5 0.588113844 0.0077668 0.0959127 
NM_004566 PFKFB3 0.588865827 0.0136729 0.1098611 
NM_004443 EPHB3 0.589677553 0.0187482 0.1218965 
NM_002661 PLCG2 0.590020743 0.035635 0.152959 
NM_006894 FMO3 0.590684268 0.0300392 0.145071 
NM_001667 ARL2 0.590825053 0.0015146 0.0760068 
NM_032236 USP48 0.590977992 0.0436502 0.1640225 
NM_018010 ESRRBL1 0.596206886 0.0084695 0.0973997 
NM_007171 POMT1 0.596482185 0.0442913 0.1639757 
NM_130806 LGR8 0.596729273 0.0263943 0.1373202 
NM_019092 KIAA1164 0.597090987 0.014906 0.1125597 
NM_002754 MAPK13 0.597218471 0.0029406 0.0780399 
NM_032595 PPP1R9B 0.597285454 0.019346 0.1237426 
NM_001003962 CAPNS1 0.597680159 0.0254831 0.1364369 
NM_174971 SIAT6 0.59826402 0.0461521 0.1657512 
NM_000234 LIG1 0.599034365 0.0003014 0.063993 
NM_003137 SRPK1 0.599583268 0.0075878 0.0960651 
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NM_004117 FKBP5 0.600816686 0.0066917 0.0921147 
NM_000855 GUCY1A2 0.60113068 0.0110279 0.1058683 
NM_004154 P2RY6 0.601188399 0.0498261 0.1707263 
NM_000351 STS 0.601222343 0.0092447 0.0994753 
NM_198951 TGM2 0.601758521 0.0009684 0.0685309 
NM_002021 FMO1 0.602065855 0.0229544 0.1310323 
NM_144581 C14orf149 0.602300115 0.0116555 0.1061689 
NM_000320 QDPR 0.602997311 0.0083105 0.0969856 
NM_003161 RPS6KB1 0.603063439 0.0273024 0.1390307 
NM_003918 GYG2 0.603714359 0.011583 0.1062095 
NM_014256 B3GNT3 0.604006836 0.0011821 0.0686863 
NM_001056 SULT1C1 0.604916863 0.0017337 0.0797486 
NM_022098 LOC63929 0.605243397 0.0055014 0.0867646 
NM_013358 PADI1 0.606979719 0.0090657 0.0990943 
NM_000741 CHRM4 0.607206284 0.0405204 0.1596521 
NM_181578 RFC5 0.607822106 0.0015698 0.0780657 
NM_032582 USP32 0.608711231 0.0489132 0.1692796 
XM_371285 LOC128102 0.609257966 0.0073032 0.0950794 
NM_130384 TREX1 0.609335989 0.0464234 0.1660772 
NM_018413 CHST11 0.609436442 0.002225 0.0802728 
NM_016616 TXNDC3 0.60962619 0.0115702 0.1062685 
NM_002663 PLD2 0.610103282 0.0038365 0.0820837 
NM_147173 NUDT2 0.61043487 0.030907 0.1470748 
NM_005518 HMGCS2 0.611468472 0.0268483 0.13812 
NM_020378 KLP1 0.612693702 0.0017788 0.0804841 
NM_003390 WEE1 0.613803508 0.0118051 0.1066516 
NM_138608 MPPE1 0.613884159 0.0324861 0.1483237 
NM_000353 TAT 0.61573104 0.0020768 0.080167 
NM_153002 GPR156 0.616499941 0.0403791 0.1594369 
NM_004388 CTBS 0.616778083 0.0065255 0.0905043 
NM_000199 SGSH 0.618577267 0.0091277 0.0995745 
NM_153809 TAF1L 0.619586798 0.0494498 0.1699644 
NM_033294 CASP1 0.620480218 0.0035705 0.0807748 
NM_182547 HNLF 0.621360183 0.0044515 0.0856168 
NM_003986 BBOX1 0.622305367 0.0239427 0.1340401 
NM_025227 BPIL1 0.625613404 0.0049732 0.0852548 
NM_007041 ATE1 0.626081973 0.0115264 0.1062202 
NM_016347 CML2 0.626721943 0.0111975 0.1060213 
NM_005309 GPT 0.626783436 0.0011814 0.069373 
NM_005173 ATP2A3 0.627154941 0.0140974 0.1100674 
NM_020960 GPR107 0.627281238 0.0033474 0.0796453 
NM_197941 ADAMTS6 0.627476229 0.0445869 0.1639703 
NM_183415 UBE3B 0.62761405 0.0092349 0.0995638 
NM_172234 IL17RB 0.629036343 0.0372194 0.1549404 
NM_002014 FKBP4 0.629862888 0.0003133 0.0617624 
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NM_004054 C3AR1 0.630710213 0.0154231 0.1130619 
NM_138327 TRAR1 0.631346468 0.0054855 0.0867625 
NM_014275 MGAT4B 0.631640548 0.0023032 0.0804675 
NM_000875 IGF1R 0.633037344 0.0121453 0.1072677 
NM_001355 DDT 0.633879169 0.0124526 0.108249 
NM_001445 FABP6 0.634237146 0.0336435 0.1508629 
NM_012460 TIMM9 0.635270062 0.004009 0.0831943 
NM_170705 ICMT 0.635701849 0.003514 0.0801539 
NM_005373 MPL 0.636111958 0.0293957 0.1438515 
NM_005605 PPP3CC 0.636322741 0.0003141 0.0597816 
NM_001683 ATP2B2 0.637090269 0.0351494 0.1524154 
NM_001008505 OPRM1 0.637171567 0.0042776 0.0852424 
NM_001005619 ITGB4 0.637353948 0.0133707 0.1101584 
NM_007180 TREH 0.637408937 0.000708 0.0685671 
NM_013382 POMT2 0.637409881 0.0389863 0.1574281 
NM_020438 DOLPP1 0.638044755 0.0426131 0.1616661 
NM_022120 OXCT2 0.638353099 0.0071393 0.09428 
NM_006610 MASP2 0.638566567 0.0236021 0.1334871 
NM_198066 GNPNAT1 0.639193548 0.0135816 0.1102507 
NM_005471 GNPDA1 0.639644785 0.0373323 0.1551763 
NM_014911 AAK1 0.640408077 0.0452324 0.1649161 
NM_002103 GYS1 0.640761325 0.0010296 0.0710457 
NM_024681 FLJ12242 0.641444177 0.0355712 0.1530422 
NM_002312 LIG4 0.641576109 0.0122672 0.1074837 
NM_001679 ATP1B3 0.642017327 0.007819 0.0959135 
NM_181468 ITGB4BP 0.642270855 0.0270808 0.1384132 
NM_022341 PDF 0.642691534 0.0395572 0.1583435 
NM_003654 CHST1 0.644429746 0.0044646 0.0855709 
NM_153699 GSTA5 0.644761056 0.0044309 0.0858199 
NM_000797 DRD4 0.644792449 0.0358351 0.1529851 
NM_000481 AMT 0.645664635 0.0008662 0.0654976 
NM_054014 FKBP1A 0.64576482 0.0003291 0.0567634 
NM_003595 TPST2 0.645769416 0.0063442 0.0897951 
NM_000740 CHRM3 0.645843857 0.0076131 0.0959463 
NM_177524 MEST 0.645866015 0.0428969 0.1622965 
NM_002676 PMM1 0.64604996 0.0002546 0.0610985 
NM_004624 VIPR1 0.646071697 0.0051226 0.0854283 
NM_198974 PTK9 0.646260808 0.001041 0.0709427 
NM_002691 POLD1 0.646310661 0.0396336 0.1584197 
NM_000750 CHRNB4 0.646724844 0.0410758 0.160466 
NM_002630 PGC 0.646801181 0.0429236 0.1622865 
NM_018060 FLJ10326 0.64683082 0.0338063 0.1508573 
NM_014413 HRI 0.648032791 0.0048498 0.0858047 
NM_002542 OGG1 0.64860652 0.0020099 0.0821818 
NM_178221 APG4C 0.649558894 0.0110738 0.1059404 
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NM_197975 BTNL3 0.649616816 0.0130022 0.1089109 
NM_002410 MGAT5 0.650583395 0.0077468 0.0960949 
NM_022481 ARAP3 0.650767829 0.0156172 0.1137292 
NM_001034 RRM2 0.651065915 0.0416831 0.1606777 
NM_152942 TNFRSF8 0.651437898 0.0193805 0.1238198 
 
Dataset 2.  
Accession No Gene Symbol Avg_POC_Ratio P-Value FDR 
NM_018324 THEDC1 0.429536424 0.0209992 0.1273799 
NM_004666 VNN1 0.429964133 0.0240549 0.1341246 
NM_080911 UNG 0.445720958 0.0154252 0.1129269 
XM_165973 USP24 0.454884119 0.0314827 0.1476503 
NM_021970 MAP2K1IP1 0.468591817 0.0403303 0.1595864 
NM_002933 RNASE1 0.469939834 0.0133807 0.109913 
NM_153189 SPAM1 0.486478025 0.0415279 0.1605281 
NM_138340 ABHD3 0.486532905 0.0067143 0.0919669 
NM_013251 TAC3 0.491722626 0.0279567 0.1404196 
NM_006327 TIMM23 0.501591174 0.0036578 0.0810883 
NM_003841 TNFRSF10C 0.512219543 0.0140413 0.1100968 
NM_172236 POFUT1 0.521360956 0.0160409 0.1146967 
NM_003799 RNMT 0.521827669 0.0118005 0.106785 
NM_003839 TNFRSF11A 0.521925008 0.0147432 0.111789 
NM_001025243 IRAK1 0.524453336 0.0053168 0.0860671 
NM_005718 ARPC4 0.526481464 0.0136158 0.1102038 
NM_002309 LIF 0.53479142 0.0026576 0.081955 
NM_173353 TPH2 0.535499705 0.0315239 0.1475927 
NM_012125 CHRM5 0.535566907 0.0201234 0.1250917 
NM_012360 OR1F1 0.540526776 0.0168029 0.1166694 
NM_003211 TDG 0.541857164 0.0034462 0.0806063 
NM_130767 CACH-1 0.544235702 0.0455433 0.1651768 
NM_005762 TRIM28 0.545059748 0.028319 0.1409565 
NM_001876 CPT1A 0.54638003 0.0023785 0.0805481 
NM_033181 CNR1 0.548978297 0.0084768 0.0972802 
NM_017686 GDAP2 0.549407967 0.0317187 0.1478776 
NM_145910 NEK11 0.551522047 0.0006802 0.0682706 
NM_014465 SULT1B1 0.552146948 0.0173686 0.118951 
NM_012387 PADI4 0.552576488 0.0187445 0.1220159 
NM_001702 BAI1 0.556730459 7.658E-05 0.0528393 
NM_199040 NUDT4 0.557359244 0.0072567 0.0949217 
NM_024608 NEIL1 0.559400704 0.0324636 0.1483438 
  130 
NM_003227 TFR2 0.559841619 0.0059989 0.0878351 
NM_012214 MGAT4A 0.560188918 0.0103896 0.1038964 
NM_001184 ATR 0.5610753 0.0363013 0.1534327 
NM_003268 TLR5 0.563577132 0.0043176 0.085424 
NM_003071 SMARCA3 0.564168075 0.0291905 0.1438677 
NM_002934 RNASE2 0.564991995 0.001158 0.0718247 
NM_002572 PAFAH1B2 0.565111742 0.0373269 0.1552708 
NM_001866 COX7B 0.565778198 0.0222086 0.1302777 
NM_003272 TM7SF1 0.569465132 0.0455148 0.1652907 
NM_005508 CCR4 0.569924369 0.0006306 0.0740637 
NM_006714 SMPDL3A 0.571885333 0.0153518 0.1132911 
NM_153446 GALGT2 0.57287254 0.0011754 0.0705242 
NM_001024592 UNG2 0.573614706 5.972E-05 0.0470927 
NM_001002019 PUS1 0.574720416 0.0017126 0.0807981 
NM_024342 GRLF1 0.575297825 0.0034254 0.080804 
NM_000814 GABRB3 0.575759866 0.0415214 0.1606154 
NM_000536 RAG2 0.575804467 0.0125883 0.1080676 
NM_007255 B4GALT7 0.575961939 0.0005847 0.0733561 
NM_177552 SULT1A3 0.577010219 0.000668 0.0695751 
NM_003650 CST7 0.579687602 0.0174241 0.1190359 
NM_023018 FLJ13052 0.581448317 0.0020006 0.0824126 
NM_000961 PTGIS 0.58160867 0.0199218 0.1245393 
NM_000150 FUT6 0.582777658 0.0218182 0.129641 
NM_001775 CD38 0.583916315 0.0497526 0.1706863 
NM_170706 NMNAT2 0.586556927 0.015877 0.114116 
NM_014058 DESC1 0.586739966 0.0331931 0.1496942 
NM_000926 PGR 0.587029255 9.715E-05 0.0446905 
NM_138578 BCL2L1 0.587481551 0.0149647 0.1123878 
NM_145207 SPATA5 0.588113844 0.0077668 0.0959127 
NM_004566 PFKFB3 0.588865827 0.0136729 0.1098611 
NM_004443 EPHB3 0.589677553 0.0187482 0.1218965 
NM_002661 PLCG2 0.590020743 0.035635 0.152959 
NM_006894 FMO3 0.590684268 0.0300392 0.145071 
NM_001667 ARL2 0.590825053 0.0015146 0.0760068 
NM_032236 USP48 0.590977992 0.0436502 0.1640225 
NM_018010 ESRRBL1 0.596206886 0.0084695 0.0973997 
NM_007171 POMT1 0.596482185 0.0442913 0.1639757 
NM_130806 LGR8 0.596729273 0.0263943 0.1373202 
NM_019092 KIAA1164 0.597090987 0.014906 0.1125597 
NM_002754 MAPK13 0.597218471 0.0029406 0.0780399 
NM_032595 PPP1R9B 0.597285454 0.019346 0.1237426 
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NM_001003962 CAPNS1 0.597680159 0.0254831 0.1364369 
NM_174971 SIAT6 0.59826402 0.0461521 0.1657512 
NM_000234 LIG1 0.599034365 0.0003014 0.063993 
NM_003137 SRPK1 0.599583268 0.0075878 0.0960651 
NM_004117 FKBP5 0.600816686 0.0066917 0.0921147 
NM_000855 GUCY1A2 0.60113068 0.0110279 0.1058683 
NM_004154 P2RY6 0.601188399 0.0498261 0.1707263 
NM_000351 STS 0.601222343 0.0092447 0.0994753 
NM_198951 TGM2 0.601758521 0.0009684 0.0685309 
NM_002021 FMO1 0.602065855 0.0229544 0.1310323 
NM_144581 C14orf149 0.602300115 0.0116555 0.1061689 
NM_000320 QDPR 0.602997311 0.0083105 0.0969856 
NM_003161 RPS6KB1 0.603063439 0.0273024 0.1390307 
NM_003918 GYG2 0.603714359 0.011583 0.1062095 
NM_014256 B3GNT3 0.604006836 0.0011821 0.0686863 
NM_001056 SULT1C1 0.604916863 0.0017337 0.0797486 
NM_022098 LOC63929 0.605243397 0.0055014 0.0867646 
NM_013358 PADI1 0.606979719 0.0090657 0.0990943 
NM_000741 CHRM4 0.607206284 0.0405204 0.1596521 
NM_181578 RFC5 0.607822106 0.0015698 0.0780657 
NM_032582 USP32 0.608711231 0.0489132 0.1692796 
 
Dataset 3.  
Accession No Gene Symbol Avg_POC_Ratio P-Value FDR 
NM_018324 THEDC1 0.429536424 0.0209992 0.1273799 
NM_004666 VNN1 0.429964133 0.0240549 0.1341246 
NM_080911 UNG 0.445720958 0.0154252 0.1129269 
XM_165973 USP24 0.454884119 0.0314827 0.1476503 
NM_021970 MAP2K1IP1 0.468591817 0.0403303 0.1595864 
NM_002933 RNASE1 0.469939834 0.0133807 0.109913 
NM_153189 SPAM1 0.486478025 0.0415279 0.1605281 
NM_138340 ABHD3 0.486532905 0.0067143 0.0919669 
NM_013251 TAC3 0.491722626 0.0279567 0.1404196 
NM_006327 TIMM23 0.501591174 0.0036578 0.0810883 
NM_003841 TNFRSF10C 0.512219543 0.0140413 0.1100968 
NM_172236 POFUT1 0.521360956 0.0160409 0.1146967 
NM_003799 RNMT 0.521827669 0.0118005 0.106785 
NM_003839 TNFRSF11A 0.521925008 0.0147432 0.111789 
NM_001025243 IRAK1 0.524453336 0.0053168 0.0860671 
  132 
NM_005718 ARPC4 0.526481464 0.0136158 0.1102038 
NM_002309 LIF 0.53479142 0.0026576 0.081955 
NM_173353 TPH2 0.535499705 0.0315239 0.1475927 
NM_012125 CHRM5 0.535566907 0.0201234 0.1250917 
NM_012360 OR1F1 0.540526776 0.0168029 0.1166694 
NM_003211 TDG 0.541857164 0.0034462 0.0806063 
NM_130767 CACH-1 0.544235702 0.0455433 0.1651768 
NM_005762 TRIM28 0.545059748 0.028319 0.1409565 
NM_001876 CPT1A 0.54638003 0.0023785 0.0805481 
NM_033181 CNR1 0.548978297 0.0084768 0.0972802 
NM_017686 GDAP2 0.549407967 0.0317187 0.1478776 
NM_145910 NEK11 0.551522047 0.0006802 0.0682706 
NM_014465 SULT1B1 0.552146948 0.0173686 0.118951 
NM_012387 PADI4 0.552576488 0.0187445 0.1220159 
NM_001702 BAI1 0.556730459 7.658E-05 0.0528393 
NM_199040 NUDT4 0.557359244 0.0072567 0.0949217 
NM_024608 NEIL1 0.559400704 0.0324636 0.1483438 
NM_003227 TFR2 0.559841619 0.0059989 0.0878351 
NM_012214 MGAT4A 0.560188918 0.0103896 0.1038964 
NM_001184 ATR 0.5610753 0.0363013 0.1534327 
NM_003268 TLR5 0.563577132 0.0043176 0.085424 
NM_003071 SMARCA3 0.564168075 0.0291905 0.1438677 
NM_002934 RNASE2 0.564991995 0.001158 0.0718247 
NM_002572 PAFAH1B2 0.565111742 0.0373269 0.1552708 
NM_001866 COX7B 0.565778198 0.0222086 0.1302777 
NM_003272 TM7SF1 0.569465132 0.0455148 0.1652907 
NM_005508 CCR4 0.569924369 0.0006306 0.0740637 
NM_006714 SMPDL3A 0.571885333 0.0153518 0.1132911 
NM_153446 GALGT2 0.57287254 0.0011754 0.0705242 
NM_001024592 UNG2 0.573614706 5.972E-05 0.0470927 
NM_001002019 PUS1 0.574720416 0.0017126 0.0807981 
NM_024342 GRLF1 0.575297825 0.0034254 0.080804 
NM_000814 GABRB3 0.575759866 0.0415214 0.1606154 
NM_000536 RAG2 0.575804467 0.0125883 0.1080676 
NM_007255 B4GALT7 0.575961939 0.0005847 0.0733561 
NM_177552 SULT1A3 0.577010219 0.000668 0.0695751 
NM_003650 CST7 0.579687602 0.0174241 0.1190359 
NM_023018 FLJ13052 0.581448317 0.0020006 0.0824126 
NM_000961 PTGIS 0.58160867 0.0199218 0.1245393 
NM_000150 FUT6 0.582777658 0.0218182 0.129641 
NM_001775 CD38 0.583916315 0.0497526 0.1706863 
  133 
NM_170706 NMNAT2 0.586556927 0.015877 0.114116 
NM_014058 DESC1 0.586739966 0.0331931 0.1496942 
NM_000926 PGR 0.587029255 9.715E-05 0.0446905 
NM_138578 BCL2L1 0.587481551 0.0149647 0.1123878 
NM_145207 SPATA5 0.588113844 0.0077668 0.0959127 
NM_004566 PFKFB3 0.588865827 0.0136729 0.1098611 
NM_004443 EPHB3 0.589677553 0.0187482 0.1218965 
NM_002661 PLCG2 0.590020743 0.035635 0.152959 
NM_006894 FMO3 0.590684268 0.0300392 0.145071 
NM_001667 ARL2 0.590825053 0.0015146 0.0760068 
NM_032236 USP48 0.590977992 0.0436502 0.1640225 
NM_018010 ESRRBL1 0.596206886 0.0084695 0.0973997 
NM_007171 POMT1 0.596482185 0.0442913 0.1639757 
NM_130806 LGR8 0.596729273 0.0263943 0.1373202 
NM_019092 KIAA1164 0.597090987 0.014906 0.1125597 
NM_002754 MAPK13 0.597218471 0.0029406 0.0780399 
NM_032595 PPP1R9B 0.597285454 0.019346 0.1237426 
NM_001003962 CAPNS1 0.597680159 0.0254831 0.1364369 
NM_174971 SIAT6 0.59826402 0.0461521 0.1657512 
NM_000234 LIG1 0.599034365 0.0003014 0.063993 
NM_003137 SRPK1 0.599583268 0.0075878 0.0960651 
NM_004117 FKBP5 0.600816686 0.0066917 0.0921147 
NM_000855 GUCY1A2 0.60113068 0.0110279 0.1058683 
NM_004154 P2RY6 0.601188399 0.0498261 0.1707263 
NM_000351 STS 0.601222343 0.0092447 0.0994753 
NM_198951 TGM2 0.601758521 0.0009684 0.0685309 
NM_002021 FMO1 0.602065855 0.0229544 0.1310323 
NM_144581 C14orf149 0.602300115 0.0116555 0.1061689 
NM_000320 QDPR 0.602997311 0.0083105 0.0969856 
NM_003161 RPS6KB1 0.603063439 0.0273024 0.1390307 
NM_003918 GYG2 0.603714359 0.011583 0.1062095 
NM_014256 B3GNT3 0.604006836 0.0011821 0.0686863 
NM_001056 SULT1C1 0.604916863 0.0017337 0.0797486 
NM_022098 LOC63929 0.605243397 0.0055014 0.0867646 
NM_013358 PADI1 0.606979719 0.0090657 0.0990943 
NM_000741 CHRM4 0.607206284 0.0405204 0.1596521 
NM_181578 RFC5 0.607822106 0.0015698 0.0780657 
NM_032582 USP32 0.608711231 0.0489132 0.1692796 
XM_371285 LOC128102 0.609257966 0.0073032 0.0950794 
NM_130384 TREX1 0.609335989 0.0464234 0.1660772 
NM_018413 CHST11 0.609436442 0.002225 0.0802728 
  134 
NM_016616 TXNDC3 0.60962619 0.0115702 0.1062685 
NM_002663 PLD2 0.610103282 0.0038365 0.0820837 
NM_147173 NUDT2 0.61043487 0.030907 0.1470748 
NM_005518 HMGCS2 0.611468472 0.0268483 0.13812 
NM_020378 KLP1 0.612693702 0.0017788 0.0804841 
NM_003390 WEE1 0.613803508 0.0118051 0.1066516 
NM_138608 MPPE1 0.613884159 0.0324861 0.1483237 
NM_000353 TAT 0.61573104 0.0020768 0.080167 
NM_153002 GPR156 0.616499941 0.0403791 0.1594369 
NM_004388 CTBS 0.616778083 0.0065255 0.0905043 
NM_000199 SGSH 0.618577267 0.0091277 0.0995745 
NM_153809 TAF1L 0.619586798 0.0494498 0.1699644 
NM_033294 CASP1 0.620480218 0.0035705 0.0807748 
NM_182547 HNLF 0.621360183 0.0044515 0.0856168 
NM_003986 BBOX1 0.622305367 0.0239427 0.1340401 
NM_025227 BPIL1 0.625613404 0.0049732 0.0852548 
NM_007041 ATE1 0.626081973 0.0115264 0.1062202 
NM_016347 CML2 0.626721943 0.0111975 0.1060213 
NM_005309 GPT 0.626783436 0.0011814 0.069373 
NM_005173 ATP2A3 0.627154941 0.0140974 0.1100674 
NM_020960 GPR107 0.627281238 0.0033474 0.0796453 
NM_197941 ADAMTS6 0.627476229 0.0445869 0.1639703 
NM_183415 UBE3B 0.62761405 0.0092349 0.0995638 
NM_172234 IL17RB 0.629036343 0.0372194 0.1549404 
NM_002014 FKBP4 0.629862888 0.0003133 0.0617624 
NM_004054 C3AR1 0.630710213 0.0154231 0.1130619 
NM_138327 TRAR1 0.631346468 0.0054855 0.0867625 
NM_014275 MGAT4B 0.631640548 0.0023032 0.0804675 
NM_000875 IGF1R 0.633037344 0.0121453 0.1072677 
NM_001355 DDT 0.633879169 0.0124526 0.108249 
NM_001445 FABP6 0.634237146 0.0336435 0.1508629 
NM_012460 TIMM9 0.635270062 0.004009 0.0831943 
NM_170705 ICMT 0.635701849 0.003514 0.0801539 
NM_005373 MPL 0.636111958 0.0293957 0.1438515 
NM_005605 PPP3CC 0.636322741 0.0003141 0.0597816 
NM_001683 ATP2B2 0.637090269 0.0351494 0.1524154 
NM_001008505 OPRM1 0.637171567 0.0042776 0.0852424 
NM_001005619 ITGB4 0.637353948 0.0133707 0.1101584 
NM_007180 TREH 0.637408937 0.000708 0.0685671 
NM_013382 POMT2 0.637409881 0.0389863 0.1574281 
NM_020438 DOLPP1 0.638044755 0.0426131 0.1616661 
  135 
NM_022120 OXCT2 0.638353099 0.0071393 0.09428 
NM_006610 MASP2 0.638566567 0.0236021 0.1334871 
NM_198066 GNPNAT1 0.639193548 0.0135816 0.1102507 
NM_005471 GNPDA1 0.639644785 0.0373323 0.1551763 
NM_014911 AAK1 0.640408077 0.0452324 0.1649161 
NM_002103 GYS1 0.640761325 0.0010296 0.0710457 
NM_024681 FLJ12242 0.641444177 0.0355712 0.1530422 
NM_002312 LIG4 0.641576109 0.0122672 0.1074837 
NM_001679 ATP1B3 0.642017327 0.007819 0.0959135 
NM_181468 ITGB4BP 0.642270855 0.0270808 0.1384132 
NM_022341 PDF 0.642691534 0.0395572 0.1583435 
NM_003654 CHST1 0.644429746 0.0044646 0.0855709 
NM_153699 GSTA5 0.644761056 0.0044309 0.0858199 
NM_000797 DRD4 0.644792449 0.0358351 0.1529851 
NM_000481 AMT 0.645664635 0.0008662 0.0654976 
NM_054014 FKBP1A 0.64576482 0.0003291 0.0567634 
NM_003595 TPST2 0.645769416 0.0063442 0.0897951 
NM_000740 CHRM3 0.645843857 0.0076131 0.0959463 
NM_177524 MEST 0.645866015 0.0428969 0.1622965 
NM_002676 PMM1 0.64604996 0.0002546 0.0610985 
NM_004624 VIPR1 0.646071697 0.0051226 0.0854283 
NM_198974 PTK9 0.646260808 0.001041 0.0709427 
NM_002691 POLD1 0.646310661 0.0396336 0.1584197 
NM_000750 CHRNB4 0.646724844 0.0410758 0.160466 
NM_002630 PGC 0.646801181 0.0429236 0.1622865 
NM_018060 FLJ10326 0.64683082 0.0338063 0.1508573 
NM_014413 HRI 0.648032791 0.0048498 0.0858047 
NM_002542 OGG1 0.64860652 0.0020099 0.0821818 
NM_178221 APG4C 0.649558894 0.0110738 0.1059404 
NM_197975 BTNL3 0.649616816 0.0130022 0.1089109 
NM_002410 MGAT5 0.650583395 0.0077468 0.0960949 
NM_022481 ARAP3 0.650767829 0.0156172 0.1137292 
NM_001034 RRM2 0.651065915 0.0416831 0.1606777 
NM_152942 TNFRSF8 0.651437898 0.0193805 0.1238198 
NM_000928 PLA2G1B 0.651517841 0.036521 0.1540076 
NM_002529 NTRK1 0.651678416 0.0449509 0.1647603 
NM_006039 MRC2 0.652198766 0.0050108 0.0851064 
NM_199283 LOC220686 0.653181345 0.0464494 0.165955 
NM_198584 CA13 0.653337445 0.0388229 0.157113 
NM_000476 AK1 0.654123518 0.0056323 0.0878264 
NM_017784 OSBPL10 0.65425603 8.99E-05 0.0496239 
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NM_012330 MYST4 0.654294965 0.0403303 0.1594722 
NM_005299 GPR31 0.656339085 0.0295267 0.1441092 
NM_173490 LOC134285 0.656569671 0.0023369 0.0811287 
NM_001004056 GRK4 0.656952826 0.0349507 0.1523917 
NM_052937 LOC115294 0.657658683 0.019758 0.1242188 
NM_152910 DGKH 0.657893406 0.0110532 0.1059266 
NM_004129 GUCY1B2 0.658032167 0.0028169 0.0805659 
NM_002501 NFIX 0.658226633 0.0034335 0.0806513 
NM_002736 PRKAR2B 0.658436006 0.0373593 0.1550553 
NM_173200 NR4A3 0.659488791 0.0120367 0.107512 
NM_016341 PLCE1 0.659502531 0.0123266 0.1076626 
NM_138424 KIF12 0.660339152 0.0380171 0.1561415 
NM_014893 NLGN4Y 0.66085573 0.0053907 0.0867548 
NM_017900 AKIP 0.661031432 0.0207875 0.1273549 
NM_004979 KCND1 0.6619906 0.0375173 0.1548956 
NM_146421 GSTM1 0.662236555 0.0063191 0.0899012 
NM_002601 PDE6D 0.662351041 0.0328282 0.1487781 
NM_004309 ARHGDIA 0.662460906 0.0106407 0.1035923 
NM_020126 SPHK2 0.66257518 0.016916 0.117307 
NM_020299 AKR1B10 0.662863804 0.0442284 0.164073 
NM_002633 PGM1 0.662880128 0.0031137 0.0781268 
NM_032049 AGTR1 0.663180261 0.0139065 0.1099772 
NM_018339 RFK 0.663441715 0.0209674 0.1273271 
NM_003129 SQLE 0.663545089 0.0059708 0.0878907 
NM_012413 QPCT 0.663632443 0.0312606 0.1479917 
NM_017827 SARS2 0.663705726 0.0075042 0.095445 
NM_001248 ENTPD3 0.663725011 0.0301049 0.1451347 
NM_006849 PDIP 0.663977507 0.0138641 0.1104326 
NM_183386 PTE1 0.664435297 0.0187156 0.1219716 
NM_000738 CHRM1 0.664979911 0.0237905 0.1340035 
XM_070277 OC90 0.665013566 0.0301148 0.1450555 
NM_021615 CHST6 0.665560402 0.0108472 0.1046789 
NM_001461 FMO5 0.666405064 0.0049815 0.0848696 
NM_004441 EPHB1 0.66685553 0.0252007 0.1361132 
NM_006182 DDR2 0.666943324 0.022541 0.1309749 
NM_183239 GSTO2 0.667527337 0.0120436 0.1073998 
NM_000024 ADRB2 0.667755257 0.0190932 0.1231245 
NM_032294 CAMKK1 0.667877264 0.0083602 0.0969498 
NM_005135 SLC12A6 0.66817077 0.0039956 0.0832287 
NM_003313 TSTA3 0.668746602 0.0251078 0.1362783 
NM_000936 PNLIP 0.669420476 0.0178941 0.1198728 
  137 
NM_145042 MGC16703 0.669503075 0.0398338 0.1589897 
NM_198400 NEDD4 0.669910495 0.0210623 0.1273428 
NM_014725 STARD8 0.670114672 0.0135495 0.1103149 
NM_012474 UCK2 0.670168468 0.0143033 0.1102709 
NM_001270 CHD1 0.670232554 0.0295748 0.1439619 
NM_005107 ENDOGL1 0.670276508 0.030445 0.1461359 
NM_019886 CHST7 0.670424203 0.0061752 0.089703 
NM_033266 ERN2 0.6704522 0.0133505 0.1103218 
NM_181573 RFC4 0.670500351 0.001226 0.0683604 
NM_138335 GNPDA2 0.671617032 0.008562 0.0978517 
NM_000486 AQP2 0.671975352 0.015375 0.113311 
NM_014064 AD-003 0.672678758 0.0062567 0.0894747 
NM_145798 OSBPL7 0.672814525 0.012691 0.1081088 
NM_198319 HRMT1L2 0.672839254 0.0009354 0.0670598 
NM_001911 CTSG 0.673144369 0.0428208 0.16212 
NM_024917 CXorf34 0.673284608 0.0094973 0.1004317 
NM_003052 SLC34A1 0.674121665 0.0120129 0.1078229 
NM_006570 RRAGA 0.674154049 0.0402031 0.1596554 
 
Dataset 4.  
Accession No Gene Symbol Avg_POC_Ratio P-Value FDR 
NM_018324 THEDC1 0.429536424 0.0209992 0.1273799 
NM_004666 VNN1 0.429964133 0.0240549 0.1341246 
NM_080911 UNG 0.445720958 0.0154252 0.1129269 
XM_165973 USP24 0.454884119 0.0314827 0.1476503 
NM_021970 MAP2K1IP1 0.468591817 0.0403303 0.1595864 
NM_002933 RNASE1 0.469939834 0.0133807 0.109913 
NM_153189 SPAM1 0.486478025 0.0415279 0.1605281 
NM_138340 ABHD3 0.486532905 0.0067143 0.0919669 
NM_013251 TAC3 0.491722626 0.0279567 0.1404196 
NM_006327 TIMM23 0.501591174 0.0036578 0.0810883 
NM_003841 TNFRSF10C 0.512219543 0.0140413 0.1100968 
NM_172236 POFUT1 0.521360956 0.0160409 0.1146967 
NM_003799 RNMT 0.521827669 0.0118005 0.106785 
NM_003839 TNFRSF11A 0.521925008 0.0147432 0.111789 
NM_001025243 IRAK1 0.524453336 0.0053168 0.0860671 
NM_005718 ARPC4 0.526481464 0.0136158 0.1102038 
NM_002309 LIF 0.53479142 0.0026576 0.081955 
NM_173353 TPH2 0.535499705 0.0315239 0.1475927 
  138 
NM_012125 CHRM5 0.535566907 0.0201234 0.1250917 
NM_012360 OR1F1 0.540526776 0.0168029 0.1166694 
NM_003211 TDG 0.541857164 0.0034462 0.0806063 
NM_130767 CACH-1 0.544235702 0.0455433 0.1651768 
NM_005762 TRIM28 0.545059748 0.028319 0.1409565 
NM_001876 CPT1A 0.54638003 0.0023785 0.0805481 
NM_033181 CNR1 0.548978297 0.0084768 0.0972802 
NM_017686 GDAP2 0.549407967 0.0317187 0.1478776 
NM_145910 NEK11 0.551522047 0.0006802 0.0682706 
NM_014465 SULT1B1 0.552146948 0.0173686 0.118951 
NM_012387 PADI4 0.552576488 0.0187445 0.1220159 
NM_001702 BAI1 0.556730459 7.658E-05 0.0528393 
NM_199040 NUDT4 0.557359244 0.0072567 0.0949217 
NM_024608 NEIL1 0.559400704 0.0324636 0.1483438 
NM_003227 TFR2 0.559841619 0.0059989 0.0878351 
NM_012214 MGAT4A 0.560188918 0.0103896 0.1038964 
NM_001184 ATR 0.5610753 0.0363013 0.1534327 
NM_003268 TLR5 0.563577132 0.0043176 0.085424 
NM_003071 SMARCA3 0.564168075 0.0291905 0.1438677 
NM_002934 RNASE2 0.564991995 0.001158 0.0718247 
NM_002572 PAFAH1B2 0.565111742 0.0373269 0.1552708 
NM_001866 COX7B 0.565778198 0.0222086 0.1302777 
NM_003272 TM7SF1 0.569465132 0.0455148 0.1652907 
NM_005508 CCR4 0.569924369 0.0006306 0.0740637 
NM_006714 SMPDL3A 0.571885333 0.0153518 0.1132911 
NM_153446 GALGT2 0.57287254 0.0011754 0.0705242 
NM_001024592 UNG2 0.573614706 5.972E-05 0.0470927 
NM_001002019 PUS1 0.574720416 0.0017126 0.0807981 
NM_024342 GRLF1 0.575297825 0.0034254 0.080804 
NM_000814 GABRB3 0.575759866 0.0415214 0.1606154 
NM_000536 RAG2 0.575804467 0.0125883 0.1080676 
NM_007255 B4GALT7 0.575961939 0.0005847 0.0733561 
NM_177552 SULT1A3 0.577010219 0.000668 0.0695751 
NM_003650 CST7 0.579687602 0.0174241 0.1190359 
NM_023018 FLJ13052 0.581448317 0.0020006 0.0824126 
NM_000961 PTGIS 0.58160867 0.0199218 0.1245393 
NM_000150 FUT6 0.582777658 0.0218182 0.129641 
NM_001775 CD38 0.583916315 0.0497526 0.1706863 
NM_170706 NMNAT2 0.586556927 0.015877 0.114116 
NM_014058 DESC1 0.586739966 0.0331931 0.1496942 
NM_000926 PGR 0.587029255 9.715E-05 0.0446905 
  139 
NM_138578 BCL2L1 0.587481551 0.0149647 0.1123878 
NM_145207 SPATA5 0.588113844 0.0077668 0.0959127 
NM_004566 PFKFB3 0.588865827 0.0136729 0.1098611 
NM_004443 EPHB3 0.589677553 0.0187482 0.1218965 
NM_002661 PLCG2 0.590020743 0.035635 0.152959 
NM_006894 FMO3 0.590684268 0.0300392 0.145071 
NM_001667 ARL2 0.590825053 0.0015146 0.0760068 
NM_032236 USP48 0.590977992 0.0436502 0.1640225 
NM_018010 ESRRBL1 0.596206886 0.0084695 0.0973997 
NM_007171 POMT1 0.596482185 0.0442913 0.1639757 
NM_130806 LGR8 0.596729273 0.0263943 0.1373202 
NM_019092 KIAA1164 0.597090987 0.014906 0.1125597 
NM_002754 MAPK13 0.597218471 0.0029406 0.0780399 
NM_032595 PPP1R9B 0.597285454 0.019346 0.1237426 
NM_001003962 CAPNS1 0.597680159 0.0254831 0.1364369 
NM_174971 SIAT6 0.59826402 0.0461521 0.1657512 
NM_000234 LIG1 0.599034365 0.0003014 0.063993 
NM_003137 SRPK1 0.599583268 0.0075878 0.0960651 
NM_004117 FKBP5 0.600816686 0.0066917 0.0921147 
NM_000855 GUCY1A2 0.60113068 0.0110279 0.1058683 
NM_004154 P2RY6 0.601188399 0.0498261 0.1707263 
NM_000351 STS 0.601222343 0.0092447 0.0994753 
NM_198951 TGM2 0.601758521 0.0009684 0.0685309 
NM_002021 FMO1 0.602065855 0.0229544 0.1310323 
NM_144581 C14orf149 0.602300115 0.0116555 0.1061689 
NM_000320 QDPR 0.602997311 0.0083105 0.0969856 
NM_003161 RPS6KB1 0.603063439 0.0273024 0.1390307 
NM_003918 GYG2 0.603714359 0.011583 0.1062095 
NM_014256 B3GNT3 0.604006836 0.0011821 0.0686863 
NM_001056 SULT1C1 0.604916863 0.0017337 0.0797486 
NM_022098 LOC63929 0.605243397 0.0055014 0.0867646 
NM_013358 PADI1 0.606979719 0.0090657 0.0990943 
NM_000741 CHRM4 0.607206284 0.0405204 0.1596521 
NM_181578 RFC5 0.607822106 0.0015698 0.0780657 
NM_032582 USP32 0.608711231 0.0489132 0.1692796 
XM_371285 LOC128102 0.609257966 0.0073032 0.0950794 
NM_130384 TREX1 0.609335989 0.0464234 0.1660772 
NM_018413 CHST11 0.609436442 0.002225 0.0802728 
NM_016616 TXNDC3 0.60962619 0.0115702 0.1062685 
NM_002663 PLD2 0.610103282 0.0038365 0.0820837 
NM_147173 NUDT2 0.61043487 0.030907 0.1470748 
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NM_005518 HMGCS2 0.611468472 0.0268483 0.13812 
NM_020378 KLP1 0.612693702 0.0017788 0.0804841 
NM_003390 WEE1 0.613803508 0.0118051 0.1066516 
NM_138608 MPPE1 0.613884159 0.0324861 0.1483237 
NM_000353 TAT 0.61573104 0.0020768 0.080167 
NM_153002 GPR156 0.616499941 0.0403791 0.1594369 
NM_004388 CTBS 0.616778083 0.0065255 0.0905043 
NM_000199 SGSH 0.618577267 0.0091277 0.0995745 
NM_153809 TAF1L 0.619586798 0.0494498 0.1699644 
NM_033294 CASP1 0.620480218 0.0035705 0.0807748 
NM_182547 HNLF 0.621360183 0.0044515 0.0856168 
NM_003986 BBOX1 0.622305367 0.0239427 0.1340401 
NM_025227 BPIL1 0.625613404 0.0049732 0.0852548 
NM_007041 ATE1 0.626081973 0.0115264 0.1062202 
NM_016347 CML2 0.626721943 0.0111975 0.1060213 
NM_005309 GPT 0.626783436 0.0011814 0.069373 
NM_005173 ATP2A3 0.627154941 0.0140974 0.1100674 
NM_020960 GPR107 0.627281238 0.0033474 0.0796453 
NM_197941 ADAMTS6 0.627476229 0.0445869 0.1639703 
NM_183415 UBE3B 0.62761405 0.0092349 0.0995638 
NM_172234 IL17RB 0.629036343 0.0372194 0.1549404 
NM_002014 FKBP4 0.629862888 0.0003133 0.0617624 
NM_004054 C3AR1 0.630710213 0.0154231 0.1130619 
NM_138327 TRAR1 0.631346468 0.0054855 0.0867625 
NM_014275 MGAT4B 0.631640548 0.0023032 0.0804675 
NM_000875 IGF1R 0.633037344 0.0121453 0.1072677 
NM_001355 DDT 0.633879169 0.0124526 0.108249 
NM_001445 FABP6 0.634237146 0.0336435 0.1508629 
NM_012460 TIMM9 0.635270062 0.004009 0.0831943 
NM_170705 ICMT 0.635701849 0.003514 0.0801539 
NM_005373 MPL 0.636111958 0.0293957 0.1438515 
NM_005605 PPP3CC 0.636322741 0.0003141 0.0597816 
NM_001683 ATP2B2 0.637090269 0.0351494 0.1524154 
NM_001008505 OPRM1 0.637171567 0.0042776 0.0852424 
NM_001005619 ITGB4 0.637353948 0.0133707 0.1101584 
NM_007180 TREH 0.637408937 0.000708 0.0685671 
NM_013382 POMT2 0.637409881 0.0389863 0.1574281 
NM_020438 DOLPP1 0.638044755 0.0426131 0.1616661 
NM_022120 OXCT2 0.638353099 0.0071393 0.09428 
NM_006610 MASP2 0.638566567 0.0236021 0.1334871 
NM_198066 GNPNAT1 0.639193548 0.0135816 0.1102507 
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NM_005471 GNPDA1 0.639644785 0.0373323 0.1551763 
NM_014911 AAK1 0.640408077 0.0452324 0.1649161 
NM_002103 GYS1 0.640761325 0.0010296 0.0710457 
NM_024681 FLJ12242 0.641444177 0.0355712 0.1530422 
NM_002312 LIG4 0.641576109 0.0122672 0.1074837 
NM_001679 ATP1B3 0.642017327 0.007819 0.0959135 
NM_181468 ITGB4BP 0.642270855 0.0270808 0.1384132 
NM_022341 PDF 0.642691534 0.0395572 0.1583435 
NM_003654 CHST1 0.644429746 0.0044646 0.0855709 
NM_153699 GSTA5 0.644761056 0.0044309 0.0858199 
NM_000797 DRD4 0.644792449 0.0358351 0.1529851 
NM_000481 AMT 0.645664635 0.0008662 0.0654976 
NM_054014 FKBP1A 0.64576482 0.0003291 0.0567634 
NM_003595 TPST2 0.645769416 0.0063442 0.0897951 
NM_000740 CHRM3 0.645843857 0.0076131 0.0959463 
NM_177524 MEST 0.645866015 0.0428969 0.1622965 
NM_002676 PMM1 0.64604996 0.0002546 0.0610985 
NM_004624 VIPR1 0.646071697 0.0051226 0.0854283 
NM_198974 PTK9 0.646260808 0.001041 0.0709427 
NM_002691 POLD1 0.646310661 0.0396336 0.1584197 
NM_000750 CHRNB4 0.646724844 0.0410758 0.160466 
NM_002630 PGC 0.646801181 0.0429236 0.1622865 
NM_018060 FLJ10326 0.64683082 0.0338063 0.1508573 
NM_014413 HRI 0.648032791 0.0048498 0.0858047 
NM_002542 OGG1 0.64860652 0.0020099 0.0821818 
NM_178221 APG4C 0.649558894 0.0110738 0.1059404 
NM_197975 BTNL3 0.649616816 0.0130022 0.1089109 
NM_002410 MGAT5 0.650583395 0.0077468 0.0960949 
NM_022481 ARAP3 0.650767829 0.0156172 0.1137292 
NM_001034 RRM2 0.651065915 0.0416831 0.1606777 
NM_152942 TNFRSF8 0.651437898 0.0193805 0.1238198 
NM_000928 PLA2G1B 0.651517841 0.036521 0.1540076 
NM_002529 NTRK1 0.651678416 0.0449509 0.1647603 
NM_006039 MRC2 0.652198766 0.0050108 0.0851064 
NM_199283 LOC220686 0.653181345 0.0464494 0.165955 
NM_198584 CA13 0.653337445 0.0388229 0.157113 
NM_000476 AK1 0.654123518 0.0056323 0.0878264 
NM_017784 OSBPL10 0.65425603 8.99E-05 0.0496239 
NM_012330 MYST4 0.654294965 0.0403303 0.1594722 
NM_005299 GPR31 0.656339085 0.0295267 0.1441092 
NM_173490 LOC134285 0.656569671 0.0023369 0.0811287 
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NM_001004056 GRK4 0.656952826 0.0349507 0.1523917 
NM_052937 LOC115294 0.657658683 0.019758 0.1242188 
NM_152910 DGKH 0.657893406 0.0110532 0.1059266 
NM_004129 GUCY1B2 0.658032167 0.0028169 0.0805659 
NM_002501 NFIX 0.658226633 0.0034335 0.0806513 
NM_002736 PRKAR2B 0.658436006 0.0373593 0.1550553 
NM_173200 NR4A3 0.659488791 0.0120367 0.107512 
NM_016341 PLCE1 0.659502531 0.0123266 0.1076626 
NM_138424 KIF12 0.660339152 0.0380171 0.1561415 
NM_014893 NLGN4Y 0.66085573 0.0053907 0.0867548 
NM_017900 AKIP 0.661031432 0.0207875 0.1273549 
NM_004979 KCND1 0.6619906 0.0375173 0.1548956 
NM_146421 GSTM1 0.662236555 0.0063191 0.0899012 
NM_002601 PDE6D 0.662351041 0.0328282 0.1487781 
NM_004309 ARHGDIA 0.662460906 0.0106407 0.1035923 
NM_020126 SPHK2 0.66257518 0.016916 0.117307 
NM_020299 AKR1B10 0.662863804 0.0442284 0.164073 
NM_002633 PGM1 0.662880128 0.0031137 0.0781268 
NM_032049 AGTR1 0.663180261 0.0139065 0.1099772 
NM_018339 RFK 0.663441715 0.0209674 0.1273271 
NM_003129 SQLE 0.663545089 0.0059708 0.0878907 
NM_012413 QPCT 0.663632443 0.0312606 0.1479917 
NM_017827 SARS2 0.663705726 0.0075042 0.095445 
NM_001248 ENTPD3 0.663725011 0.0301049 0.1451347 
NM_006849 PDIP 0.663977507 0.0138641 0.1104326 
NM_183386 PTE1 0.664435297 0.0187156 0.1219716 
NM_000738 CHRM1 0.664979911 0.0237905 0.1340035 
XM_070277 OC90 0.665013566 0.0301148 0.1450555 
NM_021615 CHST6 0.665560402 0.0108472 0.1046789 
NM_001461 FMO5 0.666405064 0.0049815 0.0848696 
NM_004441 EPHB1 0.66685553 0.0252007 0.1361132 
NM_006182 DDR2 0.666943324 0.022541 0.1309749 
NM_183239 GSTO2 0.667527337 0.0120436 0.1073998 
NM_000024 ADRB2 0.667755257 0.0190932 0.1231245 
NM_032294 CAMKK1 0.667877264 0.0083602 0.0969498 
NM_005135 SLC12A6 0.66817077 0.0039956 0.0832287 
NM_003313 TSTA3 0.668746602 0.0251078 0.1362783 
NM_000936 PNLIP 0.669420476 0.0178941 0.1198728 
NM_145042 MGC16703 0.669503075 0.0398338 0.1589897 
NM_198400 NEDD4 0.669910495 0.0210623 0.1273428 
NM_014725 STARD8 0.670114672 0.0135495 0.1103149 
  143 
NM_012474 UCK2 0.670168468 0.0143033 0.1102709 
NM_001270 CHD1 0.670232554 0.0295748 0.1439619 
NM_005107 ENDOGL1 0.670276508 0.030445 0.1461359 
NM_019886 CHST7 0.670424203 0.0061752 0.089703 
NM_033266 ERN2 0.6704522 0.0133505 0.1103218 
NM_181573 RFC4 0.670500351 0.001226 0.0683604 
NM_138335 GNPDA2 0.671617032 0.008562 0.0978517 
NM_000486 AQP2 0.671975352 0.015375 0.113311 
NM_014064 AD-003 0.672678758 0.0062567 0.0894747 
NM_145798 OSBPL7 0.672814525 0.012691 0.1081088 
NM_198319 HRMT1L2 0.672839254 0.0009354 0.0670598 
NM_001911 CTSG 0.673144369 0.0428208 0.16212 
NM_024917 CXorf34 0.673284608 0.0094973 0.1004317 
NM_003052 SLC34A1 0.674121665 0.0120129 0.1078229 
NM_006570 RRAGA 0.674154049 0.0402031 0.1596554 
NM_001837 CCR3 0.674582808 0.0293203 0.144121 
NM_000206 IL2RG 0.67501986 0.0002131 0.058805 
NM_018290 PGM2 0.675094928 0.039837 0.1588876 
NM_152889 CHST13 0.675142325 0.0253295 0.1361431 
NM_003549 HYAL3 0.675143604 0.0103898 0.10371 
NM_006528 TFPI2 0.675356169 0.0413905 0.1603335 
NM_016591 C2GNT3 0.675675628 0.012223 0.1074379 
NM_183393 CADPS 0.675737764 0.0175031 0.1189867 
NM_001527 HDAC2 0.675783842 0.0295379 0.1440363 
NM_147132 GALT 0.675967957 0.0319167 0.1480504 
NM_007202 AKAP10 0.676405388 0.0203815 0.1261275 
NM_000466 PEX1 0.676679603 0.0026693 0.0818578 
NM_023915 GPR87 0.676777159 0.0442707 0.1640096 
NM_032456 PCDH7 0.677443398 0.0044667 0.0853159 
NM_001152 SLC25A5 0.677486857 0.0147472 0.1116658 
NM_012397 SERPINB13 0.677552697 0.0436609 0.1639511 
NM_001139 ALOX12B 0.677585878 0.0242424 0.1342206 
NM_007181 MAP4K1 0.677873893 0.0103818 0.1040068 
NM_003465 CHIT1 0.677923282 0.0027708 0.0800774 
NM_002317 LOX 0.677985718 0.0057022 0.0879227 
NM_004217 AURKB 0.678181929 0.0232251 0.1317602 
NM_004897 MINPP1 0.67859448 0.0472034 0.1668136 
NM_201636 TBXA2R 0.678785356 0.0474841 0.1671635 
NM_001607 ACAA1 0.67989441 0.0110782 0.1057991 
NM_001877 CR2 0.680159969 0.012545 0.1083698 
NM_153343 ENPP6 0.680181749 0.0274232 0.1390046 
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NM_021939 FKBP10 0.680302848 0.0280914 0.1407121 
NM_006169 NNMT 0.681028202 0.0020821 0.079812 
NM_182644 EPHA3 0.681468171 0.0420049 0.1607956 
NM_018641 CHST12 0.681800646 0.0027291 0.0801303 
NM_002943 RORA 0.681805343 0.03523 0.1526451 
NM_032846 RAB2B 0.682578515 0.0456172 0.1652278 
NM_002185 IL7R 0.682596728 0.0142672 0.1106107 
NM_145752 CDIPT 0.68323425 0.0023688 0.0807154 
NM_000180 GUCY2D 0.683264171 0.0138959 0.1100504 
NM_004535 MYT1 0.68346942 0.0016479 0.0790968 
NM_004164 RBP2 0.683511985 0.0007462 0.0686511 
NM_004863 SPTLC2 0.683802243 0.0058195 0.0875311 
NM_001001928 PPARA 0.683814274 0.0022452 0.0799576 
NM_007023 RAPGEF4 0.684168328 0.0365103 0.1541981 
NM_004832 GSTO1 0.684232703 0.0008383 0.0661096 
NM_173708 MTND1 0.684517616 0.0153399 0.1133554 
NM_031934 RAB34 0.684691005 0.0204471 0.1262506 
NM_016322 RAB14 0.684741587 0.0360728 0.1529355 
NM_001396 DYRK1A 0.684898784 0.0172747 0.1186026 
NM_014317 TPRT 0.685355855 0.0051061 0.0854109 
NM_020474 GALNT1 0.685914779 0.0028542 0.0791725 
NM_005296 GPR23 0.68604417 0.0350014 0.1524925 
NM_018960 GNMT 0.686477977 0.0373668 0.1549698 
NM_005026 PIK3CD 0.686686576 0.0238126 0.1339912 
NM_001800 CDKN2D 0.686802251 0.0478851 0.1672949 
NM_000848 GSTM2 0.68698218 0.000973 0.0679882 
NM_018988 GFOD1 0.687326737 0.0006792 0.069427 
NM_024619 FN3KRP 0.687522757 0.0307653 0.1472894 
NM_012407 PRKCABP 0.687595722 0.0089856 0.0994001 
XM_291266 OPLAH 0.687876265 0.0002016 0.0585618 
NM_178155 FUT8 0.688311891 0.0069482 0.0930919 
NM_000054 AVPR2 0.688355889 0.0041551 0.0837092 
NM_006657 FTCD 0.688382932 0.0230971 0.131439 
NM_017886 FLJ20574 0.688909325 0.0236008 0.1336167 
NM_002029 FPR1 0.689110661 0.0296266 0.1439603 
NM_003554 OR1E2 0.689288079 0.0333178 0.1501342 
NM_175067 TRAR4 0.690127638 0.0169436 0.1172037 
NM_005911 MAT2A 0.690322097 0.0011085 0.0746213 
NM_021734 SLC25A19 0.690346362 0.0463213 0.1661428 
NM_020683 ADORA3 0.690355948 0.0317327 0.1478183 
NM_002310 LIFR 0.690460554 0.0249986 0.1359527 
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NM_002566 P2RY11 0.690653847 0.0155367 0.1132927 
XM_291241 IPLA2(GAMMA) 0.690793543 0.0007564 0.0673409 
 
Dataset 5. 
Enriched genes identified by NIH DAVID and 
Princeton GO Term Finder 
AAK1 
ARPC4 
ATG4C 
B3GNT3 
B4GALNT2 
B4GALT7 
BAI1 
BTNL3 
C3AR1 
CAPNS1 
CCNO 
CENTD3 
CHRM4 
CHRM5 
CHST1 
CNR1 
DDT 
DOLPP1 
EPHB3 
FKBP4 
FKBP5 
FMO3 
FUT6 
GNPDA1 
GNPNAT1 
GPR156 
GPT 
GSTA5 
HMGCS2 
ICMT 
IFT57 
IL17RB 
LIF 
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MAP2K1IP1 
MGAT4A 
MGAT5 
NAT14 
NAT8B 
NEIL1 
NEK11 
NMNAT2 
NUDT2 
NUDT4 
OPRM1 
OR1F1 
PADI1 
PADI4 
PLCG2 
PMM1 
POFUT1 
POLD1 
POMT2 
PPP1R9B 
PTGIS 
PUS1 
RAG2 
RNASE2 
RNMT 
RRM2 
SGSH 
SMPDL3A 
SPATA5 
ST3GAL3 
STS 
SULT1B1 
SULT1C2 
TAF1L 
TAT 
TDG 
TFR2 
TIMM9 
TMPRSS11E 
TNFRSF11A 
TREH 
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TREX1 
TXNDC3 
UBE3B 
UNG 
USP48 
VNN1 
WEE1 
 
Dataset 6.  
Gene 
Ontology 
term 
Corrected 
P-value 
FDR Genes annotated to the term 
protein 
amino acid 
glycosylation  
1.41E-06 0.00% 
FUT6, MGAT4A, GALGT2, POMT2, DOLPP1, B3GNT3, 
MGAT5, SIAT6, POFUT1 
biopolymer 
glycosylation 
1.41E-06 0.00% 
FUT6, MGAT4A, GALGT2, POMT2, DOLPP1, B3GNT3, 
MGAT5, SIAT6, POFUT1 
glycosylation  1.41E-06 0.00% 
FUT6, MGAT4A, GALGT2, POMT2, DOLPP1, B3GNT3, 
MGAT5, SIAT6, POFUT1 
glycoprotein 
biosynthetic 
process 
2.40E-06 0.00% 
FUT6, MGAT4A, GALGT2, POMT2, DOLPP1, B3GNT3, 
MGAT5, SIAT6, POFUT1 
carbohydrate 
metabolic 
process 
4.08E-06 0.00% 
MGAT4A, GALGT2, GPT, MGAT5, POFUT1, GNPDA1, 
B4GALT7, CHST1, SGSH, FUT6, PMM1, POMT2, 
DOLPP1, TREH, B3GNT3, SIAT6 
glycoprotein 
metabolic 
process 
9.40E-06 0.00% 
FUT6, MGAT4A, GALGT2, POMT2, DOLPP1, B3GNT3, 
MGAT5, SIAT6, POFUT1 
metabolic 
process 
0.00014 0.00% 
GALGT2, PLCG2, MGAT5, UBE3B, EPHB3, WEE1, 
PMM1, POMT2, NEK11, FKBP4, B3GNT3, GSTA5, 
NUDT2, TXNDC3, GNPNAT1, ITGB4BP, POLD1, TDG, 
GNPDA1, STS, CHST1, SGSH, PTGIS, SMPDL3A, 
HMGCS2, UNG2, NUDT4, TREH, NEIL1, TREX1, 
NMNAT2, SULT1C1, CML2, ESRRBL1, RNMT, TAF1L, 
APG4C, POFUT1, DDT, DOLPP1, USP48, BTNL3, 
TFR2, ICMT, RAG2, MGAT4A, FKBP5, TAT, RNASE2, 
PUS1, GPT, PPP1R9B, SULT1B1, UNG, RRM2, 
MAP2K1IP1, AAK1, FMO3, B4GALT7, PADI4, DESC1, 
FUT6, VNN1, USP24, KLP1, LIG4, PADI1, SIAT6, LIF 
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cellular 
metabolic 
process 
0.00023 0.00% 
APG4C, TAF1L, GALGT2, PLCG2, MGAT5, UBE3B, 
EPHB3, WEE1, POFUT1, PMM1, POMT2, DDT, 
DOLPP1, NEK11, USP48, FKBP4, B3GNT3, NUDT2, 
TFR2, ICMT, TXNDC3, MGAT4A, RAG2, FKBP5, 
ITGB4BP, TAT, RNASE2, POLD1, GPT, PUS1, UNG, 
SULT1B1, PPP1R9B, RRM2, MAP2K1IP1, AAK1, TDG, 
GNPDA1, PADI4, B4GALT7, STS, CHST1, SGSH, 
PTGIS, DESC1, FUT6, USP24, VNN1, KLP1, SMPDL3A, 
LIG4, HMGCS2, PADI1, UNG2, NUDT4, TREH, NEIL1, 
TREX1, NMNAT2, SIAT6, SULT1C1, ESRRBL1, 
RNMT, LIF 
primary 
metabolic 
process 
0.00024 0.00% 
APG4C, TAF1L, GALGT2, PLCG2, MGAT5, UBE3B, 
EPHB3, WEE1, POFUT1, PMM1, POMT2, DDT, 
DOLPP1, NEK11, USP48, FKBP4, B3GNT3, NUDT2, 
BTNL3, TFR2, ICMT, TXNDC3, MGAT4A, RAG2, 
FKBP5, ITGB4BP, TAT, RNASE2, POLD1, GPT, PUS1, 
UNG, SULT1B1, PPP1R9B, RRM2, MAP2K1IP1, AAK1, 
TDG, GNPDA1, PADI4, B4GALT7, STS, CHST1, SGSH, 
PTGIS, DESC1, FUT6, USP24, KLP1, SMPDL3A, LIG4, 
HMGCS2, PADI1, UNG2, NUDT4, TREH, NEIL1, 
TREX1, NMNAT2, SIAT6, ESRRBL1, RNMT, LIF 
cellular 
process 
0.00039 0.00% 
GALGT2, PLCG2, MGAT5, UBE3B, EPHB3, WEE1, 
ARL2, GABRB3, PMM1, POMT2, NEK11, FKBP4, 
B3GNT3, NUDT2, P2RY6, TXNDC3, ITGB4BP, POLD1, 
TNFRSF11A, TDG, GNPDA1, STS, CHST1, OPRM1, 
SGSH, PTGIS, SMPDL3A, HMGCS2, UNG2, NUDT4, 
TREH, NEIL1, TREX1, SPATA5, NMNAT2, GPR156, 
CNR1, SULT1C1, CHRM4, ESRRBL1, ARPC4, RNMT, 
APG4C, TAF1L, TAC3, CAPNS1, BAI1, TIMM9, 
POFUT1, IL17RB, DDT, DOLPP1, USP48, TNFRSF10C, 
TFR2, ICMT, RAG2, MGAT4A, FKBP5, TAT, RNASE2, 
PUS1, GPT, SULT1B1, UNG, PPP1R9B, RRM2, 
MAP2K1IP1, TRAR1, AAK1, ARAP3, B4GALT7, 
PADI4, OR1F1, DESC1, FUT6, VNN1, USP24, C3AR1, 
KLP1, LIG4, CHRM5, PADI1, SIAT6, LGR8, LIF 
cellular 
carbohydrate 
metabolic 
process 
0.00081 0.00% 
FUT6, PMM1, GALGT2, GPT, TREH, POFUT1, 
B4GALT7, GNPDA1, CHST1, SGSH 
base-
excision 
repair 
0.00253 0.00% NEIL1, TDG, UNG2, UNG 
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nitrogen 
compound 
metabolic 
process 
0.00326 0.00% 
VNN1, TAT, DDT, GPT, PADI1, SULT1B1, SULT1C1, 
PADI4, B4GALT7, CHST1, SGSH 
cellular 
response to 
stimulus  
0.00339 0.00% 
APG4C, POLD1, LIG4, NEK11, PPP1R9B, UNG2, UNG, 
NEIL1, TREX1, TDG 
biopolymer 
modification 
0.00452 0.13% 
MGAT4A, GALGT2, PUS1, MGAT5, UBE3B, EPHB3, 
MAP2K1IP1, AAK1, WEE1, POFUT1, B4GALT7, 
PADI4, FUT6, POMT2, DOLPP1, NEK11, USP48, 
PADI1, B3GNT3, SIAT6, ICMT, LIF 
protein 
modification 
process 
0.00864 0.12% 
MGAT4A, GALGT2, MGAT5, UBE3B, EPHB3, 
MAP2K1IP1, AAK1, WEE1, POFUT1, PADI4, 
B4GALT7, FUT6, POMT2, DOLPP1, NEK11, USP48, 
PADI1, B3GNT3, SIAT6, ICMT, LIF 
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APPENDIX D. ALKYLATION SENSITIVITY SCREENS REVEAL A CONSERVED 
CROSS-SPRECIES FUNCTIONOME 
Submitted to Molecular Cancer Research and compiled paper is below.   
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Abstract 
To identify genes that contribute to chemotherapy resistance in glioblastoma, we conducted a 
synthetic lethal screen in a chemotherapy-resistant glioblastoma derived cell line with the clinical 
alkylator temozolomide (TMZ) and an siRNA library tailored towards “druggable” targets. We 
compared the human TMZ sensitizing genes identified in our screen with those identified from 
alkylator screens previously conducted in E. coli and S. cerevisiae. The conserved biological 
processes across all three species composes an Alkylation Functionome that includes many 
novel proteins not previously thought to impact alkylator resistance and our validation studies 
suggested additive or epistatic relationships between corresponding processes. The conserved 
processes of base excision repair (BER) and protein modification were dual targeted and 
yielded additive sensitization to alkylators in yeast. In contrast, dual targeting of BER and protein 
modification genes in human cells did not increase sensitivity, suggesting an epistatic 
relationship. Importantly, these studies provide potential new targets to overcome alkylating 
agent resistance and also provide potential mechanistic insight for the regulation of DNA repair 
and/or DNA damage response proteins.  
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Introduction 
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor (1). 
Temozolomide (TMZ), radiation and surgery are currently used for treatment of GBM, yet 
median survival is still less than 2 years (2-4). Chemotherapy resistance and difficulties in 
surgical removal contribute to poor prognosis (1). TMZ methylates several bases in DNA, 
including the O6 position of guanine (O6-MeG), the N7 position of guanine (N7-MeG) and the N3 
position of adenine (N3-MeA). Two of the lesions (N7-MeG and N3-MeA) account for greater 
than 80% of the DNA lesions induced by TMZ, yet result in negligible clinical toxicity due to 
robust repair mechanisms (5). These lesions are predominantly repaired by the base excision 
repair (BER) pathway (6), initiated by one of eleven lesion specific DNA glycosylases (7).  
 Virtually all of TMZ’s clinical cytotoxicity is attributable to the O6-methylguanine (O6-MeG) 
lesion, which accounts for approximately 5% of TMZ induced lesions (5). The O6-MeG lesion is 
repaired via a direct reversal mechanism by the protein O6-methylguanine-DNA 
methyltransferase (MGMT), which transfers the O6-methyl group from the guanine base onto a 
Cys residue in the MGMT protein (8). If the O6-MeG lesion is not removed by MGMT, during 
cellular replication the mis-pairing of O6-MeG with thymine is detected by the mismatch repair 
enzymes, triggering apoptosis signaling and cytotoxicity (9). However, 5-year survival rates still 
remain low in TMZ treated patients (3, 4), and TMZ resistance and/or recurrence with 
chemotherapy resistant tumors is common. Resistant cells can harbor mutations in mismatch 
repair proteins such as mutS homolog 6 (MSH6) (10) or have elevated expression of MGMT (as 
in the T98G cell line) (11). Earlier endeavors to enhance TMZ efficacy by using MGMT inhibitors 
to prevent the repair of O6-MeG lesions have not shown an increase in sensitivity or efficacy in 
clinical trials (12), especially in TMZ-resistant GBM (13). 
   Because GBM tumors can be resistant to TMZ therapy and recurring tumors may acquire 
resistance to the O6-MeG lesion (14, 15), we explored novel mechanisms of TMZ resistance in 
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tumor cells independent of the O6-MeG lesion. To discover genes that sensitize cells to TMZ, 
we undertook a synthetic lethal screen using Ambion’s Silencer® Human Druggable Genome 
siRNA library, the chemotherapeutic agent TMZ and the T98G cell line, a TMZ resistant cell line 
derived from a GBM tumor (16). We determined that several biological pathways were enriched 
for TMZ sensitizing genes, including proteins involved in BER, response to DNA damage, 
cellular proliferation, and protein modification. Many similar biological processes were also 
highly enriched in DNA alkylation screens performed in S. cerevisiae and E. coli (17, 18). We 
combined the selected hits from all three species and performed a functionome analysis to 
identify significantly enriched biological processes conserved across all three organisms (19). 
This allowed us to create a cross-species network representing the shared alkylation response 
from bacteria, yeast and humans and suggest that this network represents an Alkylation 
Functionome that includes many novel proteins not previously thought to impact alkylation 
resistance. Our identification of evolutionarily conserved mechanisms affecting TMZ sensitivity 
suggests that although many proteins and processes impact sensitivity to alkylators, several 
critical survival pathways can be targeted to improve chemotherapy efficacy. Simultaneous 
inhibition of both DNA repair and protein modification processes in yeast yielded greater 
sensitivity to alkylating agents than inhibition of either process alone. However, knockdown of 
both protein modification and DNA repair genes did not have an increased effect on alkylation-
induced toxicity in human cells. This potential epistatic interaction between the ubiquitin protein 
ligase E3B (UBE3B) and the DNA repair protein uracil-DNA glycosylase (UNG) suggests they 
may be in the same survival pathway. Many DNA repair genes are regulated by ubiquitinylation 
and several crucial DNA repair proteins are E3 ligases such as BRCA1 (20). UBE3B previously 
has not been implicated in DNA repair or alkylation survival and elucidating its role and 
substrates will be important to discover how it improves alkylation survival. Importantly, the 
biological processes and corresponding genes identified in our functionome analysis represent 
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novel potential drug targets to increase TMZ efficacy independent of O6-MeG mediated toxicity 
as well as potential epistatic relationships that would provide mechanistic insight into the 
function of specific activities. 
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Materials and methods 
 
Chemicals and reagents 
 DharmaFECT 2 transfection reagent and the siGENOME Non-Targeting siRNA #1 were 
from Dharmacon (Lafayette, CO). CellTiter-Blue Cell Viability Assay and CellTiter 96 AQueous 
One Solution Cell Proliferation Assay were from Promega (Madison, WI). The Silencer 
Druggable Genome siRNA Library (Version 1.1) and 5x siRNA resuspension buffer were from 
Ambion (Austin, TX). Tissue culture-treated 384-well microtiter plates were from Greiner Bio-
One (GmbH, Frickenhausen, Germany). OptiMEM, EMEM, phosphate buffered saline (PBS) 
and Hoechst 33342 were from InVitrogen (Carlsbad, CA). The shRNA vectors used for stable 
KD cell creation were obtained as glycerol stocks from Sigma-Aldrich. Temozolomide was from 
the National Cancer Institute Developmental Therapeutics Program (Bethesda, MD). Puromycin 
was from Clontech Laboratories (Mountain View, CA) and gentamicin was obtained from Irvine 
Scientific (Santa Ana, CA). We used the following primary antibodies: UNG antibody 
(#MBS200056) was from MyBioSource (San Diego, CA) and PCNA antibody (#sc-56) was from 
Santa Cruz (Santa Cruz, CA). Secondary antibodies: GAM-HRP conjugates were from Bio-Rad 
(Hercules, CA). Signal generation substrates were from Bio-Rad (Hercules, CA) and Thermo 
Fisher Scientific (Waltham, MA). All electrophoresis reagents were from Bio-Rad (Hercules, 
CA). 
 
Cell lines and culture conditions 
 Cell line and culture conditions were as previously described (21-23). Briefly, T98G cells 
were cultured in EMEM with 10% heat-inactivated FBS, non-essential amino acids, sodium 
pyruvate, antibiotic/antimycotic and gentamicin. The LN428 cells were cultured in alpha MEM 
with 10% heat-inactivated FBS, antibiotic/antimycotic and gentamicin.   
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Pathway analysis and network visualization 
 Several different programs were used to analyze the hit list for pathway enrichment and 
network visualization, including NIH DAVID (DAVID), Princeton GO term finder and Ingenuity 
Pathway Analysis (IPA). DAVID and Princeton GO term finder both classify genes based on 
their gene ontology (GO) (24-26). Each gene is classified based on it’s molecular function, 
biological process, or cellular compartment and are referred to as “GO terms” (25). Enriched GO 
terms and their associated genes are more likely to be true hits because multiple genes 
affecting the same process all yield sensitization (24, 27). The gene enrichment calculations 
used the 5,520 genes screened as the background, due to the relatively small number of genes 
screened, instead of the entire human genome. The analysis with NIH DAVID was performed 
using multiple classification stringencies, gene ontology hierarchies, protein interaction 
databases and pathways. The hit list was also analyzed with IPA (Ingenuity® Systems, 
www.ingenuity.com), utilizing a proprietary, manually-curated, interaction database. Because 
IPA utilizes a different scheme and algorithm to organize proteins into networks not based on 
GO terms, it was used as a distinct method to analyze the hit list for enriched protein functions 
and networks. The Functional Analysis identified the biological functions that were most 
significant to the data set. Right-tailed Fisher’s exact test was used to calculate a p-value 
determining the probability that each biological function assigned to that data set is due to 
chance alone. Fisher’s exact test was used with α = 0.05 to compute the probability of correct 
functional assignment for the genes in the hit list. The enriched networks created by IPA were 
visualized with genes serving as nodes and edges representing known interactions. Genes 
colored green modulate toxicity to alkylating agents as determined in the screen.  
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Generation of lentiviral knockdown cell lines 
 The shuttle vectors for expression of shRNA were from Sigma (St. Louis, MO). 
Lentiviruses were prepared in collaboration with the UPCI Lentiviral facility. Lentiviral particles 
were generated by co-transfection of 4 plasmids [the shuttle vector plus three packaging 
plasmids: pMD2.g(VSVG), pVSV-REV and PMDLg/pRRE] into 293-FT cells (28, 29) using 
FuGene 6 Transfection Reagent (Roche, Indianapolis, IN), as described previously (22). 
Lentiviral transduction was performed as described earlier (22). Briefly, 6.0 × 104 cells were 
seeded into a 6-well plate 24 hours before transduction. Cells were transduced for 18 hours at 
32˚C and then cultured for 72 hours at 37˚C. Cells were then selected by culturing in growth 
media with 1.0 μg/mL puromycin, as previously described (22).     
 
Quantitative RT-PCR analysis 
 Expression of mRNA for each of ten glycosylases and five protein modification genes 
(OGG1, SMUG1, MBD4, UNG, MYH, NTHL1, MPG, NEIL1, NEIL2, NEIL3, UBE3B, ICMT, 
B4GALT7, CHRM3, and PADI1) after shRNA-mediated knockdown was measured by 
quantitative RT-PCR (qRT-PCR) using an Applied Biosystems StepOnePlus system as 
described previously (22). Applied Biosystems TaqMan® Gene Expression Assays used are as 
follows: human OGG1: Hs00213454_m1; human SMUG1: Hs00204820_m1; human MBD4: 
Hs00187498_m1; human UNG: Hs00422172_m1; human MYH: Hs01014856_m1; human 
NTHL1: Hs00267385; human MPG: Hs01012594_m1; human NEIL1: Hs0022637_m1; human 
NEIL2: Hs00376746_m1; human NEIL3: Hs00217387_m1; human UBE3B: Hs00296200_m1; 
Human ICMT: Hs00202655_m1; Human B4GALT7: Hs01011258_m1; Human CHRM3: 
Hs00265216_s1; Human PADI1: Hs00203458_m1. Gene expression of each gene was 
normalized to the expression of human ß-actin (part #4333762T).   
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Cell extract preparation and immunoblot 
 Nuclear extracts were prepared and protein concentrations were determined as 
described previously (22). Fifteen micrograms of protein was loaded on a pre-cast 4-20% Tris-
Glycine gel (InVitrogen, Carlsbad, CA). The following primary antibodies were used in 
immunoblot assays: anti-human UNG from MyBioSource.com (#MBS200056) and anti-human 
proliferating cell nuclear antigen (PCNA; Santa Cruz Biotechnology). Immunoblot membranes 
were stripped before re-probing for PCNA. The membranes were stripped with Restore PLUS 
Western Blot Stripping buffer (#46430) from Thermo Fisher Scientific (Waltham, MA) per the 
manufacturer’s instructions.  
 
DNA glycosylase molecular beacon activity assay and data analysis 
 All oligodeoxyribonucleotides in the molecular beacon assay were purchased from 
Integrated DNA Technologies (Coralville, USA) including the following: FD-Con, 6-FAM-
dGCACTATTGAATTGACACGCCATGTCGATCAATTCAATAGTGC-Dabcyl, where 6-FAM is 
carboxyfluorescein and Dabcyl is 4-(4’-dimethylaminophenylazo) benzoic acid; FD-UNG1, 6-
FAM-dGCACTUAAGAATTGACACGCCATGTCGATCAATTCTTAAGTGC-Dabcyl, where U is 
2’-deoxyuridine. All DNA glycosylase molecular beacon activity assay experiments and data 
analysis were as done as previously described (23, 30).   
Briefly, the molecular beacons form a stem-loop structure containing a 13-nucleotide loop 
and a 15 base pair stem forcing 6-FAM fluorophore at the 5’ end and the Dabcyl quencher at the 
3’ end into close proximity. When in a stem-loop structure, the 6-FAM fluorescence is efficiently 
quenched by Dabcyl in a non-fluorescent manner via Frster Resonance Energy Transfer 
(FRET) (31, 32). However, if the uracil is removed by UNG and the DNA backbone is 
hydrolyzed by APE1, the 6-FAM containing oligonucleotide (5 bases in length) will dissociate 
from the hairpin at 37˚C (Fig. 2D). This will decrease Dabcyl quenching of 6-FAM and the 
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increase in fluorescence is proportional to uracil removal. Any increase in fluorescence in a 
control beacon with no base lesion is the result of non-specific DNA backbone cleavage.   
Dialysis of nuclear lysates for molecular beacon assay were done as previously 
described (23, 30). Briefly, nuclear protein extracts were dialyzed twice for 90 min at 4°C using 
the 7,000 molecular weight cut-off Slide-A-Lyzer Dialysis Cassette (Pierce; Rockford, IL). 
Molecular beacon reactions were performed at 37°C using 2 μg of dialyzed protein extract and 
beacon substrate (final conc. = 40 nM). Fluorescence was measured every 20 seconds for 60 
minutes, using a StepOnePlus real-time PCR system and expressed as arbitrary units (AU). 
 
Cell cytotoxicity assays. Short-term MTS assay 
 TMZ induced cytotoxicity was determined as described previously (33). Briefly, cells were 
seeded into 96-well plates at a density of 2,000 cells per well. Cells were treated with TMZ for 
48 hours at 37˚C before determining the relative amount of metabolically active cells by an MTS 
assay. Results were the average of three separate experiments and normalized to vehicle 
treated control cells with error bars representing the standard error of the mean. Long-term 
CyQuant assay. Cells were grown until approximately 50-75% confluence before being 
trypsinzed and counted using a CASY counter per the manufacturer’s instructions. Cells were 
seeded into 96-well plates at a density of 120cells/well and incubated at 37˚C for 24 hrs. The 
cells were treated with vehicle or TMZ and incubated for nine days at 37˚C. Plates were 
removed and fluorescence was determined using the CyQuant kit (Invitrogen, #C7026) following 
the manufacturer’s instructions. Results were the average of two separate experiments and 
normalized to vehicle treated control cells with error bars representing the standard error of the 
mean.   
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Cross species analysis of alkylation screens 
 The enriched biological process information associated with our TMZ screen was 
compared to other alkylation screens reported for S. cerevisiae and E. coli. Our cross species 
analysis was performed similar to as reported (19). Briefly, to determine if the same gene 
ontology biological processes were enriched in the alkylation sensitive hit lists from all three 
organisms, representing X number of genes, we aligned the GO-terms from each organism. To 
identify GO-terms significantly enriched for alkylation sensitive genes from all three organisms 
we randomly sampled X genes from the complete search space for each screen and identified 
associated GO functional terms. Random sampling was performed over two hundred iterations 
and the average number of hits in each GO category and the standard deviation were 
determined. These values were than compared to the actual values to identify GO terms 
significantly (P < 0.05) enriched for alkylation sensitive genes from all three organisms. The 
molecular functions and the corresponding genes, which were significantly enriched in all three 
alkylation screen data sets, were then visualized using Cytoscape (34). Genes which modulate 
alkylator toxicity from E. coli (dark blue), S. cerevisiae (light blue) and human (light green), all 
served as protein nodes, with enriched GO terms serving as central nodes. The edges between 
GO terms and genes demarcate which genes are annotated to that biological process.  
 
Generation of yeast knockout and viability analysis 
 Media preparation and other yeast manipulations were performed using standard 
methods. Mutants were made using a G418 knock out cassette from the S. cerevisiae Gene 
Deletion Project and were selected on Yeast Peptone Dextrose (YPD) plates containing G418 
(200 mg/ml). A mag1Δ mutant was also made using a URA3 based strategy with selection 
occurring on Synthetic Defined media lacking uracil (SD-URA). Mutants were confirmed by 
PCR. Plate based MMS viability studies were performed as previously reported (35). 
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Screen siRNA transient transfection and temozolomide treatment 
 Transient transfection by siRNA was as previously described (21, 36). Briefly, T98G cells 
were wet-reverse transfected with the Ambion Silencer Druggable Genome siRNA library. The 
library consisted of siRNAs targeting 5,520 different genes. Three unique siRNA duplexes 
targeting the same gene were pooled into a single well with one-gene target per well. The 
siRNA were prepared with DharmaFECT2 and OptiMEM and split evenly into two, 384-well 
plates. T98G cells were added directly to the siRNA complexes. The plates were incubated for 
five hours at 37ºC with 5% CO2 before replacement with fresh media.  
 Cells were incubated at 37ºC with 5% CO2 for 48 hr after siRNA transfection to allow for 
gene silencing before addition of TMZ or vehicle. The media was removed and the cells were 
treated with media containing either dimethyl sulfoxide (DMSO) vehicle (final concentration 
1.0%) or the approximate EC10 of TMZ (final concentration 1 mM in 1% DMSO) for 48 hrs. Cell 
viability was measured 96 hours after siRNA transfection with the CellTiter-Blue viability assay 
according to manufacturer’s protocol. 
  
Druggable genome siRNA screen data analysis 
 The siRNA screen was performed 3 times over 6 separate weeks. Fluorescence units 
from each well were normalized to plate negative controls (scrambled siRNA) enabling cell 
viability comparisons between different plates. Data was analyzed by creating a high confidence 
hit list as described previously (37). Briefly, cell viabilities for each targeting gene from the three 
screening replicates were averaged and data was analyzed using two statistical analysis 
methods. For each gene, a two-sample t-test was performed to determine if there was a 
sensitization effect on cellular survival between ‘siRNA plus vehicle’ treated cells as compared 
to ‘siRNA plus TMZ’ treated cells. We selected targeting siRNAs with a p-value less than or 
equal to this threshold.  
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 Also, viability ratios (ratio of survival of ‘siRNA plus TMZ’ to ‘siRNA plus vehicle’) were 
calculated for each targeting siRNA to determine the magnitude of response between the two 
screening conditions. The viability ratios were sorted in descending order and targeting siRNAs 
with a viability ratio in the lowest 5th percentile were selected for further analysis. The targeting 
siRNAs identified by both methods (p-value ≤ 0.05 and viability ratio in the lowest 5th percentile) 
were included in the final high-confidence hit list for further analysis and validation.  
 
Transient siRNA knockdown for validation studies 
 T98G cells were wet-reverse transfected in six-well plates using siPORT NeoFX (Applied 
Biosystems) per the manufacturer’s instruction. Briefly, the siRNA was diluted to a working 
concentration of 2µM before being used. Cells were plated at a concentration of 300,000 cells 
per well and an siRNA final concentration of 90nM. The cells were incubated for 24 hrs at 37°C 
before replacing transfection media with fresh media. Forty-eight hours after transfection cells 
were trypsinized and seeded for mRNA quantification and MTS cytotoxicity assays as described 
above. For knockdown of UNG and UBE3B the following Silencer Select siRNAs from Applied 
Biosystems were used: UNG: s14679; UBE3B: s40200; Silencer Negative control v2: am4613. 
 
Preparation of cDNA for human astrocyte qRT-PCR 
 Total RNA was isolated and purified from T98G and LN428 glioblastoma cell lines and 
normal human astrocytes using Qiazol Lysis Reagent and MiRNeasy spin columns (Qiagen, 
Valencia, CA) according to the manufacturer’s instructions. RNA quality was assessed using an 
Agilent Bioanalyzer (Agilent Technologies, Palo Alto, CA). RNAs with an RNA integrity number 
(RIN) above 9 were used for studies. Three μg RNA was reverse transcribed into cDNA using 
the SuperScript III first-Strand synthesis kit (Invitogen, #18080-400) according to the 
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manufacturer’s instructions with Olig(dT)20 primer in a 20 μl reaction. The cDNA library was then 
diluted 10 fold for qRT-PCR as described above.  
 
REMBRANDT and TCGA queries 
 The REMBRANDT database was interrogated in February 2012 using the simple search 
functions for gene expression of UNG and UBE3B with related Kaplan-Meier survival curves 
(38, 39). The Cancer Genome Atlas GBM database was queried using the gene expression tool 
for two-fold greater or less expression of UNG and UBE3B compared to controls. Percentages 
of GBM overexpressing or underexpressing UNG or UBE3B were recorded. 
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Results 
Synthetic lethal siRNA screen and generation of high confidence hit list 
 To identify genes that when silenced confer sensitivity to the alkylating agent TMZ, we 
conducted a synthetic lethal screen (in triplicate) on a TMZ-resistant GBM cell line (T98G) using 
TMZ and an siRNA library (Fig. S1A). A concentration of 1 mM TMZ was selected due to 
minimal (~10%) toxicity measured at 48 hrs via an MTS assay. Further, T98G cells were treated 
with varying concentrations of DMSO to determine the impact of DMSO on cell survival (Fig. 
S1B). No toxicity was observed at 1% DMSO after 48 hrs, the % DMSO used for both vehicle 
and TMZ treatment in the screen.  
 The transfection conditions used in the screen maximized knockdown, similar to previous 
screens using these conditions (21). We first calculated viability ratios (ratio of survival of ‘siRNA 
plus TMZ’ to ‘siRNA plus vehicle’) and normalized to vehicle-treated scrambled siRNA, enabling 
cross plate comparisons. We then statistically analyzed the viability ratios and determined a 
group of gene targets that sensitized cells to TMZ by performing a two-tail sample t-test on each 
gene to determine the effect of siRNA and TMZ on cellular survival. Targeting siRNAs were 
selected with a p-value of less than or equal to 0.05. The high confidence hit list contained 
targets that satisfied both criteria: a p-value ≤ 0.05 and a viability ratio in the lowest 5 percent 
(Fig. S1C). By using these two methods, we created a hit list of 172 genes (Dataset S1). While 
most of the viability ratios on the hit list were between 0.4 and 0.65, these genes significantly 
modulated the toxicity of TMZ, yielding many new potential targets to increase response to 
alkylation chemotherapy. All hits were analyzed for pathway and network enrichment to 
determine the potential biological pathways that modulated alkylation toxicity 
 
Analysis of screen results for pathway and network enrichment 
 The genes contained in the hit list were analyzed with NIH DAVID, Princeton GO term 
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finder and Ingenuity Pathways Analysis (Ingenuity® Systems, www.ingenuity.com) (IPA) for 
pathway and network enrichment. The analysis with DAVID and Princeton GO term finder was 
performed to search for gene enrichment in molecular functions, cellular compartments, or 
biological processes based on the associated gene ontology terms. Each gene is linked to 
different terms based on their gene ontology in a hierarchical manner and gene enrichment was 
determined based on the probability of selecting proteins with similar terms. By focusing on 
5,520 druggable genes, we expected a small but presumably more relevant gene enrichment 
dataset compared to probing the entire human genome as background. Several different 
thresholds for viability ratio percentiles were initially analyzed for gene enrichment, including 
2.5%, 5%, 7.5% and 10% (Datasets S2-S4). The 5% group was selected for a more detailed 
analysis because it contained many of the gene enrichment groups seen in both the 7.5% and 
10% datasets, but was more focused with higher gene enrichment scores.  
 The enriched genes from the NIH DAVID analysis contained several different groups 
including DNA repair, response to DNA damage stimulus, cell proliferation, amino acid 
glycosylation and biopolymer glycosylation (Table 1). The most enriched groups have specific 
DNA repair functions including BER activity, hydrolase activity and DNA N-glycosylase activity. 
Surprisingly, four genes belonging to the three most enriched groups were DNA glycosylases 
that do not recognize alkylation damage (7). Interestingly, these genes (TDG, OGG1, NEIL1 and 
UNG) are known to recognize and repair multiple types of oxidative DNA damage (Table 2) (7).   
 There were large overlaps of enriched genes from DAVID and Princeton GO term finder 
analyses (Fig. S2 and Dataset S5). The oxidative DNA glycosylases, which sensitized cells to 
TMZ, were identified in the most significantly enriched networks determined by both DAVID and 
Princeton GO term finder (Table 1 and Dataset S6). Data were also analyzed through the use 
of IPA. IPA uses a manually curated interaction database and a right‐tailed Fisher’s exact test to 
calculate a p‐value, determining the probability that each biological function assigned to that 
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network is due to chance alone. Analysis using IPA identified several of the DNA glycosylases in 
a statistically significant network, with a network value of twenty-four (Fig. 1). The network score 
is the negative logarithm of the p-value (p-value =10-24). This network is very similar to the 
biological processes and corresponding genes overrepresented in the DAVID and Princeton GO 
analysis. Further, IPA returned several highly enriched molecular functions including DNA repair 
(p-value=5.31 x 10-4), excision repair (p-value=8.87 x 10-4), ligation of a DNA fragment (p-value= 
2.84 x 10-3), ligation of DNA (p-value= 9.07 x 10-3) and nicking of DNA (p-value=1.83 x 10-2), 
very similar to the functions returned by DAVID. 
Other highly enriched molecular functions included post-translational modifications (p-
value= 2.98 x 10-3 - 3.12 x 10-2), carbohydrate metabolism (p-value= 5.56 x 10-3 - 4.57 x 10-2), 
nucleic acid metabolism (p-value= 9.65 x 10-4 - 3.12 x 10-2), and small molecule biochemistry (p-
value= 9.49 x 10-4 - 4.7 x 10-2). Within these different functional groups, a conserved theme was 
the ability of the genes to modify DNA or proteins. The modifications of DNA most significantly 
involved the excision of uracil (p-value = 9.65 x 10-4), while the many protein modifications 
included metabolism of proteoglycan (p-value = 5.56 x 10-3), metabolism of polysaccharide (p-
value = 7.29 x 10-3), metabolism of carbohydrate (p-value = 8.05 x 10-3), generation of 
diacylglycerol (p-value = 5.56 x 10-3) and the release of acetylcholine (p-value = 9.07 x 10-3). 
The “Protein Modification” theme was also observed in the DAVID and Princeton GO analyses, 
and included protein amino acid glycosylation, bipolymer glycosylation, glycoprotein biosynthetic 
process, glycoprotein metabolic process and cellular carbohydrate metabolic process. These 
processes contained genes whose corresponding proteins are involved in protein modifications 
and when silenced, the corresponding cells are sensitive to TMZ. However, because of the 
highly significant enrichment of DNA repair processes in all three programs, genes associated 
with the DNA Repair pathway category were selected for initial biological validation. 
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Knockdown of oxidative DNA glycosylases sensitize cells to TMZ 
 In our analysis, we discovered that the DNA repair category was enriched for TMZ 
sensitizing genes. This category contained four DNA glycosylases (UNG, OGG1, TDG and 
NEIL1), each specific for the repair of oxidative DNA damage (7). To determine if other DNA 
glycosylases also sensitize cells to TMZ and to validate the siRNA synthetic lethal screen 
results, seven of the eleven DNA glycosylases were knocked down using a lentiviral system to 
create stable T98G-derived cell lines. Knockdown of glycosylase mRNA was validated by qRT-
PCR (Fig. 2A). The stable cell lines were then tested for sensitization to 1 mM TMZ in a 96-well 
plate format using a modified MTS assay (22). As confirmation of our siRNA screen analysis, 
the newly developed UNG-KD cell line was also sensitive to TMZ (Fig. 2B). Furthermore, 
knockdown of the DNA glycosylases MYH and MPG also sensitized cells to TMZ, as did 
knockdown of NEIL2 (Fig. 2B). 
 
UNG knockdown eliminates removal of uracil in glioma cells 
 Although UNG mRNA knockdown sensitized the T98G cells to TMZ in the validation 
study, we were uncertain if the mRNA knockdown affected UNG protein levels and DNA repair 
activity. First, we tested UNG protein expression via immunoblot and determined that UNG 
protein levels were decreased in T98G/UNG-KD cells as compared to T98G-GFP control cells 
(Fig. 2C). However, we were interested in ascertaining if the decrease in UNG protein levels 
affects the DNA repair capacity of the cells, because there is a large functional overlap of UNG 
with the three DNA glycoslylases SMUG1, TDG and MBD4 (7). We were concerned that 
depletion of one of these DNA glycosylases would not have a functional DNA repair defect due 
to compensation by the other glycosylases. We therefore developed a DNA glycosylase 
molecular beacon assay to quantify the functional loss of uracil removal by UNG knockdown, 
essentially as we have described previously for the analysis of MPG activity (23). The assay 
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uses a molecular beacon composed of a single stranded DNA molecule with a 5’ fluorophore (6-
FAM) and a 3’ quencher (Dabcyl). The oligonucleotide also contains a uracil lesion, a substrate 
for UNG. We selected uracil as the lesion because it is removed by UNG, SMUG1, TDG and 
MBD4 (7). Therefore, we could determine if UNG-KD impacts uracil removal and if 
compensation by other DNA repair proteins occurred. A similar oligonucleotide with a normal 
base was used as a control substrate. Removal of the uracil lesion by UNG and hydrolysis of 
the DNA backbone by APE1 results in separation of the 6-FAM fluorophore from the Dabcyl 
quencher and the increase in 6-FAM fluorescence is proportional to uracil removal (Fig. 2D). 
The T98G-SCR cell lysate (from cells expressing a scrambled shRNA) incubated with control 
beacon (Fig. 2E, red circles) had a minimal increase in fluorescence, signifying the control 
beacon is intact. However, the T98G-SCR lysate incubated with the beacon containing uracil 
(Fig. 2E, blue squares) exhibited a large increase in fluorescence (17.69 fold at 60 min) 
compared to the control beacon, indicative of robust uracil removal. The T98G/UNG-KD lysates 
incubated with either the control beacon (Fig. 2E, green diamonds) or the uracil-containing 
beacon (Fig. 2E, yellow triangles) contained no difference in fluorescence. 
 These results support our conclusion that the T98G/UNG-KD cells have impaired uracil 
removal due to UNG knockdown as compared to the T98G-SCR control, with no evidence for 
repair compensation by SMUG1, TDG or MBD4. The scrambled shRNA control was used 
instead of the GFP control for the activity assay due to the interference of GFP fluorescence 
with the molecular beacon fluorophore 6-FAM. Although uracil can also be removed by SMUG1, 
TDG and MBD4, UNG-KD alone was sufficient to deplete uracil removal activity (7).   
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Cross-species functionome analysis creates a network of conserved processes 
important for survival after alkylation damage 
 After biological validation, we then compared our T98G siRNA screen results to other 
alkylation screens conducted in S. cerevisiae and E. coli, using GO molecular function terms 
(17, 18). This was done by compiling the sensitizing genes from all the screens and linking them 
to their specific Gene Ontology Biological Process. The list of sensitizing genes from E. coli, S. 
cerevisiae and human was then computationally analyzed to identify GO-functional categories 
over-represented with genes from human and either E. coli or S. cerevisiae (Supplemental 
Table S1). The molecular functions enriched in all three alkylation screen datasets were then 
visualized using Cytoscape to create a cross species functionome of proteins which modulate 
toxicity to alkylating agents in S. cerevisiae, E. coli and human (Fig. 3). This network of proteins 
has several “GO-hubs” of proteins from all three species clustered around a conserved 
biological process (node) that significantly impacts the survival of correspondingly depleted cells 
after exposure to alkylating agents. These include proteins involved in global processes such as 
response to drugs or changes in pH. There was also a collection of processes involved in 
macromolecule biosynthesis and modifications including fatty acid biosynthetic processes, 
transcription, regulation of transcription, transcription initiation, negative regulation of translation, 
protein modification process, protein processing and protein targeting to membrane. These 
results suggest that synthesis of new RNA, protein, and fatty acids are essential for survival to 
alkylation.   
 
Protein Modifications are essential for yeast and human cell survival to TMZ 
 Many genes in yeast and humans whose corresponding activities are involved in protein 
modification are required for protection from alkylation damage mediated by TMZ or methyl 
methanesulfonate (MMS) exposure. Several different types of protein modifications including 
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ubiquitinylation, methylation, glycosylation and deimination are present in the hub (Fig. 3). 
These include two of the four known human peptidyl arginine deiminases, type I and type IV 
(PADI1 and PADI4) (40). Petidyl arginine deiminases catalyzes the post-translational 
deimination of proteins by converting arginine residues into citrullines (40). The PADs have 
distinct substrate specificities and tissue-specific expression patterns (41, 42). The enzymatic 
reaction is highly dependent on pH and calcium concentrations, with the different PAD isoforms 
containing different activity profiles (41). The differential expression patterns, substrates and 
activity profiles all contribute to the distinct functions of the PAD genes. Currently, the most 
prevalent function of PADI1 is its role in epidermal differentiation, where it deiminates filaggrin 
and keratin (41, 42). However, its role in DNA repair or survival to alkylation exposure has not 
been determined. In contrast, PADI4 is likely involved in DNA repair and cell death signaling as 
it can modulate p53 signaling and p53 gene target expression levels (43, 44). PADI4 can also 
antagonize histone methylation by arginine deimination to citruline, thus removing the 
methylation mark (45). PADI4 also regulates gene expression by associating with histone 
deacetylase 2 (HDAC2) (46). HDAC2 is known to modulate the DNA damage response and 
cells depleted of HDAC2 are hypersensitive to DNA damaging agents (47). Further, 
glioblastoma cells pretreated with the HDAC inhibitor MS275 were sensitized to TMZ (48). 
These data suggest that PADI4 sensitivity may result from interference with multiple steps in the 
DNA damage response, likely through deregulation of HDAC2, but PADI4’s interaction with p53 
likely contributes to alkylation survival as well.   
One of the human genes in this sensitization node is isoprenylcysteine carboxyl 
methyltransferase (ICMT), a gene that is ubiquitously expressed and encodes the last of three 
steps for isoprenylation (49, 50). Methylation of isoprenylcysteine allows movement of the 
protein from the endoplasmic reticulum to the plasma membrane (50). ICMT has been of 
interest to cancer researchers because ICMT inhibition can disrupt RAS signaling in several 
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model systems (51-53). Knockout of ICMT prevented oncogenic transformation of cells with 
oncogenic K-RAS or B-RAF in soft agar and mice models (52). Although there is interest in 
creating potent and selective ICMT inhibitors, there has been no link for ICMT to DNA repair or 
response to alkylation exposure (54). ICMT may play a role downstream of the DNA damage 
cascade and regulate signaling for cell death, as it has been linked with both autophagic and 
apoptotic cell death (55).   
Another gene in the protein modification group is the human ubiquitin protein ligase E3B 
(UBE3B), suggested herein to play a role in the repair of or cellular response to alkylation 
damage. The activity of many DNA repair proteins can be affected by ubiquitinylation such as 
FANCD2 (56) and PCNA (57). Monoubiquitinylation of FANCD2 is used as a marker of intra-
strand crosslink (ICL) repair activity, while ubiquitinylation of PCNA determines polymerase 
switching (58). Furthermore, the E3 ubiquitin ligase activity is critical for the function of several 
crucial DNA repair proteins, for example BRCA1, CUL4A and CUL4B (20, 59). The E3 activity of 
BRCA1 is esential for its role in cell cycle checkpoint activation and sensitivity to DNA damage, 
while CUL4A and CUL4B regulates chromatin structure and access of DNA repair proteins to 
the DNA in nucleotide excision repair (NER) (20, 59, 60). The potential role of UBE3B and its 
substrates in DNA repair are of great interest, but has yet to be defined.   
 
DNA repair defects increase sensitivity to alkylating agents across species 
 Another conserved theme involved DNA metabolism and included the GO hubs of DNA 
metabolic process, DNA replication, negative regulation of DNA replication, response to DNA 
damage stimulus, DNA repair, DNA recombination, mismatch repair, nucleotide excision repair, 
BER and DNA dealkylation. The prevalence of DNA replication and DNA recombination genes 
emphasizes the importance of new DNA synthesis and repairing damaged DNA via 
recombination mechanisms. Many genes involved in other DNA repair pathways including 
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nucleotide excision repair, mismatch repair and BER are present in the DNA repair hub. The 
BER subset from all three organisms was predominantly composed of DNA glycosylases that 
recognize and remove base lesions. This subset contained several known alkylation resistance 
genes such as the 3-methyl-adenine DNA glycosylases alka and MAG1, in E. coli and S. 
cerevisiae, respectively. Also included were human DNA glycosylases that recognize and repair 
oxidative base lesions including UNG, OGG1, TDG and NEIL1 (7). The alkA gene product has 
diverse substrate specificity and also removes oxidative lesions such as xanthine, oxanine, 5-
formyluracil and hypoxanthine (61-64). The ability of AlkA to remove oxidation induced lesions 
correlates with the results seen in the human screen and may affect the sensitivity of alkA 
mutants to alkylation damage. The emphasis on proteins that recognize and remove DNA 
lesions further demonstrates that the DNA lesions themselves are cytotoxic, with removal of 
both alkylation and oxidative lesions being important for survival.   
Many of the biological processes identified from our cross-species functionome analysis 
are conserved, containing multiple proteins from each organism. We have used this approach to 
discover a network of proteins that constitutes a cross-species functionome of evolutionarily 
important processes essential for survival after alkylation exposure. The functionome analysis 
affirms that our TMZ screen results from human cells are consistent with previous alkylation 
studies in other species. This network links seemingly disparate genes that may prevent cell 
death after alkylation damage through their crucial biological processes and represents novel 
targets for adjuvant chemotherapy.  
 
Disruption of protein modification processes sensitizes human cells to alkylators 
 Based on the functionome network we identified, we chose to further validate another 
node of proteins to improve sensitivity to alkylators. The protein modifications node was chosen 
due to enrichment in the cross-species analysis, good sensitization in the screening studies and 
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the observation that this node had multiple genes in both human and yeast cells. Human 
knockdown cell lines were generated using lentivirus shRNA vectors as described above. 
Knockdown levels of mRNA were determined using qRT-PCR (Fig. S3A). The cell lines with 
mRNA knockdown were then tested for sensitivity to TMZ treatment using a modified MTS 
assay. The knockdown of UBE3B and ICMT significantly sensitized the glioblastoma cells to 
TMZ resulting in viability ratios of 0.6 and 0.7, respectively (Fig. 4B), as compared to the 
control. We then tested each knockdown cell line for sensitivity to TMZ in a long-term assay 
similar to a clonogenic cell survival assay. The CyQuant assay utilizes a highly sensitive 
fluorescent intercalating DNA dye to determine relative DNA content and cell number nine days 
after TMZ or vehicle treatment. The UBE3B-KD cell lines were approximately 45% more 
sensitive compared to control cells in the CyQuant assay at concentrations as low as 50μM TMZ 
(Fig. 4C).     
 
Protein modification gene knockout sensitizes yeast to alkylators, while simultaneous 
knockout of protein modification genes and an alkylbase DNA glycosylase yields the 
greatest sensitivity 
 We have previously reported that aim22Δ, lip22Δ, pby1Δ and stp22Δ cells from S. 
cerevisiae, which belong to the protein modification node, are sensitive to the alkylating agent 
MMS (17). In addition, it has been firmly established that mag1Δ cells are sensitive to MMS 
because of their alkylbase DNA glycosylase deficiency and inability to repair damaged DNA.  
We assayed all individual knockouts to further validate our previously reported screening results 
(Fig. 4A) and demonstrate decreased growth after MMS treatment for all five mutants. Based on 
our functionome results, we reasoned that there would be increased alkylation sensitivity when 
deficiencies in protein modification and BER were combined. We generated double knockouts in 
the four protein modification associated mutants, using a mag1Δ deletion cassette. We 
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demonstrate that there is increased sensitivity in all of the double mutants tested, relative to the 
individual parent or mag1Δ knockout strains. The protein modification genes correspond to 
activities involved in the modification of mitochondrial enzymes by the attachment of lipoic acid 
groups (Lip2), a protein that works with Lip2 (Aim22), a tubulin tyrosine ligase associated with P-
bodies (Pby1) and a component of the ESCRT complex that is involved in ubiquitin-dependent 
sorting of proteins into the endosome (Stp22).  We note that Pby1 is homologous to the mouse 
and human Tsg101 tumor susceptibility genes, which are homologs of ubiquitin-conjugating 
enzymes implicated in being involved in cell cycle regulation and genome maintenance. The 
mag1Δstp22Δ double mutant is the most sensitive to MMS, but there also appears to be a 
growth defect in these strains on untreated media, suggesting some synthetic lethal interaction 
outside of alkylation damage. Nonetheless, our results with combined protein modification and 
BER mutants in budding yeast supports the idea that similar dual knockouts in humans may 
confer increased sensitivity to TMZ. 
 
Dual disruption of both DNA repair and protein modification nodes reveals a potential 
epistatic relationship between UNG and UBE3B 
 Although the UNG-KD and UBE3B-KD cell lines were both more sensitive to TMZ when 
compared to control cells, we were interested in determining if the double-KD cells would have 
an increased TMZ sensitivity, as was seen for the double KO lines in S. cerevisiae (Fig. 4A). To 
this end, we investigated if simultaneous inhibition of both DNA repair and protein modification 
genes increased sensitivity compared to either inhibition alone. However, we noticed during 
long-term passaging of the UBE3B-KD cell line that sensitivity and knockdown levels 
diminished, suggesting outgrowth of WT cells in a pooled population.  
To prevent the loss of mRNA knockdown, we returned to using an siRNA transient 
transfection approach to knockdown both UNG and UBE3B. We transfected parental T98G cells 
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with a scrambled control siRNA, UNG siRNA, UBE3B siRNA, or UNG plus UBE3B siRNA before 
determining mRNA levels by qRT-PCR (Fig. S3B). Cells were seeded for qRT-PCR and 
sensitivity determination by MTS assay at the same time. Wells with less than 35% mRNA for 
either UNG or UBE3B remaining were analyzed for sensitivity to TMZ. We expected the dual 
knockdown of UNG and UBE3B to confer at least an additive effect to TMZ sensitivity, 
suggesting that the sensitivity observed after knockdown of the proteins resulted from 
independent mechanisms. However, although UNG and UBE3B knockdown alone both confer 
sensitivity to TMZ, when they are simultaneously knocked down there is no significant increase 
in sensitivity to TMZ below the level of either single knockdown (Fig. 4D). Thus, TMZ sensitivity 
to knockdown of UNG and UBE3B are not independent events, demonstrating a possible 
epistatic relationship between the UNG and UBE3B genes. The conserved biological processes 
also enrich for possible alkylation sensitivity gene interactions as seen with UNG and UBE3B. 
The activity of many DNA glycosylases are regulated by post-translational modifications (6). 
SUMOylation of TDG promotes its catalytic activity by increasing catalytic turnover by 
decreasing TDG’s affinity for the abasic site product (65). Although it is more likely UBE3B has 
an indirect role in UNG sensitivity, it is possible that ubiquitinylation of UNG by UBE3B can 
modify protein localization, abundance or activity as it has been suggested that UNG is targeted 
for ubiquitin-mediated proteolysis during the S phase of the cell cycle (66, 67).   
 
UNG and UBE3B are differentially expressed in various cancer cell lines 
 Expression of UBE3B affected GBM sensitivity to TMZ and may impact response of 
various cancers to other chemotherapeutic alkylating agents such as cyclophosphamide, 
chlorabucil and dacarbazine. With little known on the function or expression of UBE3B in normal 
and cancerous tissue, we wanted to determine if UBE3B expression levels vary in different 
cancer cell lines. To determine if UBE3B is differentially expressed in different cancer types we 
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quantified relative expression levels of UBE3B mRNA by qRT-PCR. We discovered that UBE3B 
mRNA expression varies by approximately 7-8 fold in the tumor cell lines tested (Figure 5A). 
UBE3B expression fluctuates in our different cancer cell lines and we sought to determine if 
UBE3B and UNG levels vary in the LN428 and T98G cell lines when compared to normal 
human astrocyte controls. We determined relative mRNA levels of UNG and UBE3B in LN428 
and T98G cell lines compared to normal human astrocyte controls using qRT-PCR (Figure 5B). 
Although UBE3B levels did not fluctuate in the three cell lines, there was a 2-fold increase in 
UNG expression in both cancer cell lines when compared to human astrocyte controls.     
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Discussion  
GBMs are the most common and aggressive primary brain tumor; the current standard of 
care consists of maximum surgical removal, radiation and TMZ (2-4). Many tumors are 
refractory to TMZ treatment, resulting in very poor outcomes. Difficulties in treating GBM make it 
a candidate for drug research since an increase in therapeutic options is necessary to improve 
survival rate. Because TMZ clinical efficacy is primarily due to the toxicity of the O6-MeG DNA 
lesion, much of the alkylation damage sensitization research has focused on this lesion. 
Unfortunately, previous attempts to improve efficacy of O6-MeG lesion-mediated cytotoxicity 
have been futile. The clinical trials testing the effectiveness of MGMT inhibitors do not show an 
increase in efficacy or sensitivity (12), particularly in TMZ-resistant GBM (13). Due to the 
inherent difficulties and resistance of GBM to chemotherapies, any increase in cancer 
sensitization could greatly impact patient outcomes.  
 To discover “druggable” targets that contribute to TMZ sensitivity, independent of the O6-
MeG lesion, we conducted a synthetic lethal siRNA screen against 5,520 genes in a TMZ-
resistant cell line that has elevated expression of MGMT (T98G), uncovering enriched biological 
processes independent of MGMT and O6-MeG lesion induced cell death that included 172 
genes (Dataset S1), many corresponding to similar or over-lapping biological processes as 
determined by NIH DAVID, Princeton GO term finder and IPA. After enrichment analysis, 
increased TMZ-mediated sensitization in cells depleted of UNG (UNG-KD) was validated using 
a separate shRNA targeting sequence and an independent experimental design. Thus, cell 
sensitization to alkylating agents with UNG-KD is not due to RNAi off-target effects or artifacts of 
the screening protocol. We could not create stable knockdowns of the other DNA glycosylase 
hits, likely because the knockdown of OGG1, TDG and NEIL1 created cells with a growth 
disadvantage compared to cells expressing normal levels of the corresponding protein.  
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Although UNG has not been reported to repair alkylation damage, knockdown of UNG 
sensitizes T98G cells to TMZ. It is possible that TMZ induces toxic oxidative lesions by 
increasing reactive oxygen species (ROS) levels as seen with MMS in yeast (68). TMZ may 
directly alkylate the electron transport chain proteins and mitochondrial DNA, which could impair 
electron flow through the chain by direct alkylation damage of the protein and decreased 
functional protein expression due to replication blocking lesions or mutated DNA. It is possible 
that mitochondrial alkylation damage induces an increase in ROS formation. Mitochondrial ROS 
production can increase from defects in electron transport chain proteins, such as complex I 
(69). Cells lacking oxidative DNA glycosylases may be more sensitive to ROS because repair of 
oxidative lesions is compromised. For example, cells lacking NEIL1 are more sensitive to 
gamma-irradiation (70) and NEIL1-/- mice have decreased expansion of germinal center B cells 
(71).  Thus, an increase in ROS may create lethal oxidative lesions that UNG (e.g., 5,6-dihydro-
2’-deoxyuridine) and other oxidative DNA glycosylases must repair to prevent cell death after 
alkylation exposure (7). NAD kinase, which phosphorylates NAD to form NADP+, was also a hit 
in our screen. Cells keep NADP+ in its reduced state, NADPH, to use NADPH’s reducing 
potential in many different pathways including glutathione regeneration for oxidant defense, 
reduction of RNA to DNA, and synthesis of fatty and amino acids. New synthesis and repair of 
macromolecules is essential for alkylation survival (18, 35, 72). NAD kinase may affect 
alkylation survival via NADPH production by its positive effect on DNA and RNA synthesis and 
also for its central role in creating reducing equivalents for antioxidant defense. Support for a 
potential role of ROS in alkylation sensitivity was also shown by others using mouse embryonic 
fibroblasts and several human cancer cell lines, which were treated with the alkylating agent 
MNNG and contained greater ROS production from both NADPH oxidase and mitochondria 
sources (73, 74). In the report by Chiu et at, MNNG cytotoxicity could be completely abrogated 
by pretreatment with N-acetylcysteine, demonstrating that increased ROS formation may 
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contribute to alkylation toxicity and is a likely source of cytotoxic DNA lesions (74). Cells 
expressing UNG may be less sensitive to TMZ because the increase in ROS produces cytotoxic 
oxidative DNA lesions removed by UNG, promoting cellular survival. 
 UNG was not the only DNA glycosylase to sensitize cells to alkylation exposure in the 
validation experiments. MPG and MYH knockdown (KD) also sensitized T98G cells to TMZ. 
This was unexpected because MPG did not sensitize in the siRNA screen, perhaps due to lack 
of knockdown. However, our results are consistent with previous reports from several labs, as 
MPG-KD led to either an increase or decrease in cell death after alkylation exposure depending 
on the system under study (75-78). Further, MPG status alone does not adequately predict 
response to alkylators, but instead the balance of the entire BER pathway must be investigated 
to predict sensitivity to DNA damage (23, 30, 79). The ability of MYH-KD to sensitize cells to 
alkylators was not anticipated since expression of MYH had been previously shown to promote 
cell death after alkylator exposure (80). In that study, however, the authors used a clonogenic 
cell survival assay that interrogates cell death related to the O6-MeG lesion because the cells 
can undergo two or more replication cycles (80). In contrast, in our initial validation experiments, 
cell survival was determined after 48 hours post TMZ treatment, too short for two replication 
cycles to occur (81). Therefore, the role of MYH in O6-MeG mediated cell death is likely very 
different than its role in cell survival after 48hr exposure to TMZ as described in this study. MYH 
is primarily known for the removal of the mismatched A opposite 8-oxoG lesions (82, 83) and 
MYH deficiency does not sensitize cells to H2O2, IR, or cis-platinum (7). Therefore, the 
sensitization of MYH depletion to TMZ treatment may be the result of an increase in ROS 
induced lesions.  
 After biological validation was completed, the results were compared to similar alkylator 
sensitivity screens done in S. cerevisiae and E. coli (17, 18). Many of the same biological 
processes significantly enriched in the human screen were enriched in both screens from yeast 
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and bacteria. There are a diverse collection of biological processes, ranging from DNA repair to 
modulation of transcription, translation, protein modifications and fatty acid biosynthesis that 
appear to be essential for survival after alkylation exposure. The many processes necessary for 
cellular survival after alkylation exposure likely stem from the alkylator’s ability to modify all 
macromolecules in a cell, thereby requiring repair of not only DNA, but also of RNA, proteins 
and fatty acids. In the human siRNA screen, these data suggests a novel epistatic relationship 
between UNG and UBE3B. This is likely an indirect interaction with downstream targets of 
UBE3B modulating TMZ cytotoxicity through a UNG dependent pathway. However, we find 
UBE3B expression to be highly variable when comparing many cancer cell lines but expression 
is lower than that found in cultured astrocytes (Fig. 5). A direct interaction between UBE3B and 
UNG may be exist, since UNG is a known target of ubiquitinylation (67, 84, 85), although the 
data described herein would not implicate UBE3B in the cell cycle-regulated proteolysis of UNG.  
 The analysis of the three screens revealed that many biological processes modulate 
survival after alkylation damage. The greatest alkylator toxicity in yeast cells was generated by 
dual inhibition (KO) of both BER and the protein modification processes, suggesting that 
simultaneous inhibition may be required to achieve a clinically significant sensitization for 
chemotherapies, provided this approach can provide tumor selectivity. In that regard, we 
evaluated the range of UNG expression levels in primary patient tumors by interrogating the 
Cancer Genome Atlas (TCGA) dataset on GBM. UNG expression is two-fold greater in 
approximately 14% of the GBMs studied in the TCGA. Interestingly, there are no samples with a 
two-fold decrease in UNG expression in the TCGA database. We also queried the Rembrandt 
database for UNG gene expression data and found that greater than 33% of GBMs contained 2-
fold or greater expression of UNG (39). These results, from a separate database, reinforced our 
hypothesis that expression levels of UNG varied significantly in tumors. The directionality of the 
changes were consistent and it appears that over-expression of UNG is beneficial for GBM 
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tumor growth or survival, with less than 1% of tumors containing a two-fold decrease in UNG 
expression in the REMBRANDT database. This trend also extended to other brain tumor types 
such as astrocytomas, which had greater than 14% of tested tumors containing two-fold greater 
expression of UNG and no samples with a two-fold down regulation of UNG (39).  
Knowing that the expression levels of UNG fluctuate in primary tumor samples, we asked 
if expression levels of UNG and UBE3B correlated with response to therapy or survival. We 
would predict the increase in UNG expression levels would correlate with reduced survival due 
to the ability of the cells to repair their DNA more efficiently, especially TMZ induced lesions. We 
also queried the REMBRANDT database for clinical outcomes related to UNG overexpression 
compared to intermediate expression in all glioma: two-fold over-expression of UNG correlated 
with a decrease in the probability of survival compared to intermediate expression of UNG, with 
a log-rank p-value, calculated using the Mantel-Haenszel procedure, of 1.0177x10-4. This 
correlation matches our prediction based on our cell culture data, suggesting that increased 
expression of UNG negatively impacts brain tumor patient survival, possibly from increased 
resistance to chemotherapeutic treatment.   
 In summary, these studies suggest that alkylation resistance mechanisms are 
evolutionarily conserved. The collection of conserved biological processes in E. coli, S. 
cerevisiae and humans composes an Alkylation Functionome that includes many novel proteins 
not previously thought to impact alkylation resistance (Figure 6). We can begin to appreciate 
the multiple processes that are required for cellular survival after alkylation damage and form an 
unbiased approach to discover targets for adjuvant chemotherapy. This is an important next 
step, so as to determine if genes that were not tested in the screen, but share conserved 
biological pathways, are also possible targets to enhance TMZ response. Because the analysis 
has also been enriched for the most essential pathways and genes, there may be functional 
overlap of the conserved genes and pathways. The highly conserved nature of these biological 
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processes lends mechanistic insight into potential gene and pathway interactions. Determining 
the relationships between these genes and biological processes is important to determine 
pathway redundancy. Due to the plethora of resistance mechanisms, it is possible that depletion 
or inhibition of one gene in a conserved biological process cannot overcome the drug resistance 
due to compensation by another gene or biological process. By investigating multiple pathways 
and processes we can determine important interactions that promote tumor survival to be 
targeted for improved chemotherapy response.    
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Figure Legends 
Figure 1. Analysis with NIH DAVID, Princeton GO term finder and Ingenuity Pathway Analysis 
yield similar gene enrichments, biological processes and pathways. The high confidence hit list 
was also analyzed by IPA for biological pathway enrichment. One highly significant network 
generated by Ingenuity Pathway Analysis containing similar biological processes with other 
analysis methods is shown. The network is composed of many overlapping genes with genes in 
the high confidence hit list colored green. The top functions in the network are nucleic acid 
metabolism, small molecule biochemistry and metabolic disease with a network score of 24. The 
network score is the negative logarithm of the p-value. 
 
 
Figure 2. Glioma cells with shRNA knockdown of DNA glycosylases are more sensitive to the 
clinical alkylator TMZ. (A) Quantification of DNA glycosylase mRNA knockdown in cells as 
determined by qRT-PCR. TaqMan probes were used to quantify mRNA levels on an Applied 
Biosystems StepOnePlus machine. The qRT-PCR data was analyzed using the ΔΔCt method 
and was normalized to GFP infected plate controls. Gene expression of each gene was 
normalized to the expression of human ß-actin. The mean of three independent experiments is 
plotted ± SEM. (B) Validation of TMZ sensitization with knockdown of specific DNA glycosylases 
T98G DNA glycoylase knockdown cell line sensitivity to TMZ was determined by an MTS assay 
48 hr after exposure to 1 mM TMZ. The viability ratio is double normalized to account for both 
vehicle treated shRNA mediated growth defects and toxicity of control cells to TMZ. The mean 
viability ratio of three independent experiments is plotted ± SEM. (C) Knockdown of UNG mRNA 
corresponds with decreased UNG protein levels. Control and UNG-KD cell line nuclear extracts 
were resolved in a 4-20% SDS/PAGE gel and immunoblotted for UNG. The blot was stripped 
and re-probed for PCNA, which was used as a loading control. (D) Molecular beacon model for 
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real-time detection of uracil removal at 37°C in nuclear extracts. (E) Knockdown of UNG 
abolishes ability to remove uracil from DNA as determined by DNA Glycosylase Molecular 
Beacon Activity Assay. Specific activity of DNA glycosylase activity for the uracil lesion was 
measured in nuclear extracts from T98G-SCR (control-beacon, red circles; uracil-beacon, blue 
squares) and T98G/UNG-KD (control-beacon, green diamonds; uracil-beacon, yellow triangles). 
The mean fluorescence response unit of three experiments is plotted ± SEM. 
 
 
Figure 3. Biological processes necessary for survival after alkylation damage are conserved 
and when compiled generate a cross-species functionome. The conserved biological processes 
with their corresponding genes were visualized using Cytoscape. Red nodes denote conserved 
biological processes. The remaining nodes are alkylation-modulating proteins belonging to E. 
coli (dark blue), S. cerevisiae (light blue) and humans (light green). The edges connect specific 
biological processes to each protein belonging to the processes. Many proteins are involved in 
more than one biological process to affect alkylation exposure survival and therefore are 
connected to several biological processes nodes.  
 
 
Figure 4. Knockout or depletion of protein modification genes sensitizes S. cerevisiae and 
human glioma cells to alkylating agents. (A) A dilution series of yeast single and double 
knockouts were tested in YPD and YPD + MMS containing media. (B) Knockdown of protein 
modification genes sensitize glioma cells to TMZ. The T98G cell lines with protein modification 
gene knockdown were treated with 1mm TMZ to determine sensitivity by an MTS assay 48 
hours after exposure. The mean viability ratio of three independent experiments is plotted ± 
SEM. (C) Knockdown of UBE3B sensitizes glioma cells to TMZ at clinically achievable doses. 
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The T98G/UBE3B-KD cell line was treated with 50μM of TMZ and survival was determined by 
CyQuant assay 9 days after exposure. The percent survival of two independent experiments is 
plotted ± SEM(D) Sensitivity to TMZ via knockdown of UNG and UBE3B are not 
independentT98G cells transiently transfected with siRNA that was scrambled, targeting UNG, 
UBE3B or both UNG and UBE3B. Forty-eight hours after transfection cells were seeded to 
determine sensitivity to TMZ by MTS assay. Both individual knockdowns of UNG and UBE3B 
sensitized glioma cells to TMZ, but dual knockdown did not have a greater effect than either 
single knockdown, suggesting an epistatic relationship between UNG and UBE3B. 
 
Figure 5. UBE3B and UNG expression fluctuate in cancer cell lines. (A) UBE3B is differentially 
expressed with a seven-fold difference in cancer cell lines. Relative mRNA expression of 
UBE3B in cells various cancer cell lines as determined by qRT-PCR. Gene expression of 
UBE3B was normalized to T98G (gray bar) across cell lines and normalized to expression of 
human ß-actin within each cell line. The relative expression of UBE3B in the T98G cell line is 
shown as a dashed red line. The mean of three independent experiments is plotted ± SEM. (B) 
UNG is expressed at higher levels in brain tumor cell lines, when compared to non-tumor 
controls. Quantification of UNG and UBE3B mRNA by qRT-PCR compared to human astrocyte 
controls. Gene expression of each gene was normalized to the expression of human ß-actin. 
The mean of three independent experiments is plotted ± SEM. 
 
Figure 6. Graphical depiction of the Alkylation Functionome.  The “Alkylation Functionome” is a 
gene list that encompasses a diverse collection of similar biological processes crucial to survival 
of human, bacteria and yeast cells following alkylation damage.  
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Supporting information  
Supplemental Figure 1 
Supplemental Figure 2 
Supplemental Figure 3 
Supplemental Figure 4 
Supplemental Table S1 
 
Datasets S1-S6: 
Dataset 1 
Genes of interest from the siRNA screen that satisfied both selection criteria: a p-value less than 
0.05 and a viability ratio in the lowest 5% 
 
Dataset 2 - Second group of genes from the siRNA screen analyzed for gene enrichment using 
selection criteria of a p-value less than 0.05 and a viability ratio in the lowest 2.5% 
 
Dataset 3 - Third group of genes from the siRNA screen analyzed for gene enrichment using 
selection criteria of a p-value less than 0.05 and a viability ratio in the lowest 7.5% 
 
Dataset 4 - Fourth group of genes from the siRNA screen analyzed for gene enrichment using 
selection criteria of a p-value less than 0.05 and a viability ratio in the lowest 10% 
 
Dataset 5 - Enriched genes identified by both NIH DAVID and Princeton GO Term Finder 
 
Dataset 6 - Enriched biological processes and associated genes as determined by Princeton 
GO Term Finder 
 
 






Table 1. Top gene enrichment groups determined by NIH DAVID 
 
 
 
 
Gene Ontology Term p-value Genes* Fold Enrichment FDR 
Base excision repair 2.92E-05 OGG1, NEIL1, POLD1, TDG, UNG 14.7 0.054348
Hydrolase activity, Hydrolyzing 
N-glycosyl compounds 4.71E-05 CD38, OGG1, TDG, UNG, NEIL1 13.48214 0.083124
Glycosidase 9.54E-05 SPAM1, SMPDL3A, OGG1, TDG, TREH, CTBS, UNG, NEIL1 5.992216 0.148149
DNA N-glycosylase activity 1.07E-04 OGG1, TDG, UNG, NEIL1 17.47685 0.188687
DNA repair 1.73E-04 LIG4, OGG1, TDG, ATR, TREX1, LIG1, UNG, NEIL1 5.522238 0.269107
DNA damage 1.99E-04 LIG4, OGG1, TDG, ATR, TREX1, LIG1, UNG, NEIL1 5.416041 0.309503
*CCNO is incorrectly labeled in NIH DAVID as UNG2.  UNG2 is a DNA glycosylase so it originally 
appeared in our analysis.  However, CCNO does not have a similar function to UNG2 and was removed 
from further analysis.   
Table 2: Sensitizing DNA glycosylases and their known substrates 
 
Gene 
Symbol Gene Name Known Substrate* 
Screen 
Viability Ratio 
OGG1 
8-oxoguanine 
DNA 
glycosylase 
8-oxoG:C=T=G; me-FapyG:C; FapyG:C; 8-oxoA:C; urea 0.648 
UNG Uracil DNA glycosylase 
ssU; U:G; U:A; 5-fluorouracil; 5,6-Dihydroxy-U:G; 5-OH-
U:G; Isodialuric acid; Alloxan 0.446 
TDG Thymine DNA glycosylase 
U:G; T:G and ethenoC:G; 5-Fluorouracil; 5-fluorouracil 
(ss); 5-Hydroxymethyluracil; hypoxanthine:G; 5-
bromouracil; εC:A 
Tg:G; 5-formyl-U 
0.541 
NEIL1 
Nei 
endonuclease 
VIII-like 1 (E. 
coli) 
TgG; 5-OH-C; 5-OH-U:AT>G; Guanidinohydantoin; 
guanidinohydantoin (ss); Iminoallantoin; Iminoallantoin 
(ss); Spiroiminodihydantoin; Spiroiminodihydantoin (ss); 
5,6-Dihydro-T; 5,6-Dihydro-U:G=C=A>T; FapyG:C; 
8-Oxo-G:C=G>T>A; FapyA:T; (5’R)-8,5’-Cyclo-2’-
deoxyadenosine; (5’S)-8,5’-Cyclo-2’-deoxyadenosine; 8-
Oxo-A:C 
0.559 
*For mismatched base pairs, the repaired or removed base is configured on the left in each case.  
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